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Abstract 
THE INDEPENDENT CONTRIBUTION OF DIABETIC FOOT ULCER ON LOWER EXTREMITY AMPUTATION AND MORTALITY RISK 
 
Aims: To estimate 3-year risk for diabetic foot ulcer (DFU), lower extremity amputation (LEA) and 
death; determine predictive variables and assess derived models accuracy. 
Material and Methods: Retrospective cohort study including all subjects with diabetes enrolled in our 
diabetic foot outpatient clinic from beginning 2002 until middle 2010. Data was collected from clinical 
records. 
Results: 644 subjects with mean age of 65.1 (±11.2) and diabetes duration of 16.1 (±10.8) years. 
Cumulative incidence was 26.6% for DFU, 5.8% for LEA and 14.0% for death. In multivariate analysis, 
physical impairment, peripheral arterial disease complication history, complication count and previous 
DFU were associated with DFU; complication count, foot pulses and previous DFU with LEA and age, 
complication count and previous DFU with death. Predictive models’ areas under the ROC curves 
ranged from 0.80 to 0.83. A simplified model including previous DFU and complication count presented 
high accuracy. Previous DFU was associated with all outcomes, even when adjusted for complication 
count, in addition to more complex models. 
Conclusions: DFU seems more than a marker of complication status, having independent impact on 
LEA and mortality risk. Proposed models may be applicable in healthcare settings to identify patients 
at higher risk of DFU, LEA and death. 
 
Keywords: Diabetes ∙ Diabetic Foot ∙ Foot ulcer 
 
EFFECT OF HYPERBARIC OXYGEN THERAPY IN DIABETIC FOOT ULCER HEALING: A SYSTEMATIC REVIEW AND META-ANALYSIS 
 
Aims: Conduct a systematic review, with meta-analysis (MA), considering hyperbaric oxygen therapy 
(HBOT) efficacy for diabetic foot ulcer (DFU) treatment; identify variables affecting outcome; grade 
overall methodological quality. 
Material and Methods: We searched the National Library of Medicine, Rubicon Foundation Research 
Repository and hand-searched relevant scientific meeting abstract books. Two investigators 
independently extracted data concerning study characteristics and clinical outcomes, one assessed 
methodological quality. 
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Results: Forty studies were included: 11 randomized controlled trials (RCT), 8 non-randomized 
comparative trials (NRT) and 22 observational studies. The mean proportion of items satisfied, using 
CONSORT and STROBE, when pertinent, methodological quality reporting checklists, was 47% and 29% 
respectively. Wound area reduction of 92-100% in the HBOT group at 6 months was reported, but MA 
was not possible. Pooled difference in time to healing was 0.8 months less in HBOT group (not 
statistically significant). More ulcers healed with HBOT than without and the chance of healing a DFU 
was significantly greater with HBOT. There were also significantly fewer major amputations in those 
undergoing HBOT. Pooled estimates did not achieve statistical significance when RCTs alone were 
included in analysis. Ten studies assessed independent variables’ impact on healing; only age and 
TcPO2 were evaluated in 2 or more studies. Two models proposed to identify subjects that would 
benefit most of HBOT were never externally validated. 
Conclusions: Although the overall methodological quality of these studies is poor, the existing evidence 
does suggest that HBOT is effective in DFU healing and decreasing the rate of major amputations. 
 
Keywords: Diabetes ∙ Diabetic Foot ∙ Foot ulcer ∙ Hyperbaric Oxygen Therapy ∙ Systematic review ∙ 
Therapy 
 
MOLECULAR ENVIRONMENT CHARACTERIZATION, HYPERBARIC OXYGEN THERAPY MODULATOR EFFECT AND CLINICAL 
IMPACT ON DIABETIC FOOT ULCERS’ HEALING 
 
Aims: To compare, in subjects with diabetes mellitus (DM), molecular serum environment (angiogenic, 
vasculogenic and inflammatory markers) between those with and without active diabetic foot ulcer 
(DFU); assess hyperbaric oxygen therapy (HBOT) efficacy in DFU reduction and closure, serum markers 
modulation and microvasculature improvement. 
Material and Methods: We conducted a non-randomized trial enrolling a group of patients with DM 
without active DFU (n=5) and one with active DFU with no significant wound evolution after 8 weeks 
of standard therapy. We compared those treated with HBOT (n=14) with untreated ones (n=6), due to 
treatment refusal or contra-indication. Endpoints (determined at 3, 6 and 12 months) included: 
laboratory markers, clinical outcome, DFU size, percentage of epithelialization. 
Results: The sample mean age was 62 and DM duration 18 years. The majority were men, with type 2 
DM, insulin-treated, with several complications and acceptable glycaemic and lipid control. After 3 
months of HBOT, patients had a significant reduction in leukocyte and C-reactive protein serum levels, 
and of all DFU measurements. At every time points, the HBOT group achieved better outcomes (less 
amputation and death) and DFU reduction, with consequent increasing epithelialization percentage. 
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Comparison was not possible with the non-HBOT group as only one patient remained alive with active 
DFU and without major amputation at 3 months. Data points that after 1 month of HBOT, vessel 
number in the DFU tends to increase. 
Conclusions: Our data reinforces the potential molecular and clinical efficacy and benefit of HBOT when 
added to current standard treatment of DFU. 
 
Keywords: Diabetes ∙ Diabetic Foot ∙ Foot ulcer ∙ Hyperbaric Oxygen Therapy ∙ Therapy 
 
IMPROVING HYPERBARIC OXYGEN THERAPY REFERRAL FOR DIABETIC FOOT ULCER TREATMENT: A NATIONWIDE MODELS’ 
VALIDATION AND REFINEMENT STUDY 
 
Aims: This study characterizes the population with diabetic foot ulcer (DFU) undergoing hyperbaric 
oxygen therapy (HBOT) in Portugal over the last 5 years. 
Material and Methods: Validation and optimization of the existing models for the prediction of healing 
of HBOT treated DFU; through a multicentre retrospective cohort study of all patients undergoing such 
therapy due to DFU from 2008 to mid-2013 in Portuguese continental hyperbaric medicine centres 
(n=2).  
Results: We included 128 individuals. 66.4% underwent HBOT in Lisbon’s former Navy’s Hospital. 
Subjects from this hospital presented less frequently retinopathy (19.6% versus 74.5%, p<0.001) and  
previous DFU (29.2% versus 53.5%, p=0.02) and had ulcers of shorter duration (median 1.8 versus 4.0 
months, p<0.001) than Pedro Hispano’s Hospital. Overall, 53.1% healed, which was more likely in non-
smoking females without arterial disease, previous DFU or history of lower extremity amputation. Both 
completion of the planned series of treatments and increasing number of treatments had a positive 
impact on outcome. Available models had low predictive accuracy. We propose an optimized version 
of the Hawkins’ model that has higher accuracy.  
Conclusions: There were some differences in the patients referred to each of these facilities, but 
healing rates were similar. Further studies are still needed to improve referral criteria for HBOT. 
 
Keywords: Diabetes ∙ Diabetic Foot ∙ Foot ulcer ∙ Hyperbaric Oxygen Therapy ∙ Therapy
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Sumário 
ÚLCERA DE PÉ DIABÉTICO EM INDIVÍDUOS COM DIABETES COMO FACTOR DE RISCO INDEPENDENTE DE AMPUTAÇÃO E 
MORTALIDADE 
 
Objectivos: Estimar o risco de úlcera de pé diabético (UP), amputação do membro inferior (AMI) e 
morte a 3 anos; determinar as variáveis preditivas e avaliar a validade do modelos derivados. 
Material e Métodos: Estudo de coorte retrospectivo incluindo todos os sujeitos com diabetes seguidos 
na nossa consulta de Pé Diabético entre o início de 2002 e meados de 2010. Os dados foram colhidos 
dos registos clínicos.  
Resultados: Incluímos 644 sujeitos com idade média de 65.1 (±11.2) e duração de diabetes de 16.1 
(±10.8) anos. A incidência cumulativa foi de 26.6% para UP, 5.8% para AMI e 14.0% para mortalidade. 
Na análise multivariada, limitação física, história de complicação de doença arterial periférica, número 
de complicações e UP prévia demonstraram associação com UP; número de complicações, pulsos 
podológicos e UP prévia com AMI e idade, número de complicações e UP prévia com morte. As áreas 
sob a curva ROC dos modelos derivados variaram entre 0.80 e 0.83. Um modelo simplificado incluindo 
apenas UP prévia e número de complicações apresentou validade elevada. UP prévia associou-se com 
todos os outcomes, mesmo quando ajustada para número de complicações ou para modelos mais 
complexos. 
Conclusão: UP parece ser mais do que um marcador de complicações instaladas, tendo um impacto 
independente no risco de AMI e mortalidade. Os modelos propostos podem ser utilizados em diversos 
contextos clínicos para identificar os sujeitos em maior risco de UP, AMI e morte. 
 
Palavras-Chave: Diabetes ∙ Pé Diabético ∙ Úlcera 
 
EFEITO DA OXIGENOTERAPIA HIPERBÁRICA NO TRATAMENTO DE ÚLCERAS DE PÉ DIABÉTICO: UMA REVISÃO SISTEMÁTICA E 
META-ANÁLISE 
 
Objectivos: Realizar uma revisão sistemática e meta-análise (MA), avaliando a eficácia da 
oxigenoterapia hiperbárica (OHB) no tratamento de úlceras de pé diabético (UP) em indivíduos com 
Diabetes Mellitus; identificar as variáveis preditivas; avaliar a qualidade metodológica da evidência 
disponível. 
Material e Métodos: Foi realizada uma pesquisa electrónica nos National Library of Medicine e Rubicon 
Foundation Research Repository e manual dos resumos de reuniões científicas relevantes. Dois 
XX 
 
investigadores seleccionaram os estudos e extraíram os dados e desfechos clínicos de forma 
independente, um avaliou a qualidade metodológica. 
Resultados: Foram incluídos 40 estudos: 11 ensaios clínicos randomizados (ECR), 8 não randomizados 
(ECNR) e 22 estudos observacionais. A média de proporção de items reportados foi 47% e 29% para a 
CONSORT e a STROBE, respectivamente. A redução da área da ferida foi 92-100% no grupo OHB aos 6 
meses (não foi possível MA). O grupo OHB demorou menos 0.8 meses até cicatrização (sem atingir 
significância estatística). As feridas com OHB cicatrizaram mais frequentemente. Ocorreram 
significativamente menos amputações major nos indivíduos sob OHB. As estimativas agregadas, 
incluindo somente os ECNR, não atingiram significância estatística. Apenas 10 estudos analisaram a 
associação de variáveis independentes com a cicatrização; só a idade e TcPO2 foram avaliadas por 2 ou 
mais estudos. Os 2 modelos existentes para identificar os sujeitos que mais beneficiarão da OHB nunca 
foram validados externamente. 
Conclusões: Embora a qualidade metodológica dos estudos seja baixa, a evidência existente sugere 
que a OHB é eficaz na cicatrização das UP em indivíduos com diabetes, diminuindo o risco de 
amputações major. 
 
Palavras-chave: Diabetes ∙ Pé Diabético ∙ Úlcera ∙ Oxigenoterapia Hiperbárica ∙ Revisão Sistemática ∙ 
Terapêutica 
 
A OXIGENOTERAPIA HIPERBÁRICA NA EVOLUÇÃO CLÍNICA DE PATIENTES COM ÚLCERA DE PÉ DIABÉTICO ACTIVA: MELHORIA 
LOCAL E SISTÉMICA 
 
Objectivos: Comparar, em indivíduos com diabetes mellitus (DM), com e sem úlcera de pé diabético 
activa (UP), o ambiente molecular sérico (marcadores angiogénicos, vasculogénicos, inflamatórios); 
avaliar a eficácia da oxigenoterapia hiperbárica (OHB) na redução e cicatrização de UP, modelação de 
marcadores séricos e melhoria da microvascularização. 
Material e Métodos: Efectuámos um ensaio clínico não randomizado incluindo um grupo de 
participantes sem (n=5) e outro com UP sem melhoria após 8 semanas de tratamento convencional. 
Comparámos os sujeitos tratados com OHB (n=14) com os não tratados (n=6), por recusa ou contra-
indicação. Os objectivos (aos 3, 6 e 12 meses) foram: marcadores laboratoriais, desfecho clínico, 
dimensões da UP e percentagem de epitelização. 
Resultados: Na amostra, a idade média foi 62 e duração de DM 18 anos. A maioria eram homens, com 
DM tipo 2, várias complicações e controlo glicémico e lipídico aceitável. Após 3 meses de OHB, ocorreu 
uma redução significativa do nível sérico de leucócitos e proteína C-reactiva e de todas as dimensões 
da UP. Em todos os períodos, o grupo OHB apresentou melhores desfechos (menos amputações e 
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morte), redução da UP e consequente aumento da percentagem de epitelização. Não foi possível 
comparar com o grupo não-OHB visto apenas um indivíduo se manter vivo e sem amputação major 
aos 3 meses. Os resultados indicam que 1 mês de OHB tende a aumentar o número de vasos no leito 
da UP. 
Conclusões: Os resultados reforçam o potencial efeito e benefício da OHB a nível molecular e clínico, 
quando adicionada ao tratamento convencional da UP. 
 
Keywords: Diabetes ∙ Pé Diabético ∙ Úlcera ∙ Oxigenoterapia Hiperbárica ∙ Terapêutica 
 
OPTIMIZAÇÃO DA REFERENCIAÇÃO DE INDIVÍDUOS COM DIABETES COM ÚLCERAS DE PÉ DIABÉTICO PARA TRATAMENTO 
COM OXIGENOTERAPIA HIPERBÁRICA: VALIDAÇÃO E REFINAMENTO DE MODELO COM BASE NACIONAL  
 
Objectivos: Este estudo caracteriza a população com diabetes e úlcera de pé diabético (UP) activa que 
efectuaram Oxigenoterapia Hiperbárica (OHB) em Portugal nos últimos 5 anos. 
Material e Métodos: Validação e optimização dos modelos existentes para a predição de cicatrização 
de UP tratadas com OHB, através de um estudo de coorte retrospectivo multicêntrico de todos os 
pacientes tratados com OHB, de 2008 a meados de 2013, nos centros de Medicina Hiperbárica em 
Portugal continental (n=2). 
Resultados: Foram incluídos 128 indivíduos; 66.4% realizam OHB no Antigo Hospital da Marinha de 
Lisboa. Utentes provenientes deste hospital apresentavam menos retinopatia (19.6% versus 74.5%, 
p<0.001) e história de UP prévia (29.2% versus 53.5%, p=0.02) e as UP tinham menor duração (mediana 
1.8 versus 4.0 meses, p<0.001) do que os do Hospital Pedro Hispano. No total, 53.1% das UP 
cicatrizaram, mais frequentemente em mulheres, não fumadoras, sem doença arterial periférica, 
história prévia de UP ou amputação. A realização da totalidade do tratamento prescrito e um maior 
número de sessões influenciaram positivamente o desfecho. Os modelos preditivos disponíveis 
apresentaram baixa validade, pelo que propusemos uma versão optimizada do modelo de Hawkins 
com melhores resultados. 
Conclusões: Verificámos diferenças nas características dos indivíduos de cada instituição, mas a 
proporção de cicatrização foi semelhante. São necessários mais estudos para que se possa melhorar 
os critérios de referenciação para OHB.  
 
Palavras-chave: Diabetes ∙ Pé Diabético ∙ Úlcera ∙ Oxigenoterapia Hiperbárica ∙ Terapêutica
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II. Aims and outline 
With this project we aimed to study the effects of hyperbaric oxygen therapy (HBOT) in the treatment 
of diabetic foot ulcers (DFU), namely the molecular and clinical effects, and consequently to improve 
the available evidence supporting this therapy.  
In order to do so we have developed 4 main studies presented throughout this thesis. 
 
In this Chapter II the structure of the thesis is described, while in Chapter III a short comment 
concerning the importance of this thesis conduction is performed. 
 
Chapter IV, Section A, diabetic foot epidemiology and healing process impairment are overviewed and 
the results of a retrospective cohort study, characterizing the population followed in our Outpatient 
Diabetic Foot Clinic, where the molecular studies were conducted, in terms of demographic and clinical 
variables; estimating the 3- and 5-year risk of DFU development, lower extremity amputation (LEA) 
and death; and determining causes and predictive variables for these outcomes occurrence, are 
presented. 
 
Chapter IV, Section B consists in detailing HBOT mechanisms, physiologic and therapeutic effects, side 
effects and complications, as well as, its clinical application. 
 
Chapter IV, Section C is composed of a systematic review and meta-analysis (MA) assessing the 
available evidence concerning systemic HBOT effectiveness for the DFU treatment. With this study, we 
aimed to a) characterize available evidence assessing HBOT effectiveness for the DFU treatment, b) 
assess independent variables’ associated with healing, c) calculate pooled measures for minor and 
major LEA risk and d) identify methodological limitations of the published data. 
 
In Chapter V, HBOT effectiveness in DFU is assessed. A non-randomized human trial is described, 
assessing molecular environment characterization, along with HBOT modulator effects in order to a) 
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identify and compare baseline angiogenic, vasculogenic and inflammatory markers in 3 groups of 
patients: 1) subjects with diabetes and without DFU, 2) with DFU and 3) with DFU treated with HBOT. 
In the last 2 groups, markers reassessment is performed at 3 months, to detect molecular differences 
due to HBOT. To understand if those effects persisted long term, in the HBOT group, a re-evaluation 
was carried out at 6 months. HBOT effectiveness in DFU healing was made by comparing outcome 
(healing, improvement, LEA and death), DFU dimensions, percentage of wound epithelialization and 
microvessel density analysis at different time points (3, 6 and 12 months) in the DFU groups. 
 
Chapter VI consists in a nationwide multicentre retrospective cohort study, assessing the variables 
associated with DFU’s outcome when treated with HBOT, validating and refining a predictive model 
for DFU outcome in subjects undergoing this therapy, and reporting prognostic accuracy measures. 
 
In Chapter VII, main conclusions and limitations are described in a standardized manner, addressing 
the studies strengths and limitations, and future research to overcome them is presented. 
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III. Rationale 
Worldwide, diabetes mellitus (DM) is one of the most frequent metabolic disorders [Wild S 2004, IDF 
2013] and its global burden is attributed to its several complications, namely DFU with impaired 
healing, that frequently requiring LEA [Frykberg R et al, 2006; Margolis D et al, 2008; Sun J et al, 2012]. 
The occurrence of a DFU bodes poorly for the clinical course of patients with diabetes, with higher 
rates of re-ulceration, LEA, contralateral LEA and death, compared to persons with diabetes who 
have not experienced a DFU [Frykberg R et al, 2006].  
Given the limited health care resources, it is important to optimize their allocation. To do so, an 
adequate stratification of subjects with diabetes by their risk of morbidity, namely DFU and LEA, 
as well as mortality, is crucial. Thus, identification of variables associated with these outcomes is 
the first step in the pathway for the creation or optimization of preventive/therapeutic 
programmes.   
Even though the cascade of diabetic foot complications-DFU-LEA has been linked to higher 
mortality risk [Fortington LV, 2013], increasing number of DM complications is also associated with 
higher mortality [Brownrigg JR, 2012]. DFU is usually considered a marker of diabetes complication 
status, i. e., a marker for neuropathy and associated disease in the foot. Still, some authors 
hypothesized that DFU occurrence could be, per se, an independent predictive variable of LEA as 
well as mortality [Boyko EJ et al, 1996]. 
Nevertheless, adjustment for baseline complications was rarely conducted when assessing the 
impact of DFU on LEA, and of both on the mortality risk [Boyko EJ et al, 1996]. In addition, simple models 
for their prediction (specially using the same core variables) were seldom proposed. 
Given the current state of knowledge, we considered essential to estimate the risk for DFU, LEA 
and death in a cohort of patients with diabetes followed in our Diabetic Foot Outpatient Clinic and 
determine factors that independently predict LEA and mortality. This was the first step of this 
thesis, in order to assess whether it was pertinent and valuable to address a treatment modality 
for DFU in our population. 
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In our sample of 644 subjects, in a high risk setting, during 2002-2010, the 3-year cumulative 
incidence for DFU was 26.6%, for minor LEA 2.7% and for major 3.1%, and 14.0% for death. It was 
possible to derive simple models for prediction of the three outcomes, and we concluded that DFU 
was independently associated with LEA and death.  
Several mechanisms are described in the literature explaining such associations. For example, 
peripheral arterial disease (PAD) impairs wound healing, due to inadequate circulation, and has 
been independently associated with both LEA [Adler A et al, 1999] and DFU [Boyko E et al, 1999]. 
We observed a higher rate of DFU development (>8% annually), but a similar of LEA and death, 
compared to several studies [Monteiro-Soares M et al, 2011; Schaper N, 2012]. However, measures to improve 
these figures are still required, and so methods for DFU adequate treatment and prevention are 
essential.  
This thesis emphasizes DFU therapy, for it is very challenging. Reported life time LEA rates range 
from 6.4 to 43% [Margolis D et al, 2008; Sun J et al, 2012]. Non-traumatic LEAs are up to 40 times [Fard et al, 2007] 
more frequent in subjects with diabetes [Boulton A et al, 2005; Frykberg R et al, 2006]. Despite this great clinical 
need, several authors consider the available evidence addressing DFU treatment to be very poor 
[Mason et al, 1999]. 
One of such treatments is HBOT that aims to induce several physiologic and therapeutic effects. 
Nevertheless, it is an expensive therapy, with limited availability, thus, identification of patients 
with best possible response is fundamental for proper allocation of limited healthcare resources. 
Therefore, a systematic review and MA was conducted, evaluating all available evidence assessing 
the efficacy of systemic HBOT for DFU, identifying the independent predictors of outcome and the 
methodological limitations in the existing evidence. With such study, we observed that HBOT 
induces higher chance of DFU healing and lower risk of LEA. However, several limitations in the 
existing evidence were noticed, namely, small sample sizes, differences in treatment protocols, 
poor methodological quality and, for all these, a high heterogeneity in the calculated measures. 
In addition, animal studies point that HBOT, by raising tissue oxygenation in chronically hypoxic 
tissues, stimulates a number of elements required for wound healing, including angiogenesis, 
collagen synthesis and reactivation of the oxygen-dependent phagocytic capacity of leukocytes. 
Combined with the demonstrated ability of even a single HBOT session to mobilise endothelial 
progenitor cells (EPCs) from the bone marrow in diabetic individuals, all these actions  promote 
active healing in a chronic, non-healing DFU [Gallagher et al, 2006; Thom SR et al 2006; Thom SR et al, 2011; Yang B et 
al, 2007].  
However, studies in humans with diabetes and active DFU are still lacking. 
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Hence, we considered essential to compare, in subjects with diabetes, the molecular serum 
environment between those with and without active DFU and assess HBOT modulation and clinical 
efficacy at 3, 6 and 12 months. Our results showed that HBOT was effective in improving healing. 
Nevertheless, we were unable to fully understand the molecular mechanisms behind our good 
clinical results. 
With our systematic review, we detected a lack of studies addressing the factors associated with 
improved healing and only 2 predictive models were retrieved, without ever being externally 
validated, for the identification of the subjects that would benefit most of HBOT. 
In Continental Portugal, there are only two Hyperbaric Medicine Centres treating patients with 
active DFU, one in Oporto, located in Pedro Hispano’s Hospital (PHH) in Matosinhos (a public civil 
hospital, referral area from the north to the centre of the country) and one in Lisbon, in the former 
Navy’s Hospital (FNH) (military hospital, referral area from the centre to the south). Recently, 
hyperbaric centres in the archipelagos have also started treating DFU patients. In our clinical 
experience, we have noticed large variations in the clinical criteria when referring patients for 
HBOT.  
Given these disparities, we decided to characterize the Portuguese population undergoing HBOT 
in the last 5 years, to understand Portugal’s pattern of DFU referral and subsequent outcome, and 
to propose an optimal simple referral model. Such goal was achieved and, despite several 
differences were observed between the studied institutions, healing rates were similar. 
In sum, with this project we hope to have improved the evidence around DFU treatment with 
HBOT, in a translational manner. Firstly, assessing potential impact of HBOT in our context by 
evaluating diabetic foot complications development and death rates. Secondly, evaluating the 
available evidence about this topic to detect the possible need of further studies. As we concluded 
that there was a lack of biochemical and clinical studies with adequate methodological report, we 
performed one addressing molecular markers and clinical evolution and another improving 
referral protocol. 
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IV. Background 
A. Diabetic foot 
1. Healing cascade 
Wound healing is a complex biological process involving several coordinated pathways. It is 
characteristically divided in four different phases: haemostasis, inflammation, proliferation and tissue 
remodelling [Young A, 2011], that overlap in time. 
The process of healing encompasses numerous steps including haemostasis, removal of necrotic 
material and bacteria, inflammation terminus, extracellular matrix repair, neovascularization, 
epithelialization and remodeling [Li J et al, 2007; Young A, 2011]. We must emphasize that the majority of these 
stages are dependent on oxygen content [Eming SA et al, 2007 A; Sen C, 2008; Tandara A & Mustoe T, 2004; Young A, 2011]. 
Haemostasis involves arteriolar constriction and posterior dilatation, clot formation through the 
pathways of the clotting cascade and platelet activation. Platelets also synthesize many factors that 
regulate various cell types and contribute to the inflammatory phase [Li J et al, 2007; Young A, 2011]. 
Immediately after a lesion occurs, inflammation begins with different types of leukocytes being 
attracted to the wound and releasing several mediators, including growth factors, which begin, 
maintain or finish angiogenic response and also recruiting other cell types. Neutrophils, the first to 
arrive, ingest and destroy bacteria through phagocytosis, degranulate and release several substances 
to destroy microorganisms and tissue debris, and produce oxygen reactive species (ROS) that have 
bactericidal effect [Eming SA et al, 2007 A; Li J et al, 2007; Young A, 2011].   
In the proliferative phase, fibroblasts invade the wound bed, proliferate, synthesize extra-cellular 
matrix components, namely collagen, and later differentiate to a contractile phenotype, the 
myofibroblast, that connects to surrounding tissues, and is involved in wound contraction [Eming SA et al, 
2007 A; Li J et al, 2007; Young A, 2011].  
Neovascularization can occur through angiogenesis, by activation and migration of mature resident 
endothelial cells, and/or vasculogenesis, from undifferentiated angioblasts or EPCs both in 
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embryogenesis or bone marrow-derived in adults [Stavrou D, 2008; Velasquez OC, 2007]. This is an essential 
process for the different phases’ occurrence.  
During epithelialization, the epithelial cells migrate from the edges of the wound to cover its surface 
[Eming SA et al, 2007 A; Li J et al, 2007; Young A, 2011]. 
Finally, during tissue remodeling, with synthesis and degradation of several components the scar is 
altered to achieve a structure similar to unwounded tissue [Eming SA et al, 2007 A; Young A, 2011]. 
Several biochemical factors are essential for an adequate healing process. 
Vascular Endothelial Growth Factor (VEGF) family is composed of 7 elements: VEGF-A to F and 
Placental Growth Factor (PlGF). VEGF family and their receptors (VEGFR) are mediators of the embryo 
vascular development and of the adult angiogenesis processes (both physiological and pathological), 
including wound healing. VEGF-A is the most studied; its transcription is regulated by several factors 
such as growth factors, pro-inflammatory cytokines, hormones and cellular stress [including hypoxia – 
namely through action of Hypoxia Inducible Factor 1 (HIF1)] [Eming SA et al, 2007 A; Beldon P 2010]. 
It was studied, in transgenic mice, the role of PlGF in healing, which promotes faster wound repair, 
with increase of the granulation tissue vasculatization. Soluble vascular endothelial growth factor 
receptor-1 (sVEGFR-1), a splicing variant of transmembranar VEGFR-1, is considered a natural inhibitor 
of VEGF-A. Studies revealed that sVEGFR-1 concentration in chronic wounds fluid is higher than its 
concentration in wounds that heal [Eming SA et al, 2007 A]. 
In diabetic patients and animal models, the number and function of circulating EPCs is highly 
decreased, and these alterations are related to the cardiovascular and healing complications in 
diabetes [Costa C et al, 2007; Fadini GP et al, 2005; Fadini GP, 2014; Laing T et al, 2007]. 
Stromal Cell Derived Factor 1- Alpha (SDF1-α) is a cytokine that induces mobilization of bone-marrow 
derived progenitor cells, mainly through the C-X-C Chemokine receptor type 4 [Velasquez OC, 2007]. 
Tumor necrosis factor-alfa (TNF-α), a factor with multiple functions, plays a central role in 
inflammation, therefore, being an intervenient in the inflammatory phase of healing [Schreml S et al, 2010].  
DM frequently leads to foot ulcers, through an already exhaustively described pathophysiologic 
process (Figure 1), and also to a defective wound repair due to alterations in the micro- and macro-
vasculature, cellular and molecular environment, as well as to the frequent presence of infection 
and/or neuropathy [Brem H & Tomic-Canic M, 2007; Costa C et al, 2007; Laing et al, 2007; van Weel et al, 2008].  
Diabetic patients and animal models have altered vasculature. In some territories, like retina, 
angiogenesis is increased, while in others, for instance distal microvasculature of the inferior limbs, it 
is decreased [Costa C et al, 2007; van Weel et al, 2008]. Studies have shown that diabetic mice, in whom the 
healing process is altered, have lower levels of VEGF-A mRNA and of the protein’s intracellular 
processing during wound repair and decreased angiogenesis [Costa C et al, 2007; Brem H & Tomic-Canic M, 2007].  
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Additionally, the diabetic environment induces several molecular changes by advanced glycation end 
products (AGEs) that link to their receptors (RAGEs), including pathways activation, altered dermal 
fibroblasts and keratinocytes proliferation [Blakytny R & Jude E, 2009; Schreml S et al, 2010] 
 
 
Figure 1. Diabetic foot ulcer pathophysiology  
 
 
(Adapted, with permission, from Monteiro-Soares, 2010) 
 
Local hypoxia is common. The optimum oxygen tissue pressure (pO2) is 50-100 mmHg but in many 
wounds it scarcely reaches 10 to 30 mmHg [Eming SA et al, 2007; van Weel et al, 2008]. On the other hand, one of 
the main reasons for delayed wound healing is a sustained inflammatory reaction [Eming SA et al, 2007 A; 
Eming SA et al, 2007 B; Schreml S et al, 2010]. For all this (Figure 2), DFUs frequently evolve to chronic wounds, 
which are lesions that do not heal in the usual time (4-6 weeks) with conventional therapy.  
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Figure 2. Healing impairment mechanism in the diabetic foot  
 
: Increase; : Decrease; AGEs: Advanced Glycation End product; EPCs: Endothelial Progenitor Cells; MMPs: Metalloproteinases; ROS: 
Reactive Oxygen Species 
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2. Epidemiology of Diabetes: national and international 
Approximately 8.3% of the world adult population, corresponding to 382 million people, has DM which 
turns this condition in one of the most frequent metabolic disorders [IDF 2013].  
Incidence and prevalence are continuously rising, consequently carrying high rates of morbid-
mortality, with premature deaths, and economic burden [IDF 2013]. In fact, it was reported that 2.5% to 
15% of global annual health care budgets are spent on DM, with an annual direct medical cost 
worldwide of around 241 billion dollars [WHO, 2013; Alavi A et al, 2014]. 
In Europe, it is calculated that 56 million people have DM, around 28% of deaths in people under 60 
years old are due to this disease [IDF 2013] and that the majority of these could be prevented [WHO, 2013; 
Alavi A et al, 2014]. 
In Portugal, during 2012, DM caused 4880 potential years of life lost in those less than 70 years and a 
total of 4867 deaths were attributed to this condition, corresponding to 4.5% of global mortality [OND, 
2013].  
In Oporto region, DM has a prevalence of 13.9% [OND, 2009], whereas the national one is 12.9% [OND, 2013]. 
We must highlight that the referral area of the Centro Hospitalar de Vila Nova de Gaia/Espinho, 
Entidade Pública Empresarial (EPE), Diabetic Foot Outpatient Clinic, where the clinical studies of this 
thesis were conducted, belongs to this higher prevalence region. 
Diabetic foot is one of the major DM complications and causes a considerable costs in health care and 
patient well-being. It is estimated that around 10 to 25% of subjects with diabetes will develop a DFU 
[Frykberg R et al, 2006], during their lifetime, from which 50 to 70% will recur in a 5 year period [Alavi A et al, 
2014]. 
Chronic DFU have a great impact in the subjects’ quality of life. It was stated that such individuals 
present from 10 to 40% lower quality of life scores when compared to the general population, being 
comparable to those with chronic lung disease, myocardial infarction, and breast cancer [Armstrong DG et 
al, 2008]. 
On the other hand, treating DFU represents substantial costs, with the highest impact being associated 
with the consequent LEA [Akhtar S et al, 2011] and rehabilitation.  
In Portugal alone, 1493 LEA were performed in 2012 due to diabetic foot complications (730 major and 
763 minor LEA) [OND, 2013], with major differences between the regions being noticed. In the last 
National Observatory report it is stated that fewer major LEA are conducted in the North region, where 
Oporto is included. Along this thesis some possible explanations will be discussed.  
Nevertheless, several studies confirm that treating successfully a DFU is consistently more cost-
effective when compared to the expenses of performing a major LEA [Alavi A et al, 2014; Morbach S, 2003].  
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For all this, the development and/or improvement of therapeutic options for the DFU healing are 
crucial. 
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3. The independent contribution of diabetic foot ulcer on lower extremity 
amputation and mortality risk 
Material and Methods 
Subjects 
A retrospective cohort study was conducted including all subjects with diabetes followed in Centro 
Hospitalar de Vila Nova de Gaia/Espinho, Entidade Pública Empresarial (EPE), Diabetic Foot Outpatient 
Clinic from the 1st of January 2002 until the 31st of May 2010.  
Subjects were excluded if they met any of the following criteria: active DFU at the moment of inclusion, 
inability to ambulate, communication or cognitive impairment (due to aphasia and/or dementia), 
missing data on any covariate (except for vibration sensation assessed using a tuning fork and HbA1c), 
follow-up period of less than 3 years, or living outside our referral area. 
The Diabetic Foot Clinic is a tertiary care unit, with a multidisciplinary team and specialized diabetic 
foot care, treating patients from primary care institutions (usually with high risk feet and/or 
unavailable appropriate care in their residence area) or from other departments and hospitals. 
The study was approved by the Ethics Committee of our institution and no adverse event occurred in 
any subject due to participation in this research. 
 
Data collection 
Clinical records were reviewed and data collected from 1st until the 30th of June 2013. 
All variables were collected in the first podiatric appointment in the clinic, through a structured 
interview and detailed foot exam, apart from HbA1c, by one of the two department podiatrists who 
were experienced in the care of diabetic foot complications. 
Demographic characteristics (age at the time of inclusion, gender, education level), DM type (classified 
according to the World Health Organization definition [WHO, 2006]), duration and treatment (diet only, 
oral medication or insulin), metabolic control [through glycated haemoglobin (HbA1c)], physical 
(inability to reach his/hers own feet [Monteiro-Soares M et al, 2012]) and/or visual impairment and smoking 
habits (absent, current, former) were recorded. 
DM complications [retinopathy, nephropathy, neuropathy, cerebrovascular, cardiovascular, PAD and 
metabolic (ketoacidosis, hyperosmolar coma or other coma)] were classified in accordance to the 
Diabetes Complications Severity Index created by Young et al [Young BA et al, 2008], according to their 
protocol, using the International classification of diseases, 9th revision (ICD-9) Codes, through clinical 
record review. 
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As Young et al concluded that the accuracy of the number of complications was similar to the 
Complication Severity Index and as the number of complications is easier to calculate we opted to use 
it. Nephropathy was also staged by the American Diabetes Association (ADA) classification [ADA, 2013], 
using the serum creatinine value closest to the date of the first appointment. 
Participants’ feet were characterized using the variables more frequently described in DFU 
development risk stratification systems [5] and with proved association with its occurrence [Monteiro-
Soares M et al, 2012], namely, the presence of deformities, onychomycosis, diabetic peripheral neuropathy 
(DPN) [using the Texas Verbal Questionnaire [Armstrong DG et al, 1998 A], Semmes-Weinstein monofilament 
(SWM) insensitivity and tuning fork vibration sensation], PAD (characterized by total foot pulses and 
intermittent claudication), oedema and history of previous DFU or LEA. There is a lack of studies 
assessing the reliability of these measurements [Monteiro-Soares M et al, 2012]. Previous DFU was collected 
through foot assessment, patient self-report and all were additionally confirmed by medical record 
review. All the above described variables in addition to visual and/or physical impairment, presence of 
onychomycosis and DFU occurrence were collected and defined according to the protocol previously 
described by Monteiro-Soares et al [Monteiro-Soares et al, 2010 B]. 
Vibration sensation test (VST) was assessed with a 128 Hz tuning fork applied, perpendicularly with a 
constant pressure, on a bony part on the dorsal side of the distal phalanx of the first toe. 
This procedure was repeated twice and two incorrect answers were classified as altered sensation 
[Bakker K et al, 2012]. This procedure was instituted in 2008 and therefore patients that entered into the 
study prior to this time do not have this assessment. 
Subjects were followed from the time of inclusion to death or completion of the 3-year follow-up. 
Minor LEA was defined as the surgical removal of toe(s), ray(s) or forefoot. Major LEA was considered 
amputation of the entire foot by any level of the leg (including the ankle). 
HbA1c value was not always available (n= 164) as several patients were followed for their metabolic 
control mainly by primary care physicians. 
DFU and/or LEA occurrence and death dates were registered. Subjects were advised to contact the 
clinic if any lesion developed and during appointments they were asked if any DFU occurred. 
Furthermore, complete medical records from the hospital as well as primary care institutions were 
reviewed in order to detect missed events. LEA and death (date and cause) are automatically registered 
in the individuals’ computerized clinical file. Death causes were collected using the ICD-9 codes. 
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Statistical analysis 
Association between variables and outcomes (DFU, LEA or death) was conducted using univariate 
logistic regression. Values of p ≤ 0.05 were considered as statistically significant and ≤ 0.1 as pertinent 
for initial inclusion into the predictive models. Multivariate analysis to estimate odds ratios (OR) for 
amputation and mortality in relation to DFU adjusted for covariates was performed using logistic 
regression analysis employing a backwards stepwise algorithm approach. In addition, all multivariable 
models included age, gender and diabetes duration. 
After the model creation for each outcome, a multivariable score was computed for each subject using 
the β coefficient values and the actual values for the covariates for those subjects. The ability of the 
score to discriminate between patients who did and did not develop the outcomes of interest was 
assessed using the area under the receiver operating characteristic curve (AUC) with the 95% 
confidence interval (CI). 
All statistical analyses were conducted using the programme IBM SPSS, version 20.0 (Chicago, IL, USA). 
Missing and indeterminate results were excluded from analysis. 
 
 
Results 
Participant characteristics 
In this study, 644 subjects were included and followed for a median of 36 months (range 1-36). 
At baseline, patients had a mean age of 65.1 (±11.2) years; mean diabetes duration of 16.1 (±10.8) 
years; and mean HbA1c of 7.8% (±3.7). The majority had type 2 DM and less than half were on insulin. 
More than half were female; over 80% were undereducated (primary school level or less) and over a 
quarter had some form of impairment (visual and/or physical). The most frequent complications were 
PAD related (63.0%) and the least frequent was metabolic complication history (3.6%). Forty-one 
percent of our population had a history of previous DFU (Table 1). 
Cumulative incidence at 3 years for DFU and the outcomes of interest was as follows: DFU 26.6% (95% 
CI 23.2-30.0), recurrent DFU 34.5% (95% CI 27.4-48.4), minor LEA 2.7% (95% CI 1.4-4.0), major LEA 
3.1% (95% CI 1.8-4.4), total LEA 5.8% (95% CI 3.9-7.5) and death 14.0% (95% CI 11.3-16.7). 
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Table 1: Participants baseline characteristics 
Variables 
Values 
(n= 644) 
SUBJECT CHARACTERIZATION 
Age [mean (SD)] 65.1 (11.2) 
Female gender [n (%)] 339 (52.6) 
Analphabetic or primary school [n (%)] 529 (82.2) 
Visual impairment [n (%)] 248 (38.5) 
Physical impairment [n (%)] 237 (36.8) 
Past or present smoker [n (%)] 134 (20.8) 
DM AND ITS COMPLICATIONS 
Type 2 [n (%)] 629 (97.7) 
Duration (in years) [mean (SD)] 16.1 (10.8) 
Insulin use [n (%)] 260 (40.4) 
HbA1c (in %) [mean (SD)]a 7.8 (3.7) 
Cardiovascular complications history [n (%)]b 219 (34.0) 
Retinopathy [n (%)]b 297 (46.1) 
Laser photocoagulation [n (%)] 211 (32.8) 
Nephropathy [n (%)]b 98 (15.2) 
4-5 stage in ADA classification [n (%)] 37 (5.8) 
PDV complications history [n (%)]b 406 (63.0) 
Neuropathy complications history [n (%)]b 340 (52.8) 
Metabolic complications history [n (%)]b 23 (3.6) 
Complications count [mean (SD)]b 1.7 (1.1) 
FOOT CHARACTERIZATION  
Foot deformity [n (%)] 503 (78.1) 
Oedema [n (%)] 165 (25.6) 
Onychomycosis [n (%)] 379 (58.9) 
Total foot pulses ≤ 2 [n (%)] 241 (37.4) 
Intermittent claudication [n (%)]c 180 (28.2) 
DPN symptoms [n (%)] 395 (61.3) 
Altered SWM sensation [n (%)]d 309 (49.6) 
Altered VST [n (%)]e 134 (33.9) 
Previous DFU [n (%)] 264 (41.0) 
Previous LEA [n (%)] 74 (11.5) 
 
a: 164 missing values, b: Using the Young et al (2008) proposed complications’ classification,c: 7 indeterminate values, d: 21 indeterminate 
values,e:249 indeterminate/missing values, HbA1c: Glycated Hemoglobin, ADA: American Diabetes Association, DFU: Diabetic Foot Ulcer, 
DM: Diabetes Mellitus, DPN: Diabetic Peripheral Neuropathy, LEA: Lower Extremity Amputation, SD: Standard Deviation, SWM: Semmes-
Weinstein Monofilament, VST: Vibration Sensation Test 
 
DFU development risk variables 
In univariate analysis, variables associated with DFU occurrence were age, gender, visual impairment, 
physical impairment, DM duration, retinopathy, nephropathy, PAD complications history, neuropathy 
complications history, complication count, and all foot characteristic variables except oedema.  
In multivariate analysis only physical impairment, PAD complications history, complications count and 
previous DFU remained statistically significant (Table 2). Using these variables we were able to create 
a model that discriminated between those patients who did and did not develop a DFU with AUC value 
of 0.80 (Figure 3). Considering a simplified model that included complications count and previous DFU 
only, the AUC value was 0.79 (CI 95% 0.76-0.83) (Figure 4). 
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Previous DFU history remained associated with greater risk of incident DFU (p<0.001) even when 
adjusted for age, gender, visual and physical impairment, diabetes type and duration, PAD 
complications history, complication count and previous LEA. 
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Table 2: Variables association with diabetic foot ulcer, lower extremity amputation and death occurrence 
 
Variables 
DFU (n= 171) LEA (n= 37) Death (n= 90) 
Univariate OR 
(95% CI) 
Multivariate 
OR (95% CI) 
Univariate 
OR (95% CI) 
Multivariate 
OR (95% CI) 
Univariate OR 
(95% CI) 
Multivariate 
OR (95% CI) 
SUBJECT CHARACTERIZATION      
Age 
1.02 
(1.01-1.04) 
NS 
1.03 
(0.99-1.07) 
- 
1.13 
(1.09-1.16) 
1.12 
(1.09-1.15) 
Female gender 
0.49 
(0.35-0.70) 
NS 
0.47 
(0.23-0.93) 
NS 
0.65 
(0.41-1.02) 
- 
Analphabetic or primary school 
1.55 
(0.95-2.55) 
- 
1.85 
(0.64-5.32) 
- 
1.10 
(0.61-2.00) 
- 
Visual impairment 
1.60 
(1.12-2.28) 
NS 
2.20 
(1.12-4.30) 
NS 
1.73 
(1.11-2.71) 
NS 
Physical impairment 
2.38 
(1.67-3.41) 
1.73 
(1.15-2.59) 
2.11 
(1.09-4.12) 
NS 
1.99 
(1.27-3.11) 
NS 
Past or present smoker 
1.06 
(0.78-1.44) 
- 
1.05 
(0.47-2.36) 
- 
0.92 
(0.61-1.39) 
- 
DM AND ITS COMPLICATIONS      
Type 2 
2.39 
(0.53-10.69) 
NS NA a - NAa - 
Duration (in years) 
1.03 
(1.01-1.05) 
NS 
1.02 
(0.99-1.05) 
- 
1.03 
(1.01-1.05) 
NS 
Insulin use 
0.99 
(0.70-1.43) 
- 
1.64 
(0.80-3.39) 
- 
0.94 
(0.65-1.60) 
- 
HbA1c (in %) b 
1.05 
(0.97-1.14) 
- 
0.99 
(0.84-1.16) 
- 
1.02 
(0.97-1.08) 
- 
Cardiovascular complications history c 
1.32 
(0.91-1.89) 
- 
1.91 
(0.98-3.72) 
NS 
2.43 
(1.55-3.81) 
NS 
Retinopathy c 
1.62 
(1.14-2.31) 
NS 
1.57 
(0.81-3.08) 
- 
1.08 
(0.69-1.69) 
- 
Laser photocoagulation 
1.63 
(1.14-2.35) 
NS 
1.61 
(0.82-3.15) 
- 
0.71 
(0.43-1.18) 
- 
Nephropathy c 
1.71 
(1.08-2.69) 
NS 
2.56 
(1.22-5.38) 
NS 
1.63 
(0.93-2.86) 
- 
4-5 stage in ADA classification 
2.81 
(1.44-5.50) 
NS 
2.81 
(1.03-7.69) 
- 
2.44 
(1.14-5.23) 
NS 
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PAD complications history c 
11.03 
(6.09-19.96) 
2.52 
(1.17-5.45) 
23.06 
(3.14-169.31) 
NS 
3.69 
(2.03-6.68) 
NS 
Neuropathy complications history c 
3.14 
(2.14-4.60) 
NS 
3.45 
(1.55-7.67) 
NS 
1.48 
(0.94-2.34) 
- 
Metabolic complications history c 
0.57 
(0.19-1.71) 
- NAd - 
2.26 
(0.87-5.89) 
- 
Complication count c 
2.03 
(1.69-2.43) 
1.31 
(1.03-1.67) 
2.17 
(1.57-3.01) 
1.74 
(1.15-2.62) 
1.76 
(1.42-2.18) 
1.50 
(1.17-1.94) 
FOOT CHARACTERIZATION       
Foot deformity 
2.03 
(1.25-3.25) 
NS 
0.74 
(0.35-1.57) 
- 
0.85 
(0.50-1.43) 
- 
Oedema 
1.10 
(0.74-1.63) 
- 
0.93 
(0.43-2.01) 
- 
1.55 
(0.96-2.51) 
- 
Onychomycosis 
1.75 
(1.21-2.53) 
NS 
0.58 
(0.30-1.12) 
- 
1.99 
(1.22-3.25) 
NS 
Total foot pulses ≤ 2 
3.43 
(2.39-4.94) 
NS 
8.04 
(3.47-18.62) 
4.17 
(1.76-9.88) 
2.51 
(1.59-3.94) 
NS 
Intermittent claudication e 
1.70 
(1.12-2.47) 
NS 
2.03 
(1.03-3.98) 
NS 
1.10 
(0.67-1.80) 
- 
DPN symptoms 
1.52 
(1.05-2.20) 
NS 
1.53 
(0.74-3.14) 
- 
0.94 
(0.59-1.48) 
- 
Altered SWM sensation f 
3.16 
(2.16-4.64) 
NS 
3.25 
(1.50-7.02) 
NS 
1.30 
(0.82-2.04) 
NS 
Altered vibration sensation testg 
3.54 
(2.21-5.68) 
NS 
5.03 
(1.74-14.61) 
NS 
2.38 
(1.31-4.33) 
NS 
Previous DFU 
8.74 
(5.80-13.17) 
4.54 
(2.79-7.38) 
10.35 
(3.97-26.93) 
5.54 
(2.09-14.72) 
2.46 
(1.56-3.87) 
1.73 
(1.04-2.88) 
Previous LEA 
5.12 
(3.09-8.47) 
NS 
4.22 
(2.02-8.82) 
NS 
0.72 
(0.33-1.56) 
- 
 
-: Not included in the multivariate analysis, a: Model extrapolated values due to reduced number of subjects with diabetes type 1 and no event occurrence in such group, b: 164 missing values, c: Using the Young et al 
(2008) proposed complications’ classification, d: Model extrapolated values due to reduced number of subjects with history of metabolic complications and no event occurrence in such group, e: 7 indeterminate values, 
f: 21 indeterminate values, g: 249 missing values, HbA1c: Glycated Hemoglobin, ADA: American Diabetes Association, CI: Confidence Interval, DFU: Diabetic Foot Ulcer, DM: Diabetes Mellitus, DPN: Diabetic Peripheral 
Neuropathy, FU: Follow Up, LEA: Lower Extremity Amputation, NA: Not Applicable, NS: No Statistical significant association was observed, OR: Odds Ratio, SD: Standard Deviation, SWM: Semmes-Weinstein 
Monofilament 
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Figure 3: Receiver operating characteristic curve of predictive models for diabetic foot ulcer (a), lower extremity amputation (b) and death (c) occurrence 
(a) (b) (c) 
 
 
  
 
Model score calculation 
-3.29 + 0.55 x Physical impairment + 0.93 x Peripheral 
arterial disease complication history presence + 0.27 x 
Number of complications count + 1.51 x Previous 
diabetic foot ulcer presence 
 
 
 
Area under the curve 
0.80 (Confidence Interval 95% 0.76-0.84) 
 
Model score calculation 
-6.01 + 0.55 x Number of complications count + 1.43 x 
≤2 foot pulses (out of 4) presence + 1.71 x Previous 
diabetic foot ulcer 
 
 
 
 
Area under the curve 
0.83 (Confidence Interval 95% 0.78-0.89) 
 
Model score calculation 
-10.70 + 0.11 x Age (in years) + 0.41 x Number of 
complications count + 0.55 x Previous diabetic foot 
ulcer 
 
 
 
 
Area under the curve 
0.81 (Confidence Interval95% 0.76-0.85) 
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Figure 4: Receiver operating characteristic curve of predictive models for diabetic foot ulcer (a), lower extremity amputation (b) and death (c) occurrence 
using only complication count and previous diabetic foot ulcer 
(a) (b) (c) 
   
 
Model score calculation 
-2.86 +  0.46 x Number of complications count + 1.84 x 
Previous diabetic foot ulcer presence 
 
 
Area under the curve 
0.79 (Confidence Interval 95% 0.76-0.83) 
 
Model score calculation 
-5.35 + 0.61 x Number of complications count + 1.91 x 
Previous diabetic foot ulcer 
 
 
Area under the curve 
0.81 (Confidence Interval  95% 0.74-0.87) 
 
Model score calculation 
-3.02 + 0.49 x Number of complications count + 0.51 x 
Previous diabetic foot ulcer 
 
 
Area under the curve 
0.69 (Confidence Interval 95% 0.63-0.74) 
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LEA occurrence risk variables 
In univariate analysis, variables associated with LEA were gender, visual and physical impairment, 
cardiovascular complications history, nephropathy, PAD complications history, neuropathy 
complications history, complication count, two or fewer of four foot pulses, intermittent claudication, 
altered SWM sensation and VST, and previous foot complications (DFU and/or LEA). 
In multivariate analysis only complication count, two or fewer of four foot pulses and previous DFU 
maintained statistical significance (Table 2), producing a score with an AUC value of 0.83 for the 
discrimination between those who did or did not experience an incident LEA (Figure 3). When using a 
simplified model, including only complications count and previous DFU, the AUC value was 0.81 (CI 
95% 0.74-0.87) (Figure 4). 
Once more, when adjusting for age, gender, physical impairment, diabetes duration, complication 
count, total foot pulses ≤2 and previous LEA, previous DFU maintained a statistically significant 
association with LEA risk (p=0.001). 
 
Death occurrence risk variables 
In univariate analysis, variables associated with death were age, visual and/or physical impairment, 
DM duration, cardiovascular complications history, end-stage renal disease, PAD complications 
history, complication count, onychomycosis, foot pulses, altered VST and previous DFU. 
Age, complication count and previous DFU were the only variables that remained statistically 
significant in multivariate analysis (Table 2). The resultant predictive model yielded an AUC value of 
0.81 in the discrimination between patients who did and did not die during follow-up (Figure 3). 
However, using the simplified model including complications count and previous DFU the AUC value 
dropped to 0.69 (CI 95% 0.63-0.74) (Figure 4). 
Once again, DFU history was associated with a higher mortality rate independent of age, gender, visual 
and physical impairment, diabetes duration, complication count and previous LEA (p<0.05) (data not 
shown). 
We must highlight that patients developing a DFU during follow-up also had a significantly higher death 
rate (OR 1.75, CI 95% 1.09-2.79), although the same was not observed when adjusting for previous 
DFU (OR 1.18, CI 95% 0.70-1.99) or among those who had an LEA during follow-up (OR 2.09, CI 95% 
0.95-4.58). 
The most frequent causes of death were infections (27.8%), oncologic disease (20%), and heart failure 
(9%) (Figure 5). 
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Figure 5: Causes of death 
 
ESRD: End-Stage Renal Disease 
ICD-9 codes verified 
Infection 52, 421, 464, 466, 480-488, 490-508, 519, 590, 595, 681, 682, 785 
Oncologic 151, 153, 154, 157, 161, 162, 171-174, 185, 188, 189, 191, 203 
Heart failure 428 
ESRD 250.4, 585 
Stroke 434, 436 
Myocardial infarction 410 
Trauma 800-804, 820-829 
 
Discussion 
Several investigations have assessed all-cause mortality in type 2 DM with the derivation and validation 
of multivariate models [Hayes AJ et al, 2013; Yang EX et al, 2008]. However, and despite the proved impact of DFU 
on mortality risk [Monteiro-Soares M et al, 2011; Robbins JM et al, 2008], it was not included in such models. 
On the other hand, DFU’s link with death occurrence has rarely been adjusted for other pertinent 
variables (such as age and baseline complications presence) [Boyko EJ et al, 1996]. 
Therefore, we have conducted this study assessing DFU impact on LEA and death risk, in a large cohort 
of consecutively enrolled subjects (n= 644), using the Strengthening of the Reporting of Observational 
Studies in Epidemiology (STROBE) [Vandenbroucke J et al, 2007] and STARD [Bossuyt PM et al, 2003] checklists as the 
Unknown
Other
Trauma
Myocardial infarction
Stroke
ESRD
Heart failure
Oncologic
Infection
11
10
3
4
4
5
10
18
25
Number
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basis for its development and reporting, and conducting adequate statistical adjustment. Moreover, 
due to the cohort design, observers were blind to outcome occurrence when collecting baseline data. 
We observed that the different outcomes on which we focused shared several common predictive 
variables in univariate analysis, such as physical impairment; cardiovascular and PAD complications 
history, complications count; total foot pulses number, altered VST and previous DFU. However, few 
remained statistically associated in multivariate analysis, and different predictors of the outcomes of 
interest were seen across the three models for the outcomes DFU, LEA, and death, with the exception 
of complications count and previous DFU. 
On the other hand, the 3 derived models (using 3 to 5 variables) for each outcome were able to 
produce high AUC values (from 0.81 to 0.83). A simplified model that included complications count 
and previous DFU only retained high AUC values for DFU and LEA occurrence (0.79 and 0.81, 
respectively) but dropped to 0.69 in the case of death. This may be explained greatly by the fact that 
advancing age is highly and directly linked to death. 
This 2 variable model is very simple, uses easily collected data from a clinical appointment, can be 
employed in every clinical setting, from primary to tertiary care, to identify subjects at higher risk of 
developing DFU and/or LEA. This may, consequently, lead to increased surveillance of such individuals 
in order to prevent these complications from occurring. The simplified model to predict death under 
performs compared to the full model that includes age, so the full model should be used for the 
prediction of this outcome because it is more accurate. 
In the multivariate analysis, previous DFU maintained statistical significance for all the outcomes (even 
when using a broad group of variables for statistical adjustment). 
Surprisingly, LEA only achieved statistical significance in the multivariate analysis for DFU occurrence 
prediction. It was not associated with higher risk of death (not even in the univariate analysis). During 
follow-up, 10.8% of subjects with a past history of LEA died, in comparison to 24.3% of those requiring 
any type of LEA during follow-up and 35% in the case of a major LEA. 
In 1996, Boyko et al [Boyko EJ et al, 1996] assessed the relationship of DFU and mortality also adjusting the 
risk of death for some variables. However, 98% of the population were men and they tested a smaller 
range of variables. Cusick et al [Cusick M et al, 2005], in 2005, also conducted a multivariate analysis 
evaluating the association between mortality and several diabetes complications in patients with type 
1 and type 2 diabetes, although all patients had retinopathy. Moreover, in both articles evaluation of 
complications was made by assessing the presence or absence of each one at baseline while we in 
contrast used the validated complication count proposed by Young et al [Young BA et al, 2008] (its accuracy 
was considered similar to the Complication Severity Index). 
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There is substantial literature on mechanisms to explain many of the associations we describe between 
the outcomes of interest and predictors. PAD (or diminished foot pulses as its correlate) has been 
independently associated with both LEA [Adler A et al, 1999] and DFU [Boyko E et al, 1999], probably due to 
impairment in wound healing due to inadequate circulation. Diabetes complication count and physical 
impairment signal greater disease severity, which has also been shown to predict a higher risk of DFU, 
LEA, and death [Boyko E et al, 1999; Cusick M et al, 2005; Young BA et al, 2008]. Previous DFU is an instance of a diabetes 
complication signalling high disease burden of specific importance in the development of foot 
complications, such as future DFU and amputation [Adler A et al, 1999; Boyko E et al, 1999]. In addition, and not 
surprisingly, the higher disease burden also predicts greater mortality [Boyko EJ et al, 1999; Cusick M et al, 2005; 
Ramsey S et al, 1999]. 
Limitations of our study include its retrospective nature, the exclusion of patients outside our direct 
referral area, the presence and exclusion from analysis of missing data of VST and HbA1c values, as 
well as indeterminate results for intermittent claudication and SWM sensation. 
We must emphasize that, due to the selected design, all the assessed patient-related events (i.e. 
inclusion, follow-up and determination of outcomes) occurred prior to the research being undertaken. 
The VST exam only started in the middle of 2008. Regarding HbA1c values, our hospital is a tertiary 
care centre for diabetic foot care, but nevertheless a recent HbA1c value (within less than 3 months) 
was not always available. 
Even though there are works addressing the impact of depression in the mortality of patients with DFU 
[Ismail K et al, 2007; Winklei K et al, 2012], this variable is not collected in our daily practice and therefore was not 
available in the subjects’ clinical file for incorporation into prediction models. 
We have observed several indeterminate results when assessing intermittent claudication due to the 
presence of patients that have extremely reduced ambulation and/or symptoms similar to DPN. SWM 
sensation test result in some patients was difficult to assess due to the presence of several callus/dry 
skin and patients’ automatic and constantly positive response (even when false positive test points 
were being conducted). In 23 patients, where hallux or transmetatarsal LEA was present in both feet 
VST was not possible to conduct. 
We have decided to use the complication count proposed by Young et al [Young BA et al, 2008], instead of 
the Complication Severity Index. This choice was due to the fact that both report equal accuracy and 
the first was easier to apply and interpret in our population. 
Our data reveals a high rate of DFU development (> 8% annually) [Singh N et al, 2005], consistent with our 
high risk referral practice from which we selected study participants, of whom 41.0% had previous 
DFU. 
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Our mortality rate is in accordance with the ones described in the literature, namely in the Eurodiale 
study [Shaper N 2012]. In addition, our population has a high rate of comorbidities (13% cardiovascular 
disease and 63% PVD). Conversely, our LEA rate is inferior to Eurodiale results [Shaper N 2012], as it would 
be expected, since we started with a population without active DFU while they included only patients 
with active DFU. 
The referral nature of the study setting, high prevalence of type 2 diabetes (97.7%), and low education 
level (82.2% primary school level or less) may limit the generalizability of these results to dissimilar 
populations. 
As stated in the methods section, foot related variables were registered at the first podiatric 
appointment by one of 2 podiatrists with high experience in diabetic foot using a standardized form. 
We must highlight that both the professionals and form remained relatively unchanged during the 
study period. Variables that were collected by clinical interview may present information bias. 
To overcome this limitation we have searched the clinical file and the national data platform in order 
to get access to the subjects’ most complete and accurate information. For all this and the long study 
period we believe that misclassification bias may have occurred. However, due to the selected type of 
study (a cohort) we believe that it was not differential. 
Given the retrospective nature of the study we present several variables with missing data, as 
presented in the tables. However, we must emphasize that there was no missing data for the variables 
included in the models. Therefore, AUC values and respective 95% CI were calculated using the entire 
sample. On the other hand, we must highlight that we believe to have identified the great majority (if 
not all) the outcome events. We have conducted a broad search in the Hospitals’ and Health Data 
Platform (a program with access to data regarding all public healthcare institutions), in which is 
registered automatically all occurrences of LEA and death. 
We encouraged subjects to contact our service if any DFU occurred, thus enhancing our ability to 
capture this outcome. 
We only used the ICD-9 codes when considering the cause of death and grouped them, acknowledging 
the potential limitations of the existing codes. 
We conclude that DFU occurrence has a major and independent impact on LEA and death, even when 
adjusted for baseline complications. Thus the history of a DFU is a marker for poorer outcomes in 
patients with diabetes in this population. These findings also suggest that DFU prevention may be a 
potential path for better survival and diminished morbidity in persons with diabetes. New studies are 
needed in order to better understand this link. In our opinion, DFU presence implies a decrease of the 
subjects’ mobility and general well-being and, consequently, of the quality of life, higher infection risk 
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and inflammatory, immune and physiologic changes. All of these most certainly lead to a higher 
mortality risk. 
These models were obtained in a high risk context. So they should be tested in primary care to assess 
if they are clinically relevant and valid enough per se, or if they should be added to pre-existing 
models/classifications. 
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B. Hyperbaric Oxygen therapy 
 
HBOT consists in the administration of oxygen in a hyperbaric chamber, at pressures higher than the 
atmospheric pressure, usually between 1.5 and 3.0 ATA (atmospheres absolute), but can reach 6 ATA 
if needed [UHMS, 2014].  
Historically, the first reference to hyperbaric therapy is from 1662, when the British clergyman 
Henshaw intended to treat several diseases using a compartment, the “domicilium”, which was 
pressurized or depressurized. However, it was not until the 19th century that European and North 
American scientific communities regained interest in this treatment. Still, its widespread use for 
several conditions with little or none scientific base and/or results led to disbelief [Albuquerque-Sousa 2007].  
In the mid-20th century HBOT was introduced in clinical practice, with scientific support after the 
experimental studies by Boerema, where fatally anaemic (bled) pigs were maintained alive for 45 
minutes with HBOT. These experiments have drawn attention to the potential of this therapy and basic 
and clinical research have increased ever since [Albuquerque-Sousa 2007]. In fact, in the last decades there 
has been a high number of publications addressing it. For example, when searching the currently larger 
electronic repository [National Library of Medicine (MEDLINE)] for “hyperbaric oxygen therapy” we 
retrieved 11193 results [http://www.ncbi.nlm.nih.gov/pubmed/?term=hyperbaric+oxygen+treatment 
in 15/04/2014]. 
Nowadays, this treatment modality has been diffused worldwide. In Europe, several countries have 
multiple hyperbaric centres. Portugal has five located in: the FNH in Lisbon, PHH, Funchal’s Hospital, 
Ponta Delgada’s Hospital and Horta’s Hospital. 
On the other hand, the quality of the available evidence for several clinical indications is still scarce 
and with several limitations (as explained in the section 3 of this Chapter: Indications and contra-
indications). 
1. Hyperbaric chamber 
A hyperbaric chamber is a therapeutic unit constituted by a hermetic structure with a compartment 
that can be pressurized up to 6 ATA [Latham E et al, 2013]. There are two types of chambers for HBOT:  
 Type A (Multiplace) – has the capacity to treat several patients together; is pressurized with 
air; medicinal gases [oxygen (O2), helium, nitrogen] are administered in a closed circuit 
(through masks or hoods); many have facilities to treat critical care patients, including 
ventilated ones (Figure 6, Figure 7, Figure 8 and Figure 9). 
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 Type B (Monoplace) – smaller; pressurized with 100% O2 or gas mixtures; in some models, the 
patient may breath the medicinal gases through a mask; can be used for treatment or for 
transport of patients in hyperbaric conditions to other therapeutic units (for example, in diving 
accidents). 
 
Figure 6: Pedro Hispano’s Hospital multiplace chamber with capacity for 16 seating patients 
 
Figure 7: Former Navy’s Hospital chambers with total capacity of 24 seating patients 
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Figure 8: Patients undergoing treatment for different pathologies 
 
Figure 9: Monitoring panel 
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2. Effects 
HBOT effects that can be divided in physiologic and therapeutic, will be described in more detail bellow 
[Albuquerque-Sousa JG, 2002; Albuquerque-Sousa J, 2007; Bakker DJ, 2000; Bonomo SR et al, 1998; Boykin R, 2000; Boykin R & Baylis C, 
2007; Cianci P et al, 2008; Desola J et al, 1998; Gallagher KA et al, 2006; Goldstein LJ et al, 2006; Gurdol F et al, 2010; Hills BA,  1999; Hopf H 
et al, 2005; Knighton et al, 1986; Latham E et al, 2013; Liu ZJ & Velazquez OC, 2008; Mathieu D et al, 2006; Milovanova T et al, 2009; Nylander 
G et al, 1984; Roeckl-Wiedmann I et al, 2005; Sheilkh AY et al, 2000; Soares R, 2009; Thom SR, 2011; Thom SR et al, 2011; Velazquez O, 2007].  
 
Physiologic effects – depend on the increase of the environmental pressure per se and, on the other 
hand, on the elevation of oxygen partial pressure. They include: 
 Volumetric effects – according to the Boyle-Mariotte law, the increase of environmental 
pressures decreases the volume of all hollow organic cavities that are not in contact with the 
respiratory tract (bladder, gastro-intestinal tract) and of air/emboligenous bubbles, in an 
inversely proportional relation. This effect is reversible with the re-establishment of the 
atmospheric pressure.  
 Dissolution effects – under the Henry’s law, when breathing pure oxygen (O2) in hyperbaric 
conditions there is a progressive increase of the arterial O2 pressure that reach values higher 
than 2000 mm Hg at a 3 ATA pressure. So, the O2 volume dissolved and carried in the plasma, 
that is minimal at atmospheric pressure, increases more than 22 times. Consequently, venous 
O2 pressure can reach 600 mm Hg and the tissue pressure 400 mm Hg. This high driving O2 
pressure improves tissue oxygenation, even in relatively poorly perfused areas and restores 
hypoxic tissue to more normal levels. The body protects itself from this excessive amount of 
O2 through the production of free radicals, on which effects HBOT acts as modulator, and by 
dose-dependent peripheral vasoconstriction. Despite the decrease in blood flow caused by 
this vasoconstriction, plasma hyperoxia maintains O2 supply, thus it is a non-hypoxic 
vasoconstriction. This hyperoxic vasoconstriction favours oedema reabsorption and 
consequent reduction of interstitial pressure, improving O2 delivery to the tissues. The anti-
oedema effect of hyperoxia may be further enhanced by a direct osmotic effect of 
intravascular O2 at these high tensions. Hills has estimated an effect of as much as an 8.4% 
increase in oncotic pressure, which is established because O2 diffusing into the tissues is 
instantly metabolised, maintaining the steep concentration gradient across the vascular wall. 
 
Therapeutic effects consist in: 
 Direct effects – the arterial, venous and tissue hyperoxia and, specially, the great increase and 
availability of plasmatic O2 provide a possible therapeutic effect in diseases where tissue 
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hypoxia, whether systemic or local, is a predominant etiopathogenic factor or when there is 
an oxygen-dependent physiopathologic mechanism. The dissolved O2 is not affected by 
hematologic limitations or metabolic conditions that, in several situations, limit the transfer or 
use of erythrocyte O2; it is delivered to tissues, like terminal ischemic tissues, by capillarity, 
being transferred through a simple diffusion gradient.  
 Indirect effects – depending on the condition’s physiopathology there are specific therapeutic 
actions: 
o Decrease of bubbles volume in gaseous embolism and decompression sickness: the 
increase of O2 partial pressure and the reduction of the nitrogen partial pressure to 
zero accelerates the absorption of gaseous emboli through a concentration gradient 
till their elimination. 
o “Robin-Hood” effect: the hyperoxic vasoconstriction is a physiological mechanism of 
defense against hyperoxia, whereby blood flow is preferentially maintained to hypoxic 
zones and reduced in normoxic areas. 
o Micro-neovascularisation and neo-collagen synthesis stimulation: HBOT favors proline 
hydroxylation and granulation tissue production in situations where, due to hypoxia, 
they were decreased (namely, diabetic microangiopathy, irradiated tissues or 
advanced arteriopathies), and increases the synthesis of several growth factors that 
stimulate angiogenesis. On the other hand, there is evidence that local 
hyperoxia/hypoxia interchange is an angiogenic stimulus.  
o Reactivation of the leukocyte O2 dependent phagocytic ability: the higher tissue O2 
content reinforces leukodiapedesis and phagocytic capacity of the activated 
neutrophils. 
o Increase in leukocyte bactericidal power: through rise in intra-leukocyte synthesis of 
superoxide radicals due to the activation of the oxidative pathway linked to 
nicotinamide adenine dinucleotide phosphate. 
o Synergism with some antibiotics: hypoxia and anaerobiosis contribute to reduced 
action of several antimicrobials, like aminoglycosides, vancomycin, cotrimoxazole, 
fluoroquinolones, nitrofurantoin and rifamycins. The elevation of tissue O2 tension, 
through HBOT, restores the normal activity of many of these antibiotics, increasing, in 
some cases, its antimicrobial power. This, however, is not a universal effect, varying 
with antibiotic and/or microorganism involved. HBOT prolongs the post-antibiotic 
effect, enhancing efficacy and duration of action of some antibiotics. As HBOT also 
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improves wound neovascularisation, it likewise increases antimicrobial’s local 
bioavailability. 
o Bacteriostatic action on several non-sporulated anaerobic and some aerobic 
microorganisms: HBOT should be considered an adjuvant treatment in situations 
when conventional therapy (antibiotics) has failed.  
o Bactericidal action on some non-sporulated strict anaerobic microorganisms: in 
particular of the Clostridium gender, due to their lack of anti-oxidant systems.  
o Clostridium toxin production block: toxin production is dependent on the existence of 
low redox potential. The rise of the later by HBOT stops toxin production.  
o Faster elimination of carboxyhemoglobin (HbCO): HbCO half-life under environmental 
conditions is 520 minutes, when breathing 100% oxygen at the atmospheric pressure 
lowers to 80 minutes and with hyperbaric oxygen at 3 ATA it is reduced to 23 minutes. 
o Attenuation of the reperfusion injury: inappropriate leukocyte activation is 
responsible for much of the damage linked to reperfusion (an indirect injury 
mechanism). HBOT reduces it by preventing this activation. 
o Recruitment of bone marrow-derived EPCs: the hyperoxia caused by HBOT increases 
nitric oxide synthase (NOS) activity and evidence points that it stimulates the 
mobilization of EPCs from the bone marrow by a mechanism mediated by nitric oxide 
(NO).  
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Figure 10. Hyperbaric oxygen therapy mechanisms of action in wound healing 
 
(Adapted, with permission, from Albuquerque e Sousa, 2006) 
 
: Increase; : Decrease; Fi: Fraction of Inspired Oxygen; O2: Oxygen; PpO2: Partial Pressure of Oxygen 
 
From the exposed, due to the increase in the dissolved O2 in the plasma, hyperoxic vasoconstriction 
with plasma volume derived from the healthy areas to the regions with local hypoxia, stimulation of 
micro-neovascularisation and production of collagen, improvement in leukocyte phagocytic and 
bactericidal capacities, direct bactericidal or bacteriostatic effect of the higher O2 content on some 
bacterial agents, and synergism with some antimicrobial drugs, summarized in Figure 10, HBOT is used 
to treat chronic non-healing DFU that are typically ischemic and/or infected. 
 
Side effects – they are uncommon but include [Mathieu D et al, 2006; Neuman T & Thom S, 2008]: 
 Barotraumatic lesions: can occur in the ear, paranasal sinuses, lung and, less often, teeth, eyes 
or gastrointestinal hollow viscera, especially if preventive measures are not adopted. 
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 Central nervous system oxygen toxicity: ranges from simple symptoms like nausea, dizziness, 
headache, light-headedness to, when an excessively high O2 pressure is reached, generalized 
tonic-clonic seizures that stop when the O2 mask is removed with consequent decrease in the 
inspired oxygen partial pressure and may have a transitory post-ictal aura. 
 Toxic O2 effects on the respiratory tract: in case of continuous or prolonged exposures to 
hyperbaric O2 (more than 10 hours continuously or 200 cumulative). The first sign is a 
reduction in vital capacity. 
 Effects on the eye: 
o Transient myopia: it is not a true refraction change but the effect on the visual function 
is alike. However it is temporary and reverts a few days after finishing the treatment. 
o In patients with cataracts their evolution may be accelerated. Data indicates that there 
is no new cataract formation in unaffected eyes using the usual treatment schedules. 
 Claustrophobia 
 
Using treatment plans with duration inferior to 3 hours and a maximum pressure of 3 ATA, HBOT is 
considered a safe treatment, being the occurrence of side effects very rare. 
 
3. Indications and contra-indications 
The 7th European Consensus Conference on Hyperbaric Medicine of the European Committee for 
Hyperbaric Medicine (ECHM) held in 2004 in Lille, France, aimed, among other objectives, to review 
the agreement on HBOT indications based in the available evidence [ECHM, 2004]. 
The type of indication was classified using a 3 grade scale according to the strength of the 
recommendation, and the level of evidence that supported each recommendation was classified from 
A to F (A – at least 2 concordant, large, double-blind, controlled randomized studies with no or little 
methodological bias; B – double-blind controlled, randomized studies but with methodological flaws, 
studies with only small samples, or only a single study; C – consensus opinion of experts; D – only 
uncontrolled studies with no consensus opinion of expert; E – no evidence of beneficial action, or 
methodological or interpretation bias preclude any conclusion; F – existing evidence favors not to use 
HBOT). 
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 Type I recommendations – pathologies in which HBOT is strongly recommended and 
contributes to change the prognosis 
Acute:  
o Carbon monoxide intoxication (Level B) 
o Crush syndrome (Level B) 
o Decompression accident (Level C) 
o Gas embolism (Level C) 
o Anaerobic or mixed bacterial anaerobic infections (Level C) 
 
Chronic: 
o Prevention of osteoradionecrosis after dental extraction (Level B) 
o Osteoradionecrosis (mandible) (Level B) 
o Soft tissue radionecrosis (cystitis) (Level B) 
 
 Type II recommendations – HBOT is recommended and may improve outcome 
Acute: 
o Compromised skin graft and musculocutaneous flap (Level C) 
o Sudden deafness (Level C) 
 
Chronic: 
o Diabetic foot lesions (Level B) 
o Osteoradionecrosis (other bones) (Level C) 
o Radio-induced proctitis/enteritis (Level C) 
o Radio-induced lesions of soft tissues (Level C) 
o Surgery and implant in irradiated tissue (preventive action) (Level C) 
o Ischemic ulcer (Level C) 
o Refractory chronic osteomyelitis (Level C) 
o Neuroblastoma stage IV (Level C) 
 
 Type III recommendations – HBOT is optional  
Acute: 
o Post anoxic encephalopathy  (Level C) 
o Post-vascular procedure reperfusion syndrome (Level C) 
o Limb replantation (Level C) 
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o Burns > 20% of body surface area and 2nd degree (Level C) 
o Acute ischemic ophthalmological disorders (Level C) 
 
Chronic: 
o Larynx radionecrosis (Level C) 
o Radio-induce CNS lesion (Level C) 
o Selected non-healing wounds secondary to inflammatory processes (Level C) 
o Pneumatosis cystoides intestinalis (Level C) 
 
 Other indications – were considered not recommended as they had a level of evidence 
classified as D to F 
 
The Undersea and Hyperbarical Medical Society (UHMS) and Food and Drugs Administration also 
considered as indication for HBOT severe anemia when there is inability to transfuse red blood cells 
and intracranial abscess [UHMS, 2014]. 
Being a medical treatment, HBOT also has some contraindications [Latham E et al, 2013; Neuman T et al, 2002; 
Wang J et al 2002], that can be classified in two groups: 
 
 Absolute:  
o Presence of an untreated pneumothorax 
o Current treatment with bleomycin, cisplatin, disulfiram and mafenide acetate 
 Relative: 
o History spontaneous pneumothorax  
o Recent thoracic, ocular and/or otorhinolaryngologic surgery 
o Severe acute or chronic sinus infections 
o Upper respiratory infection  
o Asthma 
o Chronic obstructive pulmonary disease, especially emphysema 
o Congenital spherocytosis 
o High fever 
o Epilepsy 
o Pregnancy 
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C. Effect of Hyperbaric Oxygen therapy in diabetic foot ulcer healing: a 
systematic review and meta-analysis 
 
1. Material and methods 
Search strategy and article selection process 
A sensitive search in the MEDLINE (PubMed) database was conducted in December 2012 for studies 
addressing HBOT effectiveness for chronic DFU, using the query outlined in Figure 11. 
 
Figure 11: Systematic review flow diagram of article selection process 
 
 
Article selection process, using the following query in MEDLINE: ("Hyperbaric Oxygenation/economics"[Mesh] OR "Hyperbaric 
Oxygenation/ standards"[Mesh] OR "Hyperbaric Oxygenation/statistics and numerical data"[Mesh] OR "Hyperbaric 
Oxygenation/therapy"[Mesh] OR "Hyperbaric Oxygenation/trends"[Mesh] OR "Hyperbaric Oxygenation/utilization"[Mesh]) 
AND "Diabetic Foot/blood"[Mesh] OR "Diabetic Foot/classification"[Mesh] OR "Diabetic Foot/economics"[Mesh] OR "Diabetic 
Foot/enzymology"[Mesh] OR "Diabetic Foot/immunology"[Mesh] OR "Diabetic Foot/therapy"[Mesh])and the following terms 
in other search engines: “Diabetic Foot” AND/OR “Hyperbaric Oxygen Therapy” 
 
This search retrieved 3,872 studies. These results were examined by two independent investigators 
(Daniela Martins-Mendes and Matilde Monteiro-Soares) using the following inclusion criteria: (1) type 
Studies retrieved by electronic search 
(n= 3872)
Studies retrieved for detailed evaluation
(n=31)
Studies selected 
(n=17)
Studies included after pertinent meeting  
and  reference analysis 
(n=24)
Total studies included
(n=41)
Studies excluded after integral version analysis 
(n=14)
Articles excluded after title and abstract analysis 
(n=3841)
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of study: randomized controlled trials (RCT), non-randomized trials (NRT), cohorts, case–control 
studies and case series; (2) population: subjects with diabetes and active DFU; (3) results: reported 
healing and/or LEA proportions and/or median healing time in subjects treated with systemic HBOT, 
eventual association between systemic HBOT and DFU healing and/or between independent variables’ 
and improved outcome in those receiving HBOT; (4) outcomes: DFU total healing, LEA rates, area 
reduction or time to heal and; (5) published in the following languages: English, French, Italian, 
Portuguese or Spanish. 
Disagreements were resolved by a third investigator (Pedro Barata). In the first phase, inclusion was 
based on the title and abstract (when available). All included titles at this stage (n= 31) were then 
retrieved as full articles and a final assessment made.  At the conclusion of this process 17 articles were 
included. We then extended the search by examining the citation lists for each of the 17 included 
articles and of previous reviews on this topic [Kranke P et al, 2006; Kranke P et al, 2012; Löndahl M, 2012; Medical Advisory 
Secreteriat, 2005; Tiaka E et al, 2012], hand-searching the abstracts and proceedings of major meetings in the 
fields of both Diabetology and Hyperbaric Medicine (European Association for the Study of Diabetes, 
International Diabetes Foundation, European Underwater and Baromedical Society, South Pacific 
Underwater Medicine Society and Undersea and Hyperbaric Medical Society) and searched an on-line 
database of scholarly works in Hyperbaric Medicine (The Rubicon Foundation Research Repository). 
Using the same procedure described above, when a new study abstract was identified, a search was 
made and/or an email sent in order to ascertain if a full paper had been produced and published. If 
there was a full publication [Baroni G et al, 1987; Bishop A & Mudge E, 2012; Çerkes N et al, 1994; Doctor N et al, 1992; Faglia E et 
al, 1998; Hawkins G et al, 2006; Oriani G et al, 1992; Otto G et al, 2000; Wang CJ et al, 2009; Wattel F et al , 1991; Wattel F et al , 1995], we 
included it in our review, if not the study was included in abstract or poster form only [Buyukcakir C et al, 
1998; Fife C et al, 1997; Hawkins G et al, 2005; Jovanovic T et al, 2011; Kawashima M et al, 2006; Mathieu D et al, 1997; Mendes D et al, 2012; 
Perdrizet G et al, 2007; Ramon Y et al, 1999; Subbotina N et al, 2002; Zivkovic M et al, 1999]. These searches yielded a further 
24 articles and we have included 41 studies in this review (Figure 11). 
 
Data collection and analysis 
The following data were collected: (1) article identification: title, author(s), publication date, journal; 
(2) methods: study design, setting, sources and methods of participant selection, inclusion and 
exclusion criteria, sample size, HBOT regimen and number of sessions; (3) results: study participants’ 
characteristics, outcome prevalence (healing, minor, major or total LEA), methods of statistical 
analysis, HBOT efficacy regarding reduction of LEA risk, DFU area and time until complete healing, 
and/or association between independent variables and outcome; and (4) quality assessment: assessed 
(by Matilde Monteiro-Soares) through the number of items fulfilled in two study quality checklists 
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[STROBE for observational studies [Vandenbroucke J et al, 2007] and CONSORT (Consolidated Standards of 
Reporting Trials) for RCTs [Schulz K et al, 2010]]. Due to a lack of an implemented checklist for NRT we have 
decided to evaluate such studies by also using the STROBE checklist. 
MA was conducted for healing and LEA proportion using Microsoft Excel [Neyeloff J et al, 2012], while Review 
Manager 5.0 software was used for risk measures. Concerning HBOT effectiveness, estimates were 
made using pooled mean differences, when DFU area reduction and time until complete healing was 
reported and healing proportion in each group. Relative risk (RR) and absolute risk reduction (ARR) 
were used when DFU total healing or LEA proportions were reported. Relative risk reduction (RRR) and 
number needed to treat (NNT) were calculated for each study, using the formulas 1-RR and 1/RR, 
respectively [Bender R et al, 2005]. A pooled estimate was also calculated when heterogeneity was low, 
applying the referred formula and using the pooled RR and ARR, respectively [Bender R et al, 2005]. For all 
estimates, 95% CI were determined.  
Heterogeneity tests were conducted (Chi-square test based Q-statistic and I2 statistic) and, when 
evident (the first >10 or the second >20%), a random effects model (DerSimonian and Laird method) 
was used. Otherwise, the fixed effect model (Mantel-Haenszel’s method) was selected. Funnel plots 
were constructed to assess possible publication bias. 
A p<0.05 was considered statistically significant, and all p values were two sided. 
 
2. Results 
Included studies characterization 
A total of 41 studies assessing HBOT impact on DFU healing were included: 11 RCT, 8 NRT, 10 cohort 
studies and 12 case series (Table 3).  
The only studies reporting double blinding were Lee [Lee CT et al, 2004] and Löndahl [Löndahl M et al, 2010; Löndahl 
M et al, 2011]. 
In Kalani [Kalani M et al, 2002], only the first 14 participants were randomized while the remaining were 
allocated according to HBOT availability. 
In two studies from the same group of authors, HBOT was compared to extracorporeal shockwave 
therapy (ESWT) [Kranke P et al, 2006; Wang CJ et al, 2011] instead of standard DFU treatment. In the latter of 
these two studies (2011), a second course of therapy when the ulcer had improved but not healed 
completely was permitted, according to decision of the attending physician. 
In several studies, the selection process (n= 15), participants’ age (n= 9), gender (n= 16), HbA1c (n= 
27), diabetes duration (n= 21), ankle-brachial index (ABI) (n= 34), transcutaneous partial pressure of 
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Oxygen (TcPO2) (n= 31), wound severity (n= 25), setting (n= 17) and mean follow-up (n= 19) were not 
reported (Table 5). 
Where reported at all, most studies selected patients with DFU by simple consecutive inclusion. The 
most frequent inclusion criterion was chronic DFU, with a minimum duration of 4 [Albuquerque-Sousa J, 2005; 
Duzgun A et al, 2008] to 12 weeks [Hawkins G et al, 2005; Hankins G et al, 2006; Kessler L et al, 2003; Löndahl M et al, 2010; Löndahl M 
et al, 2011; Ramon Y et al, 1999; Wang CJ et al, 2011], while  the most frequent selection criteria for control subjects 
were those refusing, abandoning or unable to receive treatment. 
Sample size ranged from 10 [Zamboni W et al, 1997] to 1006 [Fife C et al, 1997] participants, with a total number 
of 4,347 (mean 106; median 36). 
The mean age of participants in each study was not always reported, but ranged from something more 
than 51 years [Fife C et al, 2007] to 75 years [Perdrizet G et al, 2007]. Most were men with diabetes for more than 
five years. Generally, patients included had DFU Wagner classification grades III-V. 
ABI and TcPO2 values were rarely reported, and when they were, the data was highly variable (ABI 0.64 
[Faglia E et al, 1996; Faglia E et al, 1998] to 1.26 [Wang CJ et al, 2009]; TcPO2 12 [Mendes D et al, 2012] to 60mm Hg [Zamboni 
W et al, 1997]). 
Most studies were undertaken in hospital-based hyperbaric facilities; 14 studies used multiplace 
chambers and 6 monoplace chambers (21 did not specify). When described, all used pressures of 2 to 
3 ATA and provided oxygen at 100%.There were only 3 multicentre studies, all from the same group 
[Otto G et al, 2000; Fife C et al, 1997; Fife C et al, 2007]. 
The duration of each HBOT session varied from 45 [Doctor N et al, 1992] to 120 minutes [Zamboni W et al, 1997; 
Chen CE et al, 2010; Zgonis T et al, 2005; Kaya A et al, 2009], most commonly 90 minutes, once or twice daily, from 4 
[Doctor N et al, 1992] to 7 days per week [Çerkes N et al, 1994].  
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Table 3: Characteristics of included studies ordered by study type, quality assessment and sample size 
Study 
Selection 
process 
Inclusion criteria 
Sample 
size (n) 
Controls’ 
selection 
process 
Participants’ characterization 
Setting 
HBOT characterization 
Mean  
follow up 
(months) 
Mean 
(SD) Age 
[years] 
Male 
(%) 
Mean 
(SD) 
HbA1c 
[%] 
Mean 
(SD) 
diabetes 
duration 
[years] 
Mean 
(SD) ABI 
[mmHg] 
Mean 
(SD) 
TcP02 
[mmHg] 
Wagner Grade Regimen 
Number 
of 
sessions 
(mean) 
RANDOMIZED CONTROLLED TRIALS 
Löndahl M et al, 
2010&2011 
NR 
Full-thickness DFU > 
12 weeks, followed 
in a diabetes foot 
clinic for > 8 weeks 
I: 38 
C: 37 
NA 
I: 69 
C: 68 
I: 78 
C: 84 
I: 7.8 
C: 8.1 
I: 20 
C: 23 
NR NR 
I: 24% grade II, 
75% grade III-V C: 
27% grade II, 73% 
grade III-V 
NR 
85-min daily x 5 
days/8-10 weeks 
sessions, 
max 40, 
multi chamber, 
2.5 ATA 
80% > 35 
sessions 
in total 
 
12 
Duzgun A et al, 
2008 
Consecutive 
inclusion 
Subjects >18 years 
with active DFU > 4 
weeks 
I: 50 
C: 50 
NA 
I: 58 (11) 
C: 63 (9) 
I: 74 
C:54 
I: 8.0 
(1.9) 
C: 8.7 
(2.9) 
I: 17 (6) 
C: 16 (6) 
NR NR 
I: 12% grade II, 
88% grade III-V C: 
24% grade II, 46% 
grade III-V 
University 
Hospital 
1-2 x 90-min daily 
sessions, 
mono chamber, 
2-3 ATA 
NR 23 (3) 
Wang C et al, 
2011 
NR 
Chronic  DFU > 12 
weeks 
I: 38 
C: 39 
NA 
I: 62 (14) 
C: 61 (14) 
NR 
I: 8.1 
(1.8) 
C: 8.8 
(2.2) 
I: 6a 
C: 6a 
I: 0.91 
(0.27) 
C: 1.07 
(0.10) 
NR NR NR 
90-min daily x 5 
days/week 
sessions, 
max 20 x 2, 
multi chamber, 
2.5 ATA 
Total 20 
or 40 
I: 11 (5) 
C: 14 (4) 
Abidia A et al, 
2003  
Consecutive 
inclusion 
DFU > 1cm and < 10 
cm diameter, > 6 
weeks, ABI < 0.8 or 
HBI <0.7 
I: 9 
C: 9 
NA 
I: 72 (13) 
C: 70 (7) 
I: 67 
C:33 
I: 12.7 
(1.2) 
C: 12.5 
(1.7) 
I: 13 (10) 
C: 10 (6) 
NR NR 
I: 78% grade II, 
11% grade III-V C: 
89% grade II, 11% 
grade III-V 
Hull Royal 
Infirmary 
90-min daily x 5 
days/week 
sessions, 
multi chamber, 
2.4 ATA 
Total 30 max 12 
Wang C et al, 
2009 
NR Chronic  DFU 
I: 36 
C: 34 
NA 
I: 59 (13) 
C: 63 (10) 
NR 
I: 9.1 
(1.2) 
C: 8.8 
(2.1) 
I: 19 (20) 
C: 23 (21) 
I: 1.26 
(0.27) 
C: 1.22 
(0.19) 
NR NR Hospital 
90-min daily x 5 
days/week 
sessions, max 20, 
multi chamber, 
2.5 ATA 
Total 20 
I: 12 (2) 
C: 12 (2) 
Faglia E et al, 
1996 
Consecutive 
inclusion 
Subjects 
hospitalized for DFU 
I: 33 
C: 35 
NA 
I: 62 (10) 
C: 66 (9) 
I:77 
C:64 
I: 9.3 
(2.5) 
C:8.5 
(2.3) 
I: 16 (10) 
C: 19 (9) 
I: 0.65 
(0.28) 
C: 0.64 
(0.25) 
I: 23. (11) 
C: 21 (11) 
I: 12% grade II, 
88% grade III - IV 
C: 15% grade II, 
85% grade III-V 
Hospital 
(Diabetes 
Unit) 
90-min daily 
sessions, 
multi chamber, 
2.5 ATA 
39 NR 
Kessler L et al, 
2003 
Consecutive 
inclusion 
DFU no favourable 
evolution ≥ 3 
months 
 
I: 14 
C: 13 
NA 
I: 60 (10) 
C:68 (11) 
I: 71 
C:69 
I: 9.4 
(2.4) 
C: 8.1 
(1.4) 
I: 18 (13) 
C: 22 (13) 
NR 
I: 46 (18) 
C:45 (24) 
I-III 
University 
Hospital 
2 x 90-mindaily x 
5 days/week 
sessions, 
multi chamber, 
2.5 ATA 
20 1 
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Kalani M et al, 
2002 
NR 
DFU > 2 months 
with TcPO2< 40 
mmHg, not eligible 
for vascular 
intervention 
I: 17 
C: 21 
NA 
I:54 (14) 
C:65 (11) 
I: 71 
C:86 
I: 7.1 
(1.5) 
C: 7.3 
(1.4) 
I: 28 (12) 
C: 26 (17) 
NR 
I:22 (12) 
C:25 (10) 
NR NR 
90-min x 5 
days/week 
sessions, 
mono chamber, 
250 kPa 
Total 
ranged 
40-60 
36 
Lee C 2004 
(abstract) 
Consecutive 
inclusion 
DFU after 
debridement or 
minor LEA 
I: 20 
C: 12 
NA NR NR NR NR NR NR NR 
Hospital  
(HBOT 
medicine 
dept) 
NR NR All 24 
Doctor N et al, 
1992 
Consecutive 
inclusion 
Chronic DFU 30 NA 
I: 56 (NR) 
C: 60 (NR) 
I: 75 
C: 67 
NR 
I: 10 
C: 11 
NR NR NR Hospital 
45-min x 4/2 
week sessions, 
mono chamber, 
3.0 ATA 
4 NR 
NON-RANDOMIZED TRIAL 
Zamboni W et 
al, 1997 
Consecutive 
inclusion 
Insulin dependent 
diabetics with 
chronic DFU 
I: 5 
C: 5 
Refused 
treatment 
I: 64 (4) 
C: 54 (3) 
I: 80 
C: 80 
NR NR NR 
I: 53 (4) 
C: 60 (2) 
NR NR 
120-min x 5 
days/week 
sessions, 
mono chamber, 
2.0 ATA 
Total 30 4-6 
Faglia E et al, 
1998 
Consecutive 
inclusion 
Patients 
hospitalized for DFU 
I: 51 
C: 64 
Various 
extemporan
eous reasons 
I: 61 (10) 
C: 65 (10) 
73 NR 17 (9) 
0.64 
(0.25) 
28 (13) 
11% grade II, 89% 
grade III-V 
Hospital 
90-min 5 
days/week to 
daily sessions, 
chamber type NR, 
2.2-2.5 ATA 
32 (11) NR 
Chen C et al, 
2010b 
NR DFU 
I: 21 
C: 21 
Abandoned 
treatment 
I: 66 (21) 
C: 68 (11) 
I: 52 
C: 52 
I: 9.8 
(1.9) 
C: 9.2 
(2.9) 
I:13 (8) 
C:12 (10) 
I: 0.76 
(0.30) 
C: 0.71 
(0.31) 
NR 
I: 100% grade III-V  
C: 100% grade III-
V 
NR 
120-min daily x 5 
days/week 
sessions + 
intermittent 
schedule at 
weekend, 
multi chamber, 
2.5 ATA 
I: 15 
C: 13 
I: 23 (10) 
C: 3 (2) 
Baroni G et al 
1987 
Consecutive 
inclusion 
Necrotic DFU 
I: 18 
C: 10 
Refused 
treatment 
I: 58 (7) 
C: 59 (8) 
I: 60 
C: 61 
I: 8.9 
(1.6) 
C: 8.8 
(1.2) 
I: 16 (7) 
C: 14 (6) 
NR NR NR 
Metabolic 
unit 
90-min daily 
sessions, 
multi chamber,  
2.5 or 2.8 ATA 
34 (22) 
 
14 (10) 
Oriani G et al, 
1990 
Consecutive 
inclusion 
Major ulcero-
necrotic lesions 
I: 62 
C: 18 
Refused 
treatment 
I: 53 (12) 
C: 58 (8) 
I: 58 
C: 67 
I: 9.5 
C: 8.2 
I: 14 (10) 
C: 16 (6) 
NR NR All grade IV or V NR 
5-6 days/week 
sessions 
multi chamber,  
2.5 or 2.8 ATA 
72 (29) NR 
Perdrizet G et 
al, 2007 
(abstract) 
Consecutive 
inclusion 
NR 
I: 25 
C: 25 
Matched for 
age and 
gender 
I: 64 (14) 
C: 75 (12) 
I: 56 
C: 68 
NR NR 
I: 1.1 
(0.5) 
C: 0.8 
(0.6) 
I: 31 (18) 
C: 42 (22) 
NR NR NR All 30 
C: 10 
I: 12 
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Mendes D et al, 
2012 (poster) 
Consecutive 
inclusion 
Chronic DFU 
(> 8 weeks) 
I: 9 
C: 4 
Refused 
treatment or 
had contra-
indication 
60 (11) 
I: 89 
C: 
100 
 
8.5 (2.0) NR NR 12 (9) 
100% grade III or 
IV 
NR 
90-min daily 
sessions, 
chamber type NR, 
2.1 ATA 
Total 
ranged 
56-111 
Up to 12 
Albuquerque J, 
2005 (retrosp) 
Consecutive 
inclusion 
Chronic DFU 
(>4weeks) 
I: 55 
C: 41 
Refused 
treatment 
I: 61 (13) 
C: 64 (14) 
I: 74 
C: 66 
NR 
I: 22 (10) 
C: 20 (8) 
NR NR 
I: 14% grade II, 
86% grade III-V C: 
10% grade II, 90% 
grade III-V 
Hospital 
90-min daily x 5 
days/week 
sessions, 
multi chamber, 
2.5 ATA 
54 (31) 
50 
(ranged 
17-120) 
PROSPECTIVE COHORT STUDIES 
Hawkins G et al, 
2006 
Consecutive 
inclusion 
Chronic wounds (> 3 
months) 
I: 40 NA I: 66 NR NR NR NR NR NR HBOT unit NR 23 (10) Up to 12 
Mathieu  D et 
al, 1997 
(abstract)  
Consecutive 
inclusion 
DFU I: 29 NA I: 61 (16) NR NR NR NR I: > 11 NR HBOT unit 
2 x 90-min daily x 
5 days/week 
sessions, 
chamber type NR 
2.5 ATA 
NR 
Max 6 
weeks 
Wattel F et al, 
1991 
Consecutive 
inclusion 
DFU I: 59 NA I: 60 (13) I: 58 NR NR NR NR NR HBOT unit 
2 x 90-min daily x 
5 days/week 
sessions, 
chamber type NR, 
2.5 ATA 
29 (19) NR 
Hawkins G et al, 
2005 (poster)  
Consecutive 
inclusion 
Chronic DFU 
(>12 weeks) 
I: 43 NA NR NR NR NR NR NR NR Hospital NR NR NR 
Ong M et al, 
2008 
Consecutive 
inclusion 
DFU I: 45 NA I: 59 NR NR NR NR NR NR 
HBOT 
medicine 
centre 
90-min daily 
sessions, 
chamber type NR, 
2.5 ATA 
20a NR 
Ramon Y et al, 
1999 (abstract) 
Consecutive 
inclusion 
Chronic DFU (> 3 
months) 
I: 26 NA NR NR NR NR NR NR NR NR 
90-min daily x 6 
days/week, 
chamber type NR, 
2.5 ATA 
>61 NR 
RETROSPECTIVE COHORT STUDIES 
Zgonis T et al, 
2006 
NR 
Subjects undergoing 
partial foot 
amputation 
I: 35 NA NR NR NR NR NR NR NR NR 
120-min daily 
sessions,  
mono chamber, 
2 ATA 
Total 
ranged 
16-20 
Total 
ranged 
1.5-7 
Otto G et al, 
2000 
NR 
Diabetic patients 
from HBOT facilities 
I: 180 NA I: > 62 NR NR I: > 17 NR NR NR 
Multicentre 
HBOT facilities 
NR NR NR 
Fife C et   al, 
2007 
NR 
Diabetic patients 
from HBOT facilities 
I: 971 NA I: > 51 I: 58 NR I: > 21 NR NR NR 
Multicentre 
HBOT facilities 
≥ 5 days/week 
sessions, 
chamber type NR, 
2.0-2.4 ATA 
Mean 
ranged 
24-34 
NR 
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Fife C et al, 
1997 
(abstract) 
NR 
Diabetic patients 
from hyperbaric 
facilities 
I: 1006 NA NR NR NR NR NR NR NR 
Multicentre 
HBOT facilities 
NR NR NR 
CASE SERIES 
Bishop A et al, 
2012 
Consecutive 
inclusion 
Diabetic patients 
with DFU treated 
with HBO 
I: 30 NA I: 63 I: 20 NR I: 17 NR NR NR 
HBOT medicine 
centre 
NR 40 All 3 
Mathieu D et al, 
1991 
Consecutive 
inclusion 
DFU I: 59 NA I: 60 (13) I: 58 NR NR NR I: >13 NR HBOT unit 
90-min x 2 daily x 
5 days/week 
sessions, 
chamber type NR, 
2.5 ATA 
29 (19) 
3 (2) 
weeks 
Kaya A et al, 
2009 
Consecutive 
inclusion 
Diabetic patients 
with DFU treated 
with HBO 
I: 184 NA I: 60 (11) I: 72 
I: 8.5 
(2.1) 
I: 15 (9) NR NR 
I: 31% grade 
II, 69% grade 
III-V 
NR 
120-min x 1-2 
daily x 6 
days/week 
sessions, 
multi chamber, 
2.4 ATA 
39 All 12 
Cianci P et al, 
1997 
Blindly 
selected from 
a larger group 
of 
consecutive 
inclusion 
DFU I: 41 NA I: 64  NR NR NR NR NR 
Average 
Wagner 
score: 4 
Hospital NR NR NR 
Ҫerkeᶊ N et al, 
1994 
NR 
Diabetic patients 
with DFU treated 
with HBO 
I: 30 NA I: 62 (12) I: 73 NR NR NR NR NR NR 
90-min x 1 – 2 
daily x 7 
days/week 
sessions 
multi chamber, 
2.4 – 3 ATA 
36 1.5 
Subbotina N 
etal, 2002 
(abstract) 
NR Chronic DFU I: 191 NA NR NR NR NR NR NR NR NR NR NR NR 
Jovanovic T et 
al, 2011 
(abstract) 
Consecutive 
inclusion 
DFU I: 69 NA I: 58 I: 81 NR NR NR NR NR 
HBOT medicine 
centre 
90-min daily x 5 
days/week 
sessions, 
chamber type  
NR, 
2.5 ATA 
 
Total 
ranged 
25-40 
NR 
Oriani G et al, 
1992 
NR 
Diabetic patients 
with gangrenous 
DFU treated with 
HBOT 
 
I: 151 NA I: >68 I: 63 NR NR NR NR 
I: 100% grade 
IV-V 
Hospital 
90-min daily 
sessions, 
multi chamber, 
2.5-2.8 ATA 
40 NR 
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Wattel F et al, 
1995 
Consecutive 
inclusion 
Chronic DFU 
(>6 weeks without 
revascularization 
surgery indication) 
I: 40 NA NR NR NR NR NR NR NR NR 
90-min x 2 daily x 
NR days/week 
sessions, 
chamber type  
NR, 
2.5 ATA 
NR NR 
Zivkovic M et al, 
1999 (abstract) 
NR DFU I: 41 NA I: 61 I: 66  NR I: 15 NR NR 
I: 63% grade 
I-III, 37% 
grade IV-V 
NR 
60-min x 1-2 daily 
x NR days/week 
sessions, 
mono chamber, 
2 – 2.4 ATA 
22 NR 
Kawashima M 
et al, 2006 
(abstract) 
NR 
Diabetic patients 
treated with HBOT 
I: 87 NA NR NR NR NR NR NR 
I: 72% grade 
I-III, 28% 
grade IV-V 
NR 
60-min sessions, 
chamber type NR, 
2.0 ATA 
NR NR 
Buyukcakir C et 
al, 1998 
(abstract) 
NR 
Diabetic patients 
treated with HBOT 
I: 21 NA NR NR NR NR NR NR NR NR 
90-min daily 
sessions, 
multi chamber, 
2.5 ATA 
NR NR 
In italic: statistically significant difference between groups, a Median, b intervention group: > 10 HBOT sessions and control group: < 10 HBOT sessions, ABI: Ankle Brachial-Index, ATA: Atmosphere Absolute Pressure, C: 
Control Group, cm: Centimetre, dept: Department, DFU: Diabetic Foot Ulcer, HbA1c: Glycated Haemoglobin, HBI: Hallux Brachial Index, HBOT: Hyperbaric Oxygen Therapy, I: Intervention Group, kPa: Kilopascal, max: 
Maximum, min: Minutes, mmHg: Millimetres of Mercury, n: Sample Size, NR: Not Reported, NA: Not Applicable, retrosp: Retrospective, SD: Standard Deviation, TcPO2: Transcutaneous Partial Pressure of Oxygen 
 
  
  
- 51 - 
 
Each RCT was assessed for methodological quality by compliance with the CONSORT checklist [Schulz K 
et al, 2010]. There was an adequate summary, background, objectives or hypothesis, eligibility criteria, 
participant flow, numbers of participants and results description and interpretation were described in 
more than 90% of the studies. On the other hand, adequate descriptions of trial design, methods or 
outcomes changes, interim analyses, method used and person responsible to generate random 
allocation sequence, description of the similarity of interventions, reason for the trial’s end, ancillary 
analyses and where to access the full trial protocol were reported in less than 10% of the studies. From 
a total of 37 items, completeness ranged from 8 (22%) [Doctor N et al, 1992; Lee Ct el al, 2004] to 21 (57%) [Löndahl 
M et al, 2010], with a mean of 18 (47%) (Table 4). 
In a similar analysis using the STROBE checklist [Vandenbroucke J et al, 2007], more than 90% of studies 
reported key elements of study design and results. In contrast, less than 10% described the matching 
criteria, any potential sources of bias, the reason for non-participation of the control subjects, details 
of missing data and a number of other items. From a total of 34 items, completeness varied from 4 
(12%) [Buyukcakir C et al, 1998; Kawashima M et al, 2006] to 16 (47%) [Bishop A & Mudge E, 2012], with a mean of 10 (29%) 
(Table 5, Table 6, Table 7).  
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Table 4: Randomized controlled trials methodological quality assessment using the CONSORT checklist 
                                 Study reference 
Topic / Item 
Löndahl M, 
2010 
Duzgun A, 
2008 
Wang C, 
2011 
Abidia A, 
2003 
Wang C, 
2009 
Faglia E, 
1996 
Kessler L, 
2003 
Löndahl M, 
2011 
Kalani M, 
2002 
Lee C, 
2004 
Doctor N, 
1992 
Total 
n (%) 
Title and abstract 
1a            4 (36) 
1b            10 (91) 
Introduction  
Background and objectives 
2a            10 (91) 
2b            10 (91) 
Methods 
Trial design 
3a             0 (0) 
3b            0 (0) 
Participants 
4a            10 (91) 
4b            4 (36) 
Interventions 5            9 (82) 
Outcomes 
6a            9 (82) 
6b            0 (0) 
Sample size 
7a            3 (27) 
7b            0 (0) 
Randomisation 
Sequence generation 
8a            6 (55) 
8b            1 (9) 
Allocation concealment  9            3 (27) 
Implementation 10            0 (0) 
Blinding 
11a            2 (18) 
11b            1 (9) 
Statistical methods 
12a            7 (64) 
12b            0 (0) 
Results 
Participant flow 
13a            10 (91) 
13b            5 (45) 
Recruitment 
14a            8 (73) 
14b            0 (0) 
Baseline data 15            9 (82) 
Numbers analysed 16            10 (91) 
Outcomes and estimation 
17a            10 (91) 
17b            7 (64) 
Ancillary analyses 18            1 (9) 
Harms 19            4 (36) 
Discussion              
Limitations 20            6 (15) 
Generalizability 21            2 (18) 
Interpretation 22            10 (91) 
Other information               
Registration 23            3 (27) 
Protocol 24            0 (0) 
Funding 25            6 (55) 
Total present items (possible 37)  21 20 20 20 19 16 15 14 14 8 8  
We have ordered studies by their CONSORT checklist number of fulfilled items and by sample size (the same criteria as Table 3). Dark grey represent an absent item, light grey represent a present item. n: Number 
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Table 5: Non-randomized trials methodological quality assessment using the STROBE checklist 
                                    Study ref 
Topic / Item 
Zamboni W, 1997 Faglia E,1998 Chen C,2010 BaroniG, 1987 Albuquerque  J, 2005 Oriani G,1990 Perdrizet G,2007 Mendes D, 2012 
Total 
n (%) 
Title and abstract 
1a         1(12) 
1b         6 (75) 
Introduction           
Background 2         6(75) 
Objectives 3         4 (50) 
Methods           
Study design 4         8 (100) 
Setting 5         3 (38) 
Participants 
6a         7(88) 
6b         1 (12) 
Variables 7         2 (25) 
Data sources 8         1(12) 
Bias 9         0 (0) 
Study size 10         0 (0) 
Quantitative Variables 11         3(38) 
Statistical methods 
12a         3(38) 
12b         0 (0) 
12c         0 (0) 
12d         0 (0) 
12e         0 (0) 
Results 13a         2(25) 
Participants 
13b         0 (0) 
13c         0 (0) 
Descriptive data 
14a         7 (88) 
14b         0 (0) 
14c         2(25) 
Outcome data 15         8 (100) 
Main results 
16a         5 (62) 
16b         0 (0) 
16c         0 (0) 
Other analyses 17         0 (0) 
Discussion           
Key results 18         8 (100) 
Limitations 19         4 (50) 
Interpretation 20         1(12) 
Generalizability 21         0 (0) 
Other information           
Funding 22         1(12) 
Total present items (possible 34) 13 12 12 10 10 8 8 8  
We have ordered studies by their STROBE checklist number of fulfilled items and by sample size (the same criteria as Table 3). Dark grey represent an absent item, light grey represent a present item. n: Number 
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Table 6: Cohort studies methodological quality assessment using the STROBE checklist 
                          Study ref 
Topic / Item 
Zgonis T, 2005 Hawkins G, 2006 Otto G, 2000 Mathieu D, 1997 Fife C, 2007 Wattel F, 1991 Hawkins G, 2005 Ong M, 2008 Fife C, 1997 Ramon Y, 1999 
Total 
n (%) 
Title and abstract 
1a           2 (20) 
1b           6 (60) 
Introduction             
Background 2           8 (80) 
Objectives 3           8 (80) 
Methods             
Study design 4           10 (100) 
Setting 5           3 (30) 
Participants 
6a           7 (70) 
6b           0 (0) 
Variables 7           4 (40) 
Data sources 8           2 (20) 
Bias 9           0 (0) 
Study size 10           1 (10) 
Quantitative Variables 11           1 (10) 
Statistical methods 
12a           6 (60) 
12b           0 (0) 
12c           0 (0) 
12d           0 (0) 
12e           0 (0) 
Results 13a           5 (50) 
Participants 
13b           0 (0) 
13c           0 (0) 
Descriptive data 
14a           4(40) 
14b           0 (0) 
14c           2(20) 
Outcome data 15           10(100) 
Main results 
16a           7 (70) 
16b           0 (0) 
16c           0 (0) 
Other analyses 17           0 (0) 
Discussion             
Key results 18           10(100) 
Limitations 19           4 (40) 
Interpretation 20           5 (50) 
Generalizability 21           1 (10) 
Other information             
Funding 22           1 (10) 
Total present items (possible 34) 15 13 13 12 12 11 9 7 7 6  
We have ordered studies by their STROBE checklist number of fulfilled items and by sample size (the same criteria as Table 3). Dark grey represent an absent item, light grey represent a present item. n: Number 
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Table 7: Case series methodological quality assessment using the STROBE checklist 
                                Study ref 
Topic / Item 
Bishop A, 
2012 
Mathieu D, 
1991 
Kaya A, 
2009 
Cianci P, 
1997 
Ҫerkeᶊ N, 
1994 
Subbotina N, 
2002 
Jovanovic T, 
2011 
Oriani G, 
1992 
Wattel F, 
1995 
Zivkovic M, 
1999 
Kawashima M, 
2006 
Buyukcakir C, 
1998 
Total 
n (%) 
Title and abstract 
1a             1 (8) 
1b             6 (50) 
Introduction               
Background 2             10 (83) 
Objectives 3             7 (58) 
Methods               
Study design 4             12 (100) 
Setting 5             2 (16) 
Participants 
6a             9 (75) 
6b             0 (0) 
Variables 7             0 (0) 
Data sources 8             1 (8) 
Bias 9             1 (8) 
Study size 10             4 (33) 
Quantitative Variables 11             1 (8) 
Statistical methods 
12a             6 (50) 
12b             0 (0) 
12c             0 (0) 
12d             0 (0) 
12e             0 (0) 
Results 13a             10 (83) 
Participants 
13b             2 (16) 
13c             0 (0) 
Descriptive data 
14a             7 (58) 
14b             0 (0) 
14c             4 (33) 
Outcome data 15             7 (58) 
Main results 
16a             3 (25) 
16b             0 (0) 
16c             0 (0) 
Other analyses 17             1 (8) 
Discussion               
Key results 18             12 (100) 
Limitations 19             2 (16) 
Interpretation 20             3 (25) 
Generalizability 21             1 (8) 
Other information               
Funding 22             2 (16) 
Total present items (possible 34) 16 13 12 11 11 9 8 7 7 5 4 4  
We have ordered studies by their STROBE checklist number of fulfilled items and by sample size (the same criteria as Table 3). Dark grey represent an absent item, light grey represent a present item. n: Number 
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HBOT efficacy 
Mean wound area reduction 
Only 3 studies reported crude data [Abidia A et al, 2003; Kessler L et al, 2003; Mendes D et al, 2012] for this outcome. 
Abidia [Abidia A et al, 2003] achieved 100% healing in the HBOT group and 95% in the control group, 
although no standard deviation (SD) was available. Kessler [Kessler L et al, 2003] observed no difference in 
the reduction of wound area between groups (61.9±23.3 in the HBOT group vs 55.1 ±21.5% in the 
controls). Zamboni et al [Zamboni W et al, 1997] reported that a higher area reduction occurred in the HBOT 
group, but no data was available. Mendes [Mendes D et al, 2012] reported a 92% area reduction (± 12%) in 
the HBOT group, but all control subjects had an LEA so there was no comparator. 
 
Time to complete healing 
Five studies concluded that subjects in the HBOT group took the same [Kalani M et al, 2002] or less time to 
achieve healing in DFU subjects [Abidia A et al, 2003; Albuquerque-Sousa J, 2005; Baroni G et al, 1987; Lee CT et al, 2004]. 
Abidia [Abidia A et al, 2003] and Albuquerque [Albuquerque-Sousa J, 2005] reported a shorter healing time in the 
HBOT groups (6 vs 9 and 45 vs 55 months, respectively), but SD was not reported.  Lee et al [Lee CT et al, 
2004] reported a shorter healing time in the HBOT group, but no crude data was available. The 
combination of the remaining data from Kalani’s RCT [Kalani M et al, 2002] and Baroni’s NRT [Baroni G et al, 1987], 
suggests a pooled mean difference of 0.8 months shorter healing time in the HBOT group, but this was 
not statistically significant (95%CI -2.5 to +0.9, I2=0%) (Table 8). 
Table 8: Diabetic foot ulcer time until complete healing comparison between subjects treated with or 
without Hyperbaric Oxygen therapy: meta-analysis 
Study 
Time to outcome 
(months) 
Time until complete healing (months) 
HBOT 
[mean (SD)] 
Control 
[mean (SD)] 
Mean difference 
(95% CI) 
RANDOMIZED CONTROLLED TRIALS 
Abidia A et al, 2003 6 6a (2-18) 9a (3-60) NE 
Kalani M et al, 2002 36 15 (7) 15 (4) 
0.0  
(-3.7, 3.7) 
NON RANDOMIZED TRIALS     
Baroni G et al, 1987 b 14 2 (1) 3 (3) 
-1.0  
(-2.9,0.9) 
Albuquerque J, 2005 50c 45 (NR) 55 (NR) NE 
Pooled estimate 
-0.8  
(-2.5,0.9) 
Q statistic 0.22 
I2 statistic 0 % 
a median, b 80% or more granulating tissue or partial/ complete epithelialization, c mean, CI: Confidence Interval, HBOT: Hyperbaric Oxygen 
Therapy, NE: Not Estimable, NR: Not Reported, SD: Standard Deviation 
We have ordered studies by their type, CONSORT or STROBE checklist number of fulfilled items and by sample size (the same criteria as Table 
3) 
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Proportion of ulcers healed 
A total of 15 RCT or NRT [Abidia A et al, 2003; Albuquerque-Sousa J, 2005; Baroni G et al, 1987; Chen CE et al, 2010; Duzgun A et al, 
2008; Kalani M et al, 2002; Kessler L et al, 2003; Lee CT et al, 2004; Löndahl M et al, 2010; Löndahl M et al, 2011; Mendes D et al, 2012; 
Perdrizet G et al, 2007; Wang CJ et al, 2009; Wang CJ et al, 2011; Zamboni W et al, 1997] compared the proportion of healed 
DFU with or without HBOT. In all, except Wang [Wang CJ et al, 2009; Wang CJ et al, 2011], the chance of healing 
tended to be higher in the intervention group.  
Because of clear clinical heterogeneity (both Wang studies [Wang CJ et al, 2009; Wang CJ et al, 2011] did not 
compare HBOT with standard care, but rather with extra-corporeal shock wave therapy), we excluded 
these studies and recalculated our pooled measures. The resultant pooled analysis suggests that DFUs 
are about twice as likely to heal in the HBOT group (RR 2.19, 95% CI1.05 to 4.57).  
Including all available studies, one can observe that the proportion healed was significantly higher in 
those undergoing HBOT (pooled estimate of 58.3% vs 18.5%) (Table 9). 
 
Table 9: Diabetic foot ulcer healing rate comparison between subjects treated with or without 
Hperbaric Oxygen therapy: meta-analysis 
Study 
Time to 
outcome 
(months) 
Healing proportion Association measures 
HBOT Control RR ARR 
n % (CI 95%) n % (CI 95%) (CI 95%) (CI 95%) 
RANDOMIZED CONTROLLED TRIALS   
Löndahl M et al, 2010& 
2011 
12 25  
65.8 
(40.0, 91.6) 
12  
32.4 
(14.1, 50.8) 
2.0  
(1.2, 3.4) 
0.3 
(0.1, 0.6) 
Duzgun A et al, 2008 23 33  
66.0 
(43.5, 88.5) 
0 
0.0 
(NE) 
67.0 
 (4.2, 1064.2) 
0.7 
(0.5, 0.8) 
Wang C et al, 2011 ≥ 11 11 
28.9 
(11.8, 46.0) 
31 
79.5 
(51.5, 100.0) 
0.4  
(0.2, 0.6) 
-0.5 
 (-0.7, -0.3) 
Abidia A et al, 2003 6 5  
55.6 
(6.8, 100.0) 
2 
22.2 
(0.0, 53.0) 
2.5  
(0.6, 9.7) 
0.3  
(0.1, 0.6) 
Wang C et al, 2009 12 8  
22.2 
(6.8, 37.6) 
11 
32.4 
(13.2, 51.5) 
0.7  
(0.3, 1.5) 
-0.1 
(-0.3, 0.1) 
Kessler L et al, 2003 1 2 
14.3 
(0.0, 34.1) 
0  
0.0 
(NE) 
4.7  
(0.2, 89.0) 
0.1  
(-0.07, 0.4) 
Kalani M et al, 2002 36 13  
76.5 
(34.9, 
100.0) 
10  
47.6 
(18.1, 77.1) 
1.6  
(1.0, 2.7) 
0.3  
(-0.09, 0.8) 
Lee C et al, 2004 24 16  
80.0 
(40.8, 
100.0) 
8  
66.7 
(20.5, 100.0) 
1.2  
(0.8, 1.9) 
0.1 
(-0.2, 0.4) 
Pooled estimate 
47.1 
(29.2, 65.0) 
 
25.9 
(14.3, 37.6) 
1.4  
(0.7, 2.7) 
0.2 
(-0.1, 0.5) 
Q statistic 29.2  72.5 41.6 110.4 
I2 statistic 76%  90% 83% 94% 
NON-RANDOMIZED TRIALS   
Zamboni W et al, 1997 NR 5  
100.0 
(12.3, 
100.0) 
1  
20.0 
(0.0, 59.2) 
3.7  
(0.9, 3.4) 
0.8  
(0.4, 1.2) 
Chen C et al, 2010a >6 16  
76.2 
(38.8, 
100.0) 
7  
33.3 
(8.6, 58.0) 
2.3 
(1.2, 4.4) 
0.4  
(0.2, 0.7) 
Baroni G et al, 1987 b 14 16  
88.9 
(45.3, 
100.0) 
1  
10.0 
(0.0, 29.6) 
8.9  
(1.4, 57.5) 
0.8  
(0.6, 1.0) 
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Perdrizet G et al, 2007 2.5 14  
56.0 
(26.7, 85.3) 
8  
32.0 
(9.8, 54.2) 
1.8  
(0.9, 3.4) 
0.2 
(-0.03, 0.5) 
Mendes D et al, 2012 6 5  
55.6 
(6.8, 100.0) 
0  
0.0 
(NE)  
5.5  
(0.4, 80.9) 
0.6  
(0.2, 1.0) 
Albuquerque J, 2005 50c 14  
25.4 
(12.1, 38.8) 
1  
2.4 
(0.0, 7.2) 
10.4  
(1.4, 76.2) 
0.2  
(0.1, 0.4) 
Pooled estimate 
59.7 
(33.7, 85.7) 
 
13.0 
(1.7, 24.3) 
3.2  
(2.1, 5.0) 
0.5  
(0.3, 0.7) 
Q statistic 16.4  12.8 6.8 23.1 
I2 statistic 69%  61% 27% 78% 
PROSPECTIVE COHORT STUDIES   
Hawkins G et al, 2006 NR 31 d, e 
77.5 
(50.2, 
100.0) 
NA 
Not Estimable 
Wattel F et al, 1991 NR 48 
81.4 
(58.3, 
100.0) 
NA 
Hawkins G et al, 2005 NR 
21 d, 
e 
48.8 
(27.9, 69.7) 
NA 
Ong M et al, 2008 NR 32b, f 
71.1 
(46.5, 95.7) 
NA 
Ramon Y et al, 1999 NR 19 
73.1 
(40.2, 
100.0) 
NA 
RETROSPECTIVE COHORT STUDIES 
Zgonis T et al, 2006 1.5-7 28 
80.0 
(50.4, 
100.0) 
NA Not Estimable 
CASE SERIES REPORT   
Bishop A et al, 2012 3 8 
26.7 
(81.9, 45.1) 
NA 
Not Estimable 
Mathieu D et al, 1991 0.7 52 
88.1 
(64.2, 
100.0) 
NA 
Kaya A et al, 2009 NR 115 
62.5 
(51.1, 73.9) 
NA 
Cianci P et al, 1997 NR 27 
65.8 
(41.0, 90.7) 
NA 
Ҫerkeᶊ N et al, 1994 1.5 19 
63.3 
(34.8, 91.8) 
NA 
Subbotina N et al, 2002 NR 69 
36.1 
(27.6, 44.6) 
NA 
Jovanovic T et al, 2011 NR 42 
60.9 
(42.5, 79.3) 
NA 
Wattel F et al, 1995 NR 36 
90.0 
(60.6, 
100.0) 
NA 
Kawashima M et al, 2006 NR 48 
55.2 
(39.6, 70.8) 
NA 
Buyukcakir C et al, 1996 NR 15 
71.4 
(35.3, 
100.0) 
NA 
Pooled estimate 
Q statistic 
I2 statistic 
 
63.6 
(53.6, 73.5) 
NA 
 58.1 
 74% 
TOTAL   
Pooled estimate 
 58.3 
(49.9, 66.8) 
 18.5 
(11.1, 25.8) 
2.0  
(1.2, 3.3) 
0.3  
(0.1, 0.5) 
Q statistic  120.4  88.8 60.7 141.6 
I2 statistic  76%  85% 79% 91% 
a Intervention group: > 10 HBOT sessions and control group: < 10 HBOT sessions, b 80% or more granulating tissue or partial/ complete 
epithelialization, c Mean, d 1 month after HBOT, e Substantially or completely healed, f 1 week after HBOT, ARR: Absolute Risk Reduction, CI: 
Confidence Interval, HBOT: Hyperbaric Oxygen Therapy, NA: Not Applicable, NNT: Number Needed to Treat, NR: Not Reported, RR: Relative 
Risk, RRR: Relative Risk Reduction. We have ordered studies by their type, CONSORT or STROBE checklist number of fulfilled items and by 
sample size (the same criteria as Table 3) 
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Minor lower extremity amputation proportion 
For Doctor [Doctor N et al, 1992] it was not possible to calculate risk measures because the number of 
subjects in each group was not given. 
In 2 NRTs, no minor LEA occurred and in another 2 only global LEA proportion was reported. Pooled 
data from both RCTs and NRTs failed to show any statistical difference in the risk of minor LEA (Table 
10). 
  
Proportion of patients requiring lower limb extremity amputation 
Major LEA (includes all amputations above the mid-foot level) risk was significantly lower in the HBOT 
group when pooling both RCTs and NRTs, but not significantly so when including RCTs only.  
The risk of receiving a major LEA was significantly lower in those receiving HBOT (RR with HBOT 0.4 (CI 
95% 0.1, 1.3) for RCTs, 0.4 (CI 95% 0.2, 0.5) for NRT and 0.3 (CI 95% 0.2, 0.5) combining all studies. 
Overall, when including all available studies for pooled estimate calculation, both major (5.3% vs 
22.4%) and overall LEA (14.6 vs 37.2%) were significantly less frequent in the HBOT group (Table 10).   
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Table 10: Lower extremity amputation proportion comparison between subjects treated with or without Hyperbaric Oxygen therapy: meta-analysis 
Study 
Time to 
outcome 
(months) 
LEA proportion 
Association measures 
Minor LEA 
Association 
measures 
Major LEA 
Association 
measures 
Global LEA 
HBOT Control 
RR 
(CI 95%) 
ARR 
(CI 
95%) 
RR 
(CI 95%) 
ARR 
(CI 
95%) 
RR 
(CI 
95%) 
ARR 
(CI 95%) 
Minor Major Global Minor Major Global 
n 
% 
(CI 95%) 
n 
% 
(CI 
95%) 
% 
(CI 95%) 
n 
% 
(CI 95%) 
n 
% 
(CI 95%) 
% 
(CI 95%) 
RANDOMIZED CONTROLLED TRIALS 
Löndahl M et al, 
2010& 2011 
12 4 
10.5 
(0.2, 20.8) 
3 
7.9 
(0.0, 
16.8) 
18.4 
(4.8, 
32.1) 
4 
10.8 
(0.2, 21.4) 
1 
2.7 
(0.0, 
8.0) 
13.5 
(1.7, 
25.3) 
1.0 
(0.3, 2.8) 
0.0 
(-0.1, 
0.1) 
2.9 
(0.3, 
26.8) 
0.05 
(-0.05, 
0.2) 
1.4 
(0.5, 
3.0) 
0.05 
(-0.1, 
0.2) 
Duzgun A et al, 
2008 
23 4 
8.0 
(0.2, 15.8) 
0 
0.0 
(NE) 
8.0 
(0.2, 
15.8) 
24 
48.0 
(28.8, 67.2) 
17 
34.0 
(17.8, 
50.2) 
82.0 
(56.9, 
100.0) 
0.2 
(0.06, 0.4) 
-0.4 
(-0.6,-
0.2) 
0.03 
(0.0, 
0.5) 
-0.3 
(-0.5, -
0.2) 
0.1 
(0.04, 
0.2) 
-0.7 
(-0.9, -
0.6) 
Abidia A et al, 2003 6 1 
11.1 
(0.0, 32.9) 
1 
11.1 
(0.0, 
32.9) 
22.2 
(0.0, 
53.0) 
0 
0.0 
(NE) 
1 
11.1 
(0.0, 
32.9) 
11.1 
(0.0, 
32.9) 
3.0 
(0.1, 65.2) 
0.1 
(-0.2, 
0.4) 
1.0 
(0.07, 
13.6) 
0.0 
(-0.3, 
0.3) 
2.0 
(0.2, 
18.3) 
0.1 
(-0.2, 
0.4) 
Faglia E et al, 1996 NR 21 
63.6 
(36.4, 90.8) 
3 
9.1 
(0.0, 
19.4) 
72.7 
(43.6, 
100.0) 
12 
34.3 
(14.9, 53.7) 
11 
31.4 
(12.8, 
50.0) 
65.7 
(38.8, 
92.6) 
1.7 
(1.0, 2.8) 
0.2 
(0.01, 
0.5) 
0.3 
(0.08, 
0.8) 
-0.2 
(-0.4, -
0.06) 
1.1 
(0.8, 
1.5) 
0.07 
(-0.2, 
0.3) 
Kalani M et al, 2002 36 0 
0.0 
(NE) 
2 
11.8 
(0.0, 
28.1) 
11.8 
(0.0, 
28.1) 
0 
0.0 
(NE) 
7 
33.3 
(8.6, 
58.0) 
33.3 
(8.6, 
58.0) 
Not 
Estimable 
0.0 
(-0.1, 
0.1) 
0.4 
(0.07, 
13.6) 
-0.2 
(-0.5, 
0.04) 
0.4 
(0.08, 
1.5) 
-0.2 
(-0.5, 
0.04) 
Lee C et al, 2004 24 4 
20.0 
(0.4, 39.6) 
0 
0.0 
(NE) 
20.0 
(0.4, 
39.6) 
4 
33.3 
(0.7, 66.0) 
0 
0.0 
(NE) 
33.3 
(0.7, 
66.0) 
0.6 
(0.2, 2.0) 
-0.1 
(-0.4, 
0.2) 
Not Estimable 
0.6 
(0.2, 
2.0) 
-0.1 
(-0.5, 
0.2) 
Doctor N et al, 1992 NR 4 
Not 
Estimable 
2 Not Estimable 2 
Not 
Estimable 
7 Not Estimable Not Estimable 
Pooled estimate  
13.8 
(3.4, 24.2) 
 
2.0 
(0.0, 
4.8) 
21.7 
(8.3, 
35.0) 
 
16.7 
(5.2, 28.3) 
 
15.6 
(4.9, 
26.4) 
38.9 
(0.1, 
62.4) 
0.7 
(0.3, 2.2) 
-0.04 
(-0.2, 
0.1) 
0.4 
(0.1, 
1.3) 
-0.2 
(-0.3, 
0.04) 
0.6 
(0.2, 
1.8) 
-0.2 
(-0.5, 
0.2) 
Q statistic  27.3  8.3 19.0  39.6  28.7 33.6 19.3 29.0 8.2 34.0 37.6 81.2 
I2 statistic  82%  40% 74%  87 %  82% 85% 79% 83% 51% 85% 87% 94% 
NON RANDOMIZED TRIALS 
Zamboni W et al, 
1997 
NR 0 
0.0 
(NE) 
0 
0.0 
(NE) 
0.0 
(NE) 
0 
0.0 
(NE) 
0 
0.0 
(NE) 
2.0 
(0.0, 
14.4) Not Estimable 
Not Estimable Not Estimable 
Faglia E et al, 1998 NR 0 
0 
(NE) 
7 13.7 13.7 0 
0.0 
(NE) 
20 31.2 31.2 0.4 -0.2 0.4 -0.2 
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(3.6, 
23.9) 
(3.6, 
23.9) 
(17.6, 
44.9) 
(17.5, 
44.9) 
(0.2, 
1.0) 
(-0.3, -
0.03) 
(0.2, 
1.0) 
(-0.32, -
0.03) 
Chen C et al, 2010a >6 0 
0 
(NE) 
4 
19.0 
(0.4, 
37.7) 
 
19.0 
(0.4, 
37.7) 
0 
0.0 
(NE) 
10 
47.6 
(18.1, 
77.1) 
47.6 
(18.1, 
77.1) 
0.4 
(0.1, 
1.1) 
-0.3 
(-0.5, -
0.01) 
0.4 
(0.2, 
1.1) 
-0.3 
(-0.6, -
0.01) 
Baroni et al, 1987 b 14 0 
0 
(NE) 
2 
11.1 
(0.0, 
26.5) 
11.1 
(0.0, 
26.5) 
0 
0.0 
(NE) 
4 
40.0 
(0.8, 
79.2) 
40.0 
(0.8, 
0.79) 
0.3 
(0.06, 
1.3) 
-0.3 
(-0.6, 
0.05) 
0.3 
(0.06, 
1.3) 
-0.3 
(-0.6, 
0.05) 
Oriani G et al, 1990 NR 3 
4.8 
(0.0, 
10.3) 
6 
33.3 
(6.7, 
60.0) 
Not Estimable 
0.2 
(0.04, 
0.5) 
-0.3 
(-0.5, -
0.06) 
Perdrizet G et al, 
2007 
2.5 4 
16.0 
(0.3, 
31.7) 
8 
32.0 
(9.8, 
54.2) 
Not Estimable 
0.5 
(0.2, 
1.4) 
-0.2 
(-0.4, 
0.07) 
Mendes D et al, 
2012 
6 0 
0 
(NE) 
0 
0.0 
(NE) 
1.1 
(0.0, 8.0) 
1 
25.0 
(0.0, 74.0) 
3 
75.0 
(0.0, 
100.0) 
100.0 
(2.0, 
100.0) 
0.2 
(0.01, 3.4) 
-0.2 
(-0.6, 
0.2) 
0.07 
(0.0, 
1.1) 
-0.7 
(-1.2, -
0.3) 
0.06 
(0.0, 
0.8) 
-1.0 
(-1.3, -
0.7) 
Albuquerque J, 
2005 
50c 7 
12.7 
(3.3, 22.2) 
8 
14.5 
(4.4, 
24.6) 
27.3 
(13.5, 
41.1) 
10 
24.4 
(9.3, 39.5) 
17 
41.5 
(21.8, 
61.2) 
65.8 
(41.7, 
90.7) 
0.4 
(0.2, 1.3) 
-0.2 
(-0.3, 
0.04) 
0.4 
(0.2, 
0.7) 
-0.3 
(-0.5,-
0.09) 
0.4 
(0.3, 
0.7) 
-0.4 
(-0.6, -
0.2) 
Pooled estimate  
0.8 
(0.0, 2.5) 
 
8.9 
(2.7, 
15.1) 
10.0 
(4.1, 
16.1) 
 
1.5 
(0.0, 4.6) 
 
32.0 
(13.0, 
50.9) 
36.0 
(18.6, 
53.4) 
0.5 
(0.2, 1.1) 
-0.13 
(-0.3, 
0.02) 
0.4 
(0.2, 
0.5) 
-0.3 
(-0.4, -
0.1) 
0.4 
(0.3, 
0.5) 
-0.4 
(-0.5, -
0.2) 
Q statistic  6.8  9.0 17.1  11.0  20.6 30.2 0.5 0.3 1.7 6.5 4.8 26.9 
I2 statistic  26%  45% 59%  54%  76% 77% 0% 0% 0% 38% 0% 78% 
PROSPECTIVE COHORT STUDIES 
Wattel F et al, 1991 NR 11 19 
18.6 
(7.6, 
29.7) 
Not applicable Not Estimable 
CASE SERIES REPORT 
Bishop A et al, 2012 3 1 
3.3 
(0.0, 9.9) 
Not applicable Not Estimable 
Mathieu D et al, 
1991 
0.7 7 
11.9 
(3.1, 
20.6) 
Kaya A et al, 2009 NR 29 
15.8 
(10.0, 21.5) 
9 
4.9 
(1.7, 
8.1) 
20.6 
(14.1, 
27.2) 
Cianci P et al, 1997 NR 0 
0 
(NE) 
1 
2.4 
(2.3, 
7.2) 
2.4 
(0.0, 7.2) 
Ҫerkeᶊ N et al, 1994 1.5 6 
20.0 
(4.0, 36.0) 
5 16.7 36.7 
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(2.0, 
31.3) 
(15.0, 
58.3) 
Jovanovic T et al, 
2011 
NR 9 
13.0 
(4.5, 21.6) 
0 
0.0 
(NE) 
13.0 
(4.5, 
21.6) 
Oriani G et al, 1992 NR NR 21 
13.9 
(8.0, 
19.8) 
13.9 
(8.0, 
19.8) 
Wattel F et al, 1995 NR 14 
35.0 
(16.7, 
53.3) 
Zivkovic M et al, 
1999 
NR 6 
14.6 
(2.9, 26.3) 
4 
9.8 
(0.2, 
19.3) 
24.4 
(9.3, 
39.5) 
Buyukcakir C et al, 
1996 
NR 0 
0.0 
(NE) 
6 
28.6 
(5.7, 
51.4) 
28.6 
(5.7, 
51.4) 
Pooled estimate 
8.6 
(2.8, 14.4) 
 
7.2 
(2.4, 
11.9) 
15.9 
(10.0, 
21.8) 
Q statistic 43.8  40.8 46.1 
I2 statistic 88%  85% 78% 
TOTAL                
Pooled estimate 
5.2 
(2.7, 7.6) 
 
5.3 
(3.1, 
7.5) 
14.6 
(10.6, 
18.7) 
 
5.7 
(1.9, 9.6) 
 
22.4 
(12.4, 
32.3) 
37.2 
(24.0, 
50.5) 
0.6 
(0.3, 1.6) 
-0.07 
(-0.2, 
0.1) 
0.3 
(0.2, 
0.5) 
-0.2 
(-0.4, -
0.09) 
0.4 
(0.2, 
0.7) 
-0.3 
(-0.4, -
0.09) 
Q statistic 83.7  67.9 87.8  53.8  66.3 64.1 24.1 30.3 9.5 40.0 53.7 107.6 
I2 statistic 80%  74% 73%  80%  83% 80% 75% 80% 5% 77% 78% 89% 
a intervention group: > 10 HBOT sessions and control group: < 10 HBOT sessions, b 80% or more granulating tissue or partial/ complete epithelialization, c mean, ARR: Absolute Risk Reduction, CI: Confidence Interval, 
HBOT: Hyperbaric Oxygen Therapy, min: Minor, maj: Major, NA: Not Applicable, NNT: Number Needed To Treat, NR: Not Reported, RR: Relative Risk, RRR: Relative Risk Reduction 
We have ordered studies by their type, CONSORT or STROBE checklist number of fulfilled items and by sample size (the same criteria as Table 3) 
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Predictors of healing with HBOT 
Of the reported patient characteristics, age [Chen CE et al, 2010; Wattel F et al, 1991], gender [Hawkins G et al, 
2006; Wattel F et al, 1991], diabetes duration [Chen CE et al, 2010], insulin use [Wattel F et al, 1991; Fife C et al, 2007], 
nephropathy [Wattel F et al, 1991] and retinopathy [Wattel F et al, 1991] failed to have a statistically 
significant impact on the chance of healing when considered in isolation. On the other hand, 
when chronological age and the duration of diabetes were combined [Otto G et al, 2000; Fife C et al, 1997; 
Fife C et al, 2007] there was a significant association with the chance of healing, as there was with  
renal failure (dialysis dependent or a history of kidney transplant) [Fife C et al, 2007] and smoking 
habits (> 10 packs-year) [Otto G et al, 2000; Fife C et al, 1997; Fife C et al, 2007]. 
Only Chen et al [Chen CE et al, 2010] analysed biochemical parameters and found no association with 
healing. 
As to other potential predictors, ABI [Chen CE at al, 2010; Löndahl M et al, 2011], large vessel alteration 
[Wattel F et al, 1991], laser Doppler flowmetry [Mathieu D et al, 1997], microangiopathy [Wattel F et al, 1991], 
neuropathy [Wattel F et al, 1991; Zamboni W et al, 1997], presence of a palpable dorsalis pedal pulse [Ong M, 
2008], previous LEA [Zamboni W et al, 1997], surgeries [Chen CE et al, 2010] and toe blood pressure [Löndahl M 
et al, 2011] were not associated with DFU healing. 
Ramon et al [Ramon Y et al, 1999] did not report if statistical analysis was done, nonetheless, they 
concluded that subjects with severe peripheral arterial disease had less chance of healing.  
Even though in some studies it did not achieve statistical significance [Hawkins G et al, 2006; Wattel F et 
al, 1991], higher TcPO2 values, when measured close to the wound at sea level or under HBOT 
conditions, were associated with wound healing in both in univariate and multivariate analyses 
[Fife C et al, 2007; Löndahl M et al, 2011; Mathieu D et al, 1997; Otto G et al, 2000; Wattel F et al, 1991; Zgonis T et al, 2005].  
Neither the DFUr area nor duration were associated with chance of healing in a single study 
[Hawkins G et al, 2006]. DFUs arising following trauma appeared to have a better outcome in Fife 1997 
[Fife C et all, 1997], while higher Wagner grade [Fife C et al, 1997; Fife C et al, 2007; Otto G et al, 2000] and the 
product of the total wound(s) volume (cm3) and Wagner grade value [Fife C et al, 1997] were 
associated with non-healing. 
Only ten of the included studies in our systematic review sought any association between wound 
healing and any of these potential associated factors (Table 11). 
 
  
- 64 - 
 
Table 11: Variables association with complete diabetic foot ulcer healing in subjects undergoing 
Hyperbaric Oxygen therapy 
                               Association 
Variable 
Present Absent 
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
Patient characteristics     
Age   
Chen C et al, 2010 [62];Fife 
C et al, 2007 [67]; Wattel F 
et al, 1991 [31] 
 
Age + diabetes duration ↓ Fife C et al, 1997 [43] 
↓ Otto G et al, 2000 
[42];Fife C et al 2007 [67] 
  
Gender   
Hawkins G et al, 2006 
[30];Wattel F et al, 1991 
[31] 
 
Diabetes Duration   
Chen C et al, 2010 [62];Fife 
C  et al, 2007 [67] 
 
Insulin use   
Wattel F et al, 1991 
[31];Fife C et al, 2007[67] 
 
Nephropathy   Wattel F et al, 1991 [31]  
Renal failure ↓ Fife C et al, 2007[67]    
Retinopathy   Wattel F et al, 1991 [31]  
Smoking habits 
↓ Fife C et al,2007 [67];Fife 
C et al,1997 [43] 
↓Otto G et al, 2000 
[42];Fife C et al, 2007[67] 
  
Analytic parameters     
Albumin   Chen C et al, 2010 [62]  
CRP   Chen C et al, 2010 [62]  
ESR   Chen C et al, 2010 [62]  
Haemoglobin   Chen C et al, 2010 [62]  
HbA1c   Chen C et al, 2010 [62]  
Leucocyte count   Chen C et al, 2010 [62]  
Total lymphocyte   Chen C et al, 2010 [62]  
Foot characteristics     
ABI   
Löndahl M et al, 2011 
[53];Chen C et al, 2010 
[62] 
Löndahl M et al, 2011 
[53] 
Large vessel alteration   Wattel F et al, 1991[31]  
Laser Doppler flowmetry   Mathieu D et al, 1997 [40]  
Microangiopathy   Wattel F et al, 1991 [31]  
Neuropathy   
Wattel F et al, 1991 
[31];Fife  C et al,2007[67] 
 
Palpable dorsalis pedal pulse   Ong G et al, 2008 [65]  
Previous amputation   Fife C et al,2007[67]  
Surgeries   Chen C et al, 2010 [62]  
TcPO2     
Air   Mathieu D et al, 1997 [40]  
- At wound 
↑Löndahl M et al, 2011[53]; 
Zgonis T et al, 2005 [66] 
↑Löndahl M et al, 2011 
[53]; Otto G et al, 2000 
[42];Fife C et al, 2007[67] 
Hawkins G et al, 
2006[30];Wattel F et al, 
1991 [31] 
 
- At reference point   Wattel F et al, 1991 [31]  
HBOT ↑Mathieu D et al, 1997[40]    
- At wound 
↑ Wattel F et al, 1991 
[31];Fife C et al,2007[67] 
   
- At reference point   Wattel F et al, 1991 [31]  
Toe Blood Pressure   Löndahl M et al, 2011 [53] 
Löndahl M et al, 2011 
[53] 
DFU characteristics     
Area   Hawkins G et al, 2006 [30]  
Duration   Hawkins G et al, 2006 [30]  
Traumatic aetiology  ↑ Fife C et al,1997 [43]    
Wagner grade 
↓ Fife C et al, 2007 [67]; 
Fife C et al, 1997 [43] 
↓Otto G et al, 2000 [42]; 
Fife C et al,2007 [67] 
  
All wound volume * Wagner 
grade 
↓ Fife C et al,1997 [43]    
 
↓: impairs healing, ↑: improves healing, ABI: ankle brachial index, CRP: C-Reactive Protein, DFU: Diabetic Foot Ulcer, ESR: 
Erythrocyte Sedimentation Rate, HbA1c: Glycated Haemoglobin, TcPO2: Transcutaneous Partial Pressure of Oxygen 
We have ordered studies by their type, CONSORT or STROBE checklist number of fulfilled items and by sample size (the same criteria 
as Table 3) 
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Hawkins [Hawkins G et al, 2006], considering outcome 1 month after HBOT, suggested a model 
including DFU area, DFU duration, and TcPO2, but these variables were not significant in their 
univariate analysis. Fife [Fife C et al, 2007] proposed a model, through multiple regression analysis, 
to predict outcome of patients undergoing HBOT and identify patients that would most benefit 
with this therapy. The score includes all the variables that were significantly associated with 
complete or partially healing in their multivariate analysis: the number of HBOT sessions, TcPO2, 
function for pack-years of smoking, maximal Wagner grade, age + duration of diabetes and 
interruption of the treatment regimen. For both models no prognostic accuracy measures were 
reported or possible to calculate. 
 
Publication bias assessment 
As for all outcomes we could not retrieve more than 10 studies within each type, we considered 
that funnel plot analysis would not be helpful.  
3. Discussion 
This study was designed to further establish or refute the case for the use of HBOT as an 
adjunctive treatment for DFU. We have made a systematic search for all relevant clinical studies 
and combined them where possible for statistical analysis.  
The fact that more than half of the included studies were retrieved outside the MEDLINE Indexed 
search indicates that the majority of the presented works were either never published in full, or 
only in the “Grey” literature. To the best of our knowledge, this is the first study both to meta-
analyse all the available studies for HBOT efficacy on DFU healing and to evaluate the 
methodological quality of those studies. In addition, no systematic review of factors or models 
to identify patients that would most benefit from HBOT has been done.  
Our review suggests that overall, the addition of HBOT to the care of the DFU results in a higher 
chance of healing [RR 2.2], perhaps over a shorter [0.8 months less (95%CI -2.5 to + 0.9)] and a 
lower risk of major amputation when compared with standard care. 
Regarding the average reduction in the area of a DFU only few studies with incomplete data 
assessed this outcome and further research is needed if this is to be regarded as an important 
outcome.  
In terms of LEA, in our opinion the main goal is to reduce the chance of a patient requiring a 
major LEA. Such amputations carry a considerable burden in terms of the individuals’ quality of 
- 66 - 
 
life, physical limitation and increased risk of future contralateral lesions. According to our 
results, HBOT is effective in reducing the chance of needing a major LEA. 
Our conclusions are based on all the available clinical evidence and for that reason they 
represent the best estimate we can make at this time of the true clinical impact of HBOT on this 
important complication of diabetes. However, our pooled estimates of effect are based on both 
randomised and non-randomised evidence, and should be treated with caution for a number of 
reasons discussed below. Our approach has several strengths and weaknesses. 
Although much of the data are derived from non-randomised sources, selection procedures 
when described were by consecutive case inclusion, which potentially improves the validity of 
our results. Such an inclusive sampling technique means there is less chance of selection factors 
biasing the outcome over the broad spectrum of patients with DFU. No patient is selected based 
on baseline characteristics or healing potential and, when the study period is sufficiently long, 
seasonal or other time-related factors should be accounted for [Hulley S & Cummings S, 1988]. On the 
other hand, when HBOT administration depends upon a physician decision, patient refusal or 
the presence of a contraindication, there remains a considerable possibility of selection bias, 
leading to a confounded result. 
Participant characteristics were poorly described in general, especially in cohort studies and case 
series, and nine of the studies are abstracts or posters with very limited information and limited 
peer review. 
Inclusion criteria usually included chronic DFU. The period of time these ulcers were present 
prior to enrolment varied greatly across the included studies, and this may have a considerable 
impact on the effectiveness of HBOT. We would postulate that those ulcers present for long 
periods would be more resistant to all attempts to heal, including HBOT. Unfortunately, the data 
reported in the included studies precluded any attempt to test this hypothesis.  
In more than half of the studies, total sample size was less than 50 subjects, which is probably 
responsible for the fact that few studies achieved statistically significant results and carried wide 
CI. Only 3 studies, conducted by the same group of authors in the same institutions, were 
multicentre. Studies with such small sample sizes and done in single institutions represent low 
evidence levels as they are more prone to bias and diminished generalizability. Multicentre 
studies usually include larger samples, from a wider range of population groups and different 
locations and present the possibility of comparing the result from different centers, which 
improves generalizability. 
There was considerable variation in the course of HBOT delivered across these studies. The 
mean number of sessions ranged from 4 to 111, durations of each session from 45 to 120 
- 67 - 
 
minutes, the frequency (once or twice per day, from 4 to 7 days per week), and pressure (2 to 3 
ATA). It is possible these factors are responsible for some of the heterogeneity between trial 
results. It is crucial to define the optimal HBOT protocol if standardize clinical care is to be widely 
implemented. In our opinion, the data available did not allow us to propose such a protocol; 
further research designed especially for this purpose is needed so that a consensus could be 
reached. 
The methodological quality of reporting was generally very poor in the included studies, with 
important methodological information absent from most studies. It is perhaps surprising that 
even the RCTs are so poorly reported, given the time and efforts required to plan and complete 
them. Authors should consider available checklists to improve reporting quality and, 
consequently, results’ evaluation and protocol replication. 
Even though RCTs (corresponding only to 27% of the available evidence on this topic) represent 
the highest level of evidence, they present the various limitations described above. The question 
of whether to include only RCTs or also observational studies in MA is still under debate and is 
addressed in the Shrier study [Shrier I et al, 2007]. We have decided to include all types of studies in 
order to globally evaluate available evidence and to try and understand where the results differ 
according to methodology. We hope our pooled estimates can also be useful when estimating 
sample sizes for future cost-benefit studies. 
In general, it is expected that NRTs will give larger estimates for the effect of any intervention. 
For all this, we decided not only to calculate all measures aggregating all available evidence, but 
also by study type. When considering RCTs in isolation, no statistical significance was achieved 
for the chance of healing, minor or total LEA proportions, in contrast to positive findings when 
NRTs were included in the pooled analyses. 
The largest RCT included in this review enrolled 50 subjects in each arm [Duzgun A et al, 2008]. 
However, using our pooled estimates of effect, we calculate that the sample size required to 
detect statistically significant differences (for an 80% power at the 0.05 significance level) it 
would be necessary to include 65 subjects in each arm for major LEAs and 114 for total LEAs. All 
the reported RCTs seem to be underpowered in this respect.  
All these factors could explain why RCTs did not achieve statistical significance, though pooled 
measures consistently tended to favour HBOT. 
Despite the fact that association measures for minor and major LEAs did not reveal a substantial 
difference between study types, we noted that the NRT generally reported lower rates of minor 
LEA with HBOT, while the RCTs presented lower rates of major LEA with HBOT. We do not know 
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the reason for this. It may be a product of different inclusion criteria or comparator therapy or 
simply a chance finding. 
While it is possible to draw a range of conclusions from the data presented here, overall there 
does seem to exist some support for the continued use of HBOT in the care of selected patients 
with DFUs. The question as to which patients are most likely to benefit remains of great 
importance. The analysis of those factors most strongly associated with either better or worse 
outcome has been rarely undertaken, and then most often with fewer than 100 subjects 
included and different variables assessed in each study. Only three factors have been included 
in more than one study: age, age+ duration of diabetes and TcPO2. Interestingly, while no 
statistical association between age and healing is apparent, there is such an association with the 
function of age + diabetes duration, and this deserves further investigation. 
TcPO2is another commonly discussed predictor of healing. Across these studies the O2 tensions 
have been measured at different sites and environmental pressure resulting in conflicting 
results. Smart reviewed this area and concluded that peri-wound TcPO2 measured while 
breathing air at environmental pressure confirms hypoxia, but does not predict DFU outcome 
with HBOT, whereas when measured under hyperbaric conditions and breathing 100% oxygen 
a TcPO2 superior to 200 mmHg is a useful healing predictor [Smart D et al, 2006]. We have only 
retrieved 3 studies in the latter circumstances [Doctor N et al, 1992; Oriani G et al, 1990; Wattel F et al, 1995] 
and, in all, higher values were associated with improved healing, in their univariate analysis. 
Additionally, multivariate analysis was conducted only in 3 studies. Furthermore, only two 
articles attempted to create predictive models for this purpose. Hawkins et al [Hawkins G et al, 2006] 
used variables with no significant association with healing in univariate analysis and Fife et al [Fife 
C et al, 2007] used post-HBOT variables (number of sessions and treatment interruption) that 
cannot be used to predict the outcome in patients presenting for treatment. Neither predictive 
model has been externally validated. 
This study was conducted respecting Meta-analysis Of Observational Studies in Epidemiology 
(MOOSE) [Stroup D et al, 2000] and Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) [Liberati A et al, 2009] checklists which were created to help develop and assess 
systematic reviews and MA including observational and RCT studies, respectively. 
There are a few limitations in our study, namely the exclusion of one Chinese article [Lee SS et al, 
1997] for linguistic limitations, methodological quality assessment by only one of the researchers 
and a high level of heterogeneity between the included studies.  
Publication bias was not observed across the limited sample size for the majority of the assessed 
outcomes. 
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In summary, using the SIGN (Scottish Intercollegiate Guideline Network) system for grading 
recommendations [Harbour R et al, 2001], we conclude that HBOT prevents major LEA with an A grade.  
However, for the remaining outcomes (time until complete healing, healing proportion and 
minor and total LEA) the grade lowers to a B. 
Despite a high number of studies assessing HBOT effect on DFU healing, this topic is still far from 
allowing unequivocal conclusions to be drawn. Thus, future research is crucial and should 
include therapy protocol definition improvement, use institutions’ available data for 
retrospective cohort studies creating and/or validating models for a more rational HBOT 
allocation, conduction of RCTs with larger sample sizes and improved methodological reporting 
and cost-effectiveness assessment. Scientific and medical societies in this area should consider 
creation of a specific checklist to enhance quality reporting and stimulate multicentre studies to 
allow a new and higher recommendation level. 
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V. Molecular environment 
characterization, Hyperbaric 
Oxygen therapy modulator effect 
and clinical impact on diabetic foot 
ulcers healing 
A. Material and Methods 
1. Study design and participants selection 
A non-randomized clinical trial was conducted at Centro Hospitalar de Vila Nova de 
Gaia/Espinho, EPE (Entidade Pública Empresarial) Diabetic Foot Outpatient Clinic, which is a 
tertiary care unit with a multidisciplinary team.  
The clinical trial was registered in the Brazilian Clinical Trial Registry (Registro Brasileiro de 
Ensaios Clínicos) number UTN U1111-1146-8232 and approved by the Ethics Committee of our 
institution. 
Subjects with active DFU, a full-thickness skin defect distal to the malleoli requiring more than 
15 days to heal [Boyko EJ et al, 1996], that, after 8 weeks of standard treatment (including angioplasty 
and/or revascularization surgery if needed), had no significant wound improvement (no healing 
or ulcer area reduction < 30%) were consecutively proposed to HBOT. 
Participants were included from the 1st October 2010 until the 31st December 2012.  
HBOT proposal was performed in accordance to the multidisciplinary team and financial 
department approval. Team decision relied on selecting patients that would most benefit of 
healing, excluding namely patients bedridden and dependent on third person for daily life 
activities. Therefore, HBOT was used, depending on hospital economic resources and availability 
of the HBOT facility, as last resource in people that despite maximized macrovascular blood flow 
had no healing. 
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These participants were divided in two groups: HBOT – treated with HBOT and NHBOT – patients 
that refused the treatment or had a contra-indication.  
Both groups with DFU were compared with a group of non-DFU diabetic subjects that were 
participating in an educative program on diabetes in our department.  
HBOT was performed in the referral area HBOT center (Unidade de Medicina Hiperbárica of 
PHH) according to the used treatment protocol - 80 minutes at 2.4 ATA, once a day, five days a 
week, up to a maximum of 100 sessions. 
Standard care was conveyed in the DFU groups by a team independent of the investigators. In 
case of multiple ulcers, evolution of the larger DFU was evaluated through the decrease in the 
wound measures.  
All subjects were followed for twelve months to evaluate healing in the DFU groups and the 
potential occurrence of lesions in the non-DFU subjects. 
 
2. Participants and diabetic foot ulcer characteristics  
At enrollment, the following demographic characteristics were collected: age at the time of 
inclusion; gender; DM type (classified according to the World Health Organization definition 
[WHO,2006]), duration (in years) and treatment (oral anti-diabetic agents or insulin); metabolic 
control [through HbA1C]; smoking habits; presence of any DM related complications (namely, 
retinopathy, nephropathy, neuropathy, cerebrovascular, cardiovascular and/or PAD and 
metabolic),  were registered in accordance to the definition used in the Diabetes Complications 
Severity Index created by Young et al [Young BA et al, 2008].  
For the foot characterization we used the presence of PAD, when only one or fewer pedal pulses 
were palpable on the DFU foot [Monteiro-Soares M et al, 2010 B] and/or the ankle-brachial index (ABI) 
was inferior to 0.8  [Armstrong DG et al, 1998 B]; TcPO2, determined by measuring once at 2 points peri-
DFU and reporting the highest value; DPN, defined as inability to feel the SWM at one or more 
of 4 sites in the foot [Smieja M et al, 1999]; and previous DFU or LEA. We also recorded the ulcer area 
(in cm2), reported duration (in months), location, Texas University classification (TUC) [Armstrong 
DG et al, 1998 B], number of DFUs and the presence or absence of infection.  
DFU photographic and dimensional records (area, maximum and mean depths and volume) 
were performed using a digital wound measurement device (Aranz Medical Silhouette Mobile 
TM), at baseline, and if still with active DFU, at months 3, 6 and at the end of follow-up (12 
months). Based on the area measurements, percentage of epithelialization was calculated on 
the same endpoints. 
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Considering the HBOT description, the total number of sessions, whether or not the planned 
number of sessions was completed and side-effects were registered. 
We have considered complete healing when the DFU presented full epithelialization without the 
need of further dressing [Younes N & Albsoul A, 2004]. Minor LEA was defined as amputation distal to 
or including the forefoot and major LEA was considered amputation above or by the ankle [Beckert 
S et al, 2006].  
Clinical outcome occurrence was also assessed at 3, 6 and 12 months. 
 
3. Laboratory and molecular analysis 
In all three groups (non-DFU, HBOT, NHBOT) blood samples were collected at baseline and 3 
months after, in the HBOT group a sample was drawn also at 6 months. Additionally, in the DFU 
groups ulcer debridement material was collected at 0 and 1 months. Blood samples were 
collected to EDTA (ethylenediamine tetraacetic acid) or gel and clot activator tubes.  
Full blood count was performed using an automated hematology analyzer XE 2100 or 5000 from 
the Sysmex Corporation. 
Serum was analysed for glucose, urea, creatinine, total proteins, albumin, lipid profile, uric acid 
and C-reactive protein (CRP) with the Cobas 8000c701 (Roche). 
HbA1c was determined through high pressure chromatography in the Horiba Medical G7 device. 
Microalbuminuria level was evaluated by immunoturbidimetry with Cobas 6000 c501 analyzer 
(Roche). 
Angiogenic (VEGF, PlGF), vasculogenic (SDF1-α) and inflammatory (TNF-α) markers were 
determined by enzyme-linked immunoabsorbent assay (ELISA) multiplex using Quantikine ELISA 
Immunoassay kits, according to manufacturer instructions. 
Ulcer bed tissue was collected, when DFU debridement was performed, for histological and 
immunohistochemistry studies. The tissue specimens were fixed in 10% neutral-buffered 
formalin solution and paraffin-embedded. Three-micrometer sections were stained with 
hematoxylin and eosin (H&E) or used for capillary endothelial cells immunostaining. Endogenous 
peroxidase activity was blocked with 4% hydrogen peroxide in phosphate buffered saline (PBS) 
for 30 minutes at room temperature. To retrieve antigen, sections were placed in 10 mM citrate 
buffer (pH = 6) and heated at 98°C. After blocking with 10% bovine serum albumin (BSA) in PBS 
for 1 hour, sections were incubated with primary antibody against CD31 (1:100) (Abcam, 
Cambridge, UK) overnight at 4°C. Then, anti-rabbit secondary antibody (1:200) (Santa Cruz 
Biotechnology, USA) was applied for 30 minutes. Avidin Biotin Complex (ABC) complex method 
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(Vectastain ABC kit, Vector, Burlingame, CA, USA) was used according to the manufacturer’s 
instructions. The antigen-antibody reaction was developed using diaminobenzidine (DAB) (DAB 
substract kit, Abcam, Cambridge, UK) as peroxidase substrate, rendering CD31 positive cells with 
a brown staining. Sections were counterstained with hematoxylin (Sigma-Aldrich, Portugal), 
dehydrated and coverslipped. Cluster of differentiation 31 (CD31)-expressing microvessels were 
counted in the three most vascularized areas with magnification of 200 x, and the data were 
averaged and normalized to the total area of the tissue section. Any positive-staining endothelial 
cell or endothelial cell cluster that was separated from adjacent microvessels was considered an 
individual vessel [Soares R et al, 2004]. 
All laboratory/molecular studies were performed by investigators blinded to the subjects’ group 
allocation. 
 
4. Statistical analysis 
Continuous variables will be described by mean and SD, in the case of having normal distribution, 
or median and range otherwise. Normality of the distribution will be assessed through the 
histogram analysis.  
Comparison between 2 groups will be conducted with t-test for independent samples or Mann-
Whitney U test, according to the variable distribution. For the comparison between 2 moments 
in the same group we will use the t-test for paired samples or Wilcoxon signed rank test, when 
pertinent. For the comparison between 3 moments, the Wilcoxon signed rank or the Friedman 
test were used, according to the variable distribution. 
For differences’ evaluation between variables in the 3 groups, the One-Way ANOVA test (using 
the Bonferroni correction) or the Kruskall-Wallis test will be applied. 
For categorical variables description, frequency and percentage will be used and, for association 
analysis, the Χ2 or Fisher’s exact test (when applicable). 
All tests were two sided, p values less than 0.05 were considered as statistically significant. 
Statistical analysis was performed using the IBM SPSS version 22.0 (Chicago, IL, USA). 
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B. Results 
1. Participants characteristics 
We included a total of 25 patients: 5 in the non-DFU, 6 in the NHBOT DFU and 14 in the HBOT 
DFU groups described in Table 12. 
The DFU participants were allocated not to undergo HBOT due to refusal of treatment in 5 
patients and 1 for presenting a contra-indication. 
The mean age in our sample was 62 years and DM duration 18 years, and the majority were 
men, with type 2 DM treated with insulin, with visual and physical impairment. Concerning DM 
complications, most had retinopathy, PAD complications and neuropathy. The mean 
complications count was 4 [Young BA et al, 2008] and the non-DFU group had significantly less PAD 
complications and tended to present less frequently the remaining complications. 
The non-DFU group was composed mainly by female subjects by way of chance, such difference 
presented statistical significance. 
Concerning the total foot pulses number, non-DFU persons had a significantly higher number 
comparing to both DFU groups.  
Intermittent claudication was significantly more common in the non-HBOT DFU participants, as 
they tended to present more PAD complications, ischemia diagnosed by pulses palpation and 
statistically significant less frequently DPN diagnosed by SWM. 
Almost all DFUs reached the bone and were infected and ischemic. Several were post-minor LEA 
and 25% were located in the toes. 
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Table 12. Participants baseline characteristics 
Variables 
Global 
(n=25) 
Non-DFU  
(n=5) 
 
NHBOT DFU 
(n=6) 
HBOT DFU 
(n=14) p value 
SUBJECT CHARACTERIZATION 
Age [mean (SD)] 62 (12) 68 (10) 63 (11) 61 (13) 0.6*,a 
Male gender [n (%)] 18 (72) 1 (20) 6 (100) 11 (79) 0.009/0.006¥ 
Visual impairment [n (%)] 19 (76) 3 (60) 5 (83) 11 (79) 0.6/0.5¥ 
Physical impairment [n (%)] 16 (64) 3 (60) 4 (67) 9 (64) 0.7/0.9¥ 
Past or present smoker [n (%)] 13 (52) 1 (20) 4 (67) 8 (57) 0.3/0.3¥ 
DM AND ITS COMPLICATIONS 
Type 2 [n (%)] 23 (92) 4 (80) 6 (100) 13 (93) 0.5/0.5¥ 
Duration (in years) [mean (SD)] 18 (9) 26 (19) 15 (7) 20 (10) 0.3*, a 
Insulin use [n (%)] 17 (68) 3 (60) 5 (83) 9 (64) 0.6/0.9¥ 
Cardiovascular complications history [n (%)] 7 (28) 1 (20) 1 (17) 5 (36) 0.6/0.4¥ 
Retinopathy complications history [n (%)] 21 (84) 3 (60) 6 (100) 12 (86) 0.2/0.3¥ 
Nephropathy complications history [n (%)] 12 (48) 1 (20) 5 (83) 6 (43) 0.1/0.7¥ 
Cerebrovascular complications history [n (%)] 3 (12) 0 (0) 0 (0) 3 (21) 0.3/0.1¥ 
PAD complications history [n (%)] 18 (72) 1 (20) 6 (100) 13 (93) 0.001/0.003¥ 
Neuropathy complications history [n (%)] 22 (88) 5 (100) 4 (67) 13 (93) 0.2/1.0¥ 
Metabolic complications history [n (%)] 11 (44) 2 (40) 2 (33) 7 (50) 0.8//0.6¥ 
Complications count [mean (SD)] 4 (1) 3 (1) 4 (2) 4 (2) 0.1*, a 
DFU FOOT CHARACTERIZATION 
Foot deformity [n (%)] b 14 (61) 3 (60) 2 (14) 9 (64) 0.7/0.8¥ 
Total foot pulses ≤ 1 [n (%)] 20 (80) 1 (20) 6 (100) 13 (93) 0.001/0.003¥ 
ABI < 0.8 [n (%)] 5 (75) NA 2 (33) 3 (21) 0.6γ 
TcPO2 [median (range)] 18 (67) NA 24 (34) 16 (67) 0.6 α 
Intermittent claudication [n (%)] 12 (48) 0 (0) 5 (83) 7 (50) 0.02/0.2¥ 
DPN symptoms [n (%)] 23 (92) 5 (100) 5 (83) 13 (93) 0.6/0.8¥ 
Altered SWM sensation [n (%)] c 17 (81) 3 (60) 3 (60) 11 (100) 0.07/0.04¥ 
Previous DFU [n (%)] 15 (60) 1 (20) 6 (100) 8 (57) 0.03/0.4¥ 
Previous LEA [n (%)] 7 (28) 0 (0) 3 (50) 4 (29) 0.2/0.4¥ 
DFU CHARACTERIZATION      
Texas grade       
III (Bone or joint) [n (%)] 25 (100) NA 6 (100) 14 (100) 1.0γ 
Texas stage      
B (Infection) [n (%)] 1 (5) NA 0 (0) 1 (7) 
1.0γ 
D (Infection plus ischemia) [n (%)] 19 (95) NA 6 (100) 13 (93) 
Located at toes [n (%)] 5 (25) NA 3 (50) 2 (14) 0.1γ 
 
*: One-Way ANOVA test with Bonferroni correction, : Chi-square test for association, ¥: Chi-square test for tendency, α : Mann-
Whitney U test, γ: Fisher’s exact test, a: No statistical difference between groups, b: in 2 subjects it was not applicable, c: in 4 subjects 
it was not possible to conduct, ABI: Ankle-brachial index, DFU: Diabetic foot ulcer, DPN: Diabetic peripheral neuropathy, HbA1c: 
Glycated haemoglobin, HBOT: Hyperbaric oxygen therapy, LEA: Lower extremity amputation, NA: Not applicable, NHOTB: No 
hyperbaric oxygen therapy,  PAD: Peripheral arterial disease, SD: Standard deviation, SWM: Semmes-Weistein monofilament, TcPO2: 
Transcutaneous Partial Pressure of Oxygen 
 
2. Laboratory markers 
Regarding glycaemic control and lipid profile, at baseline, patients were acceptably controlled, 
with a mean HbA1c of 7.9-8.5%, total cholesterol around 170 mg/dl and triglycerides ranging 
from 112 to 146 mg/dl (Table 13). 
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The HBOT DFU group had significantly less microalbuminuria at baseline comparing to non-HBOT 
DFU subjects. 
DFU subjects presented normal total proteins, albumin and uric acid (results not shown). 
After 3 months of therapy, HBOT DFU individuals presented significantly lower leukocyte and 
CRP level, and tended to have lower VEGF levels.  
For the remaining laboratory markers, we did not observe statistically significant differences. 
TNF-α results were not presented as the most of the serum values were undetectable (< 0.00 
pg/ml). 
 
3. Clinical outcome 
In the non-HBOT DFU group, at the 3rd month, there were four LEA (three major and one 
midfoot), from whom one patient died in the early post-operative period and another from lung 
cancer. In addition, one subject died after refusing major LEA (Table 14).  
In comparison, all HBOT DFU participants improved or presented complete healing at months 3 
and 6, and none required LEA. However three were dead at the 12th month for causes non DFU 
related. 
Therefore, we achieved statistically significant differences between groups at all endpoints. 
Besides having a poorer outcome, the deaths in the NHBOT DFU group occurred earlier (month 
3 vs month 12). 
None in the non-DFU group developed DFU. 
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Table 13. Laboratory markers 
Variables Global 
Non 
DFU 
(n=5) 
NHBOT DFU patients 
(n=6) 
Paired samples 
tests 
p value 
HBOT DFU patients 
(n=14) 
Paired 
samples tests 
p value 
Independent samples 
tests 
p value 
 
M0 
(n=25) 
M3 
(n=20) 
M6 
(n=14) 
M0 M0 M3 M0 M3 M6 M0 M3 
Glucose (mg/dl) [mean (SD)] 172 (75) 213 (82)a 211 (75) 165 (60) 
194 
(110) 
236a 
(109) 
0.3ε 165 (64) 200 (68) 211 (75) 0.2*,b 0.5ж 0.4ж 
HbA1C (in %) [mean (SD)] 8.1 (1.7) 8.3 (1.8)a 8.2 (1.6) 8.5 (1.5) 8.3 (2.1) 9.5 (2.9)a 0.2ε 7.9 (1.7) 7.8 (1.1) 8.2 (1.6) 0.8*,b 0.6ж 0.3ж 
Haemoglobin (g/dl) [mean (SD)] 12 (1) 12 (2)a 12 (2) 13 (2) 12 (1) 11 (2)a 0.3ε 12 (1) 12 (2) 12 (2) 0.8*,b 0.8ж 0.6ж 
Leukocytes (x103/dl) [mean (SD)] 9.5 (3.4) 
10.0  
(3.7)a 
7.9 (1.8) 6.6 (0.9) 
11.5 
(4.1) 
12.5 
(4.4) 
0.4ε 9.4 (3.0) 8.7 (2.7) 7.9 (1.8) 0.3*,b 0.2ж 0.03ж 
Platelets (x103/dl) [mean (SD)] 267 (71) 265 (79)a 229 (76) 236 (34) 256 (57) 305 (90)a 0.2ε 277 (81) 244 (67) 229 (76) 0.2*,b 0.6ж 0.1ж 
C-reactive protein (mg/dl) [median 
(range)] 
0.8 
(15.7) 
0.3 
(22.5)a 
0.3 (11.2) 0.7 (0.6) 2.1 (11) 
11.8 
(22.4)a 
0.1* 
0.7 
(15.7) 
0.3 (5.4) 
0.3 
(11.2) 
0.3 Ϫ 0.2 α 0.03α 
Total cholesterol (mg/dl) [mean 
(SD)] 
170 (54) 153 (37)a 151 (24) 180 (68) 163 (68) 168 (57)a 0.5ε 170 (46) 147 (26) 151 (24) 0.2*,b 0.8ж 0.3ж 
LDL cholesterol (mg/dl) [mean (SD)] 101 (47) 84 (32)a 83 (24) 98 (56) 97 (57) 97 (53)a 0.5ε 104 (43) 79 (20) 83 (24) 0.1*,b 0.8ж 0.3ж 
HDL cholesterol (mg/dl) [mean 
(SD)] 
44 (10) 41 (12)a 42 (17) 55 (10) 43 (10) 36 (13)a 0.1ε 41 (9) 43 (11) 42 (17) 0.9*,b 0.7ж 0.3ж 
Triglycerides (mg/dl) [mean (SD)] 130 (70) 143 (85)a 131 (70) 
146 
(119) 
112 (44) 177 (82)a 0.1ε 133 (60) 130 (86) 131 (70) 0.8*,b 0.5ж 0.3ж 
Creatinine (mg/dl) [median (range)] 0.8 (7.3) 0.9 (8.2)a 0.9 (2.2) 0.6 (0.8) 1.3 (7.3) 1.6 (8.2)a 0.2* 1.0 (1.8) 0.9 (2.9) 0.9 (2.3) 0.8 Ϫ 0.7α 1.0α 
Urea (mg/dl) [mean (SD)] 55 (23) 69 (47)a 63 (34) 42 (7) 66 (33) 92 (65)a 0.1ε 54 (21) 57 (32) 63 (34)  0.5ж 0.3ж 
Microalbuminuria (mg/dl) [n (%)] 12 (48) 12 (63)a 7 (64) 0 (0) 5 (83) 4 (80)a NA 7 (50) 8 (57) 7 (64) NA 0.02/0.2¥ 0.6 γ 
VEGF  (pg/ml) [median (range)] 70 (268) 66 (355)a 40 (131) 37 (101) 
189 
(236) 
99 (344)a 0.9* 72 (268) 56 (129) 40 (131) 0.6 Ϫ 0.6α 0.07α 
PlGF (pg/ml) [median (range)] 
12.6 
(66.5) 
8.5 
(65.8)a 
10.5 
(51.2) 
6.8 (8.3) 
3.1 
(14.7)) 
7.4 
(12.1)a 
0.7* 
14.8 
(65.7) 
9.6 
(64.0)) 
10.5 
(51.2) 
0.4 Ϫ 0.2α 0.4α 
SDF1- α (pg/ml) [mean (SD)] 
1911 
(642) 
2030 
(713)a 
1739 
(2136) 
1992 
(470) 
2297 
(514) 
2062 
(1054)a 
0.5ε 
1716 
(691) 
2017 
(562) 
1739 
(2136) 
0.8*,b 0.08ж 0.9ж 
 
ε: Student’s t test for paired samples, ж: Student’s t test for independent samples, α: Mann-Whitney U test, *: Wilkoxon signed ranks test, *: One-Way ANOVA test with Bonferroni correction, Ϫ: Friedman test, : Chi-
square test for association, ¥: Chi-square test for tendency, γ: Fisher’s exact test, a: 1 missing value, b: No statistical difference between groups, %: Percentage, DFU: Diabetic Foot Ulcer, dl: Deciliter, g: Gram, HbA1c: 
Glycated Hemoglobin, HBOT: Hyperbaric Oxygen Therapy, HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein, M0: Month 0, M3: Month 3, M6: Month 6, mg: Milligram, ml: Millilitre, NA: Not Applicable, 
NHOTB: No Hyperbaric Oxygen Therapy, pg: Pico gram; PlGF: Placental Growth Factor, SD: Standard Deviation, SDF1- α: Stromal Cell-derived Factor 1 Alpha, VEGF: Vascular Endothelial Growth Factor 
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Table 14. Clinical outcome 
Variables 
Global 
(n=20) 
NHBOT DFU 
patients 
(n=6) 
HBOT DFU patients 
(n=14) 
Comparison between 
groups 
Fisher’s exact test  
p value 
M3 M6 M12 M3 M6 M12 M3 M6 M12 M3 M6 M12 
Complete healing / 
improvement [n 
(%)]  
15 
(75) 
15 
(75) 
12 
(60) 
1 
(17) 
1 
(17) 
1 
(17) 
14 
(100) 
14 
(100) 
11 
(79) 
<0.001 <0.001 0.02 
LEA or death [n 
(%)] 
5 
(25) 
5 
(25) 
8 
(40) 
5 
(83) 
5 
(83) 
5 
(83) 
0  
(0) 
0  
(0) 
3 
(21) 
 
HBOT: Hyperbaric oxygen therapy, LEA: Lower extremity amputation, M0: Month 0, M6: Month 6, M12: Month 12, NHBOT: No 
hyperbaric oxygen therapy 
 
4. Diabetic foot ulcer characterization 
At baseline, DFUs had equivalent dimensions in the two groups (Table 15). 
As only one subject remained alive and without major LEA at the 3rd month in the non-HBOT 
DFU, no comparison was possible between baseline and this moment. Nevertheless, this patient 
seems to present a larger and deeper ulcer when comparing to the median values in the HBOT 
DFU group. 
All measurements presented or tended to present significantly lower values at the 3rd month of 
HBOT when comparing to baseline. 
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Table 15. Diabetic foot ulcer characteristics at baseline and third month of follow-up 
Variables 
Global 
(n=20) 
NHBOT DFU 
patients 
(n=6) 
Paired 
samples tests 
p value  
HBOT DFU patients 
(n=14) 
Paired 
samples 
tests 
p value 
Independent 
samples tests 
p value 
M0 M3 M0 M3 M0 M3 M0 M3 
Baseline ulcer area (in cm2) [median (range)] 
11.0 
(31.1)a 
2.7 
(24.8)b 
12.1 
(16.1) 
13.1 
(23.5)b 
NP 
7.3 
(31.1)a 
2.7 
(16.3) 
0.001* 0.4 α NP 
Mean depth (in mm) [median (range)] 
2.3 
(11.6)c 
1.7 
(6.5)d 
1.8 
(4.7) 
3.5 (3.6)b NP 
2.3 
(11.6)c 
1.4 
(6.5)a 
0.1* 0.6 α NP 
Maximum depth (in mm) [median (range)] 
4.6 
(18.3)c 
3.3 
(10.7)d 
3.6 
(8.2) 
7.9 (5.2)b NP 
4.6 
(18.1)c 
3.2 
(10.7)a 
0.03* 0.3 α  NP 
Volume (in cm3) [median (range)] 
1.2 
(24.8)c 
0.4 
(13.8)d 
1.5 
(10.4) 
7.0 
(13.6)b 
NP 
1.2 
(24.5)c 
0.4 
(10.7)a 
0.006* 0.8 α NP 
 
*: Wilkoxon signed ranks test, α: Mann-Whitney U test, a: 1 missing values, b: 4 missing values, c: 2 missing values, d: 5 missing values, cm2: Squared Centimetre, cm3: Cubic Centimetre, DFU: Diabetic Foot Ulcer, DFU: 
Diabetic Foot Ulcer, HBOT: Hyperbaric Oxygen Therapy, M0: Month 0, M3: Month 3, mm: Millimetre, NHBOT: No Hyperbaric Oxygen Therapy, NP: Not Possible 
 
Considering long-term follow-up, the remaining NHBOT DFU subject healed at the 6th month, so, once again, it was not possible to perform any comparison 
(Table 16). 
In the HBOT DFU group, all measurements improved at months 6 and 12 (p≤0.006). 
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Table 16. Diabetic foot ulcer characteristics at baseline, 6th and 12th month of follow-up 
 
Ϫ: Friedman test, α: Mann-Whitney U test, a: 1 missing values, b: 5 missing values, c: 8 missing values, d: 3 missing values, e: 2 missing values, f: 4 missing values, g: 7 missing values, h: 9 missing values, cm2: Squared 
Centimetre, cm3: Cubic Centimetre, DFU: Diabetic Foot ulcer, HBOT: Hyperbaric Oxygen Therapy, M0: Month 0, M3: Month 3, mm: Millimetre, NP: Not Possible, NHOTB: No Hyperbaric Oxygen Therapy 
 
 
Variables 
Global 
(n=20) 
NHBOT DFU patients 
(n=6) 
Paired samples 
tests 
p value 
HBOT DFU patients 
(n=14) 
Paired samples 
tests 
p value M0 M6 M12 M0 M6 M12 M0 M6 M12 
Baseline ulcer area (in cm2) [median 
(range)] 
11.0 (31.1)a 
0.4 
(6.3)b 
0.0 (1.9)c 12.1 (16.1) 
0.0 
(0.0)b 
0.0 
(0.0) b 
NP 7.3 (31.1)a 0.4 (6.3) 0.0 (1.9)d <0.001 Ϫ 
Mean depth (in mm) [median (range)] 2.3 (11.6)e 0.7 (2.2)f 
0.0 
(2.7)g 
1.8 (4.7) 
0.0 
(0.0)b 
0.0 
(0.0) b 
NP 2.3 (11.6)e 0.9 (2.2)e 0.4 (2.7)f 0.001 Ϫ 
Maximum depth (in mm) [median 
(range)] 
4.6 (18.3)c 1.3 (4.3)g 0.0 (4.7)h 3.6 (8.2) 
0.0 
(0.0)b 
0.0 
(0.0) b 
NP 4.6 (18.1)e 1.7 (4.3)e 1.3 (4.7)f 0.006 Ϫ 
Volume (in cm3) [median (range)] 1.2 (24.8)e 0.0 (6.2)g 0.0 (0.3)h 1.5 (10.4) 
0.0 
(0.0)b 
0.0 
(0.0) b 
NP 1.2 (24.5)e 0.0 (6.2)e 0.0 (0.3)f 0.001 Ϫ 
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5. Percentage of epithelialization 
As described above, in the non-HBOT DFU group there was only one subject remaining with 
active DFU at month 3, presenting a median percentage of epithelialization of 79.4%. The DFU 
was completely healed by month 6th and remained 100% epithelialized at month 12. 
In opposition, in the HBOT DFU group, significant and gradual improvement was observed in all 
three time points (median percentage of epithelialization of 64.4%, 85.7% and 100.0% at months 
3, 6 and 12 respectively, p=0.001). 
 
6. Immunohistochemistry  
As DFU bed tissue was gathered only when debridement was performed, not all collected 
samples presented viable tissue. So, immunohistochemistry for CD31-expressing microvessels 
samples paired by subject, were only possible in 3 and 6 patients in the NHBOT DFU and HBOT 
DFU groups, respectively. 
In the HBOT group the median number of vessels tended to increase after 1 month (617 vs 709), 
whereas the opposite occurred in the NHBOT DFU patients (746 vs 680), not achieving, however, 
statistical significance (Figure 12). Two examples are given on the table below (Table 17). 
 
Figure 12. Boxplot of number of vessels at baseline and 1 month in patients undergoing or not 
Hyperbaric Oxygen therapy 
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Table 17. Example images of wound bed histology and immunohistochemistry at baseline and month 1 in one patient of each study group with active diabetic 
foot ulcer 
 HBOT DFU NHBOT DFU 
HE, 20x10 CD 31, 20x10 HE, 20x10 CD 31, 20x10 
M0 
    
M1 
    
CD 31: Cluster of differentiation 31, DFU: Diabetic Foot ulcer, HBOT: Hyperbaric Oxygen Therapy, HE: Haematoxylin-eosin, M0: Month 0, M1: Month 1, NHOTB: No Hyperbaric Oxygen Therapy 
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C. Discussion  
 
Several studies have addressed HBOT impact on DFU healing (see Section IV C). However, this is 
the first study to simultaneously evaluate and compare biochemical markers and clinical 
outcome in subjects with no DFU and with DFU undergoing or not HBOT. 
We have concluded that, in those undergoing HBOT, merely 3 months of therapy, induced a 
significantly lower leukocyte and CRP level. These findings support the evidence of an anti-
microbial and anti-inflammatory effect of HBOT [Albuquerque-Sousa JG, 2007; Thom SR, 2011]. 
In addition, VEGF levels diminished, to values similar to those in the non-DFU group, but 
statistical significance was not achieved. From the results, we can see that DFU patients have 
higher levels of VEGF when compared to non-DFU. The decrease of VEGF with HBOT may be 
related to a correction of the hypoxia and thus tendency to return to a “normal” diabetic non-
DFU molecular serum environment. 
In the HBOT group, SDF1-α increased at month 3, returning to baseline levels at month 6. This 
fact may have occurred as in the first endpoint all subjects and, at the latter, none were receiving 
HBOT. So, we hypothesize that HBOT augments SDF1-α values, with possible rise in the number 
of circulating EPCs, but such effect seems to stop with the suspension of treatment. 
Even though, TNF-α is a main mediator of inflammation we were unable to quantify it in the 
serum.  Further studies, determining TNF-α expression in the wound bed are needed. 
Our sample presented a mean age, gender, DM duration and HbA1c, similar to the populations 
reported by several studies included in our systematic review (Table 3). Median TcPO2 was 
inferior than in most studies. Regarding depth, we included deeper DFUs than RCT but similar 
to NRT. 
At every time points, the HBOT group achieved better outcomes when compared to those with 
DFU without undergoing such adjunctive therapy. We observed less major LEA and death rates. 
Assessing all DFU measures, a high DFU reduction and an increasing epithelialization percentage 
were observed along all the study period in the HBOT group. Comparison was not possible with 
the non-HBOT group, as only one subject remained alive and without major LEA. Analyzing our 
systematic review results (Table 3), we noticed that our clinical outcomes rates were equivalent 
(within the 95% CI) to those reported by the long term, at least 12 months, to RCT and NRT for 
both groups. 
During a mean number of HBOT sessions of 86, it was observed a gradual DFU improvement that 
continued after the prescribed therapy program completion. Comparing to the available 
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literature, we observed that our patients received more sessions, this may have affected 
positively the results. 
After one month, we noticed that the median number of vessels in the HBOT group tended to 
increase, while the opposite occurred in the non-HBOT DFU patients (without statistical 
significance). 
Infection and PAD are considered by several classifications as the most important factors, along 
with depth, for DFU prognostic assessment [Monteiro-Soares M et al, 2014]. HBOT improves circulation 
by stimulating micro-vascularization and optimizes oxygen delivery ameliorating leucocytes 
function and anti-bacterial effect. We believe that such mechanisms are responsible for such 
good clinical outcomes and are translated in our results.  
We must highlight that only one subject suffered a minor side effect due to HBOT (ear 
barotrauma), that responded to treatment.  
The authors decided to conduct a non-randomized trial design. Although it represents a more 
feasible methodology in clinical practice, it presents several limitations. 
DFU control group, that is, non-HBOT subjects, was selected by refusal or contra-indication, 
instead of using randomization techniques. This may induce group differences. Comparing 
baseline characteristics, we observed that the main difference was that there was significantly 
more history of previous DFU in the non-HBOT DFU individuals than in the HBOT DFU, this might 
be one of the possible reasons for them to refuse HBOT.  
A small sample size was achieved, due to limited selection of adequate patients and financial 
constraints. Nevertheless, significant results were obtained for several measures.  
Due to ethical reasons, were not able to perform DFU biopsy. So, we only collected small 
fragments resulting from wound debridement. Therefore, not all collected samples were 
representative of the DFU bed tissue, limiting the evaluation of microvessel density. Despite this, 
it appears that HBOT DFU subjects tend to have an increase in vessel number after 1 month of 
therapy, with the opposite occurring in the non-HBOT group. 
In order to attempt to overcome the described study weaknesses, selection of DFU individuals 
for HBOT was performed by a team, independent of the study, including only patients with 
optimized standard care and still no DFU improvement; all laboratory/molecular and 
microvessel density evaluation analysis were performed by investigators blinded to the group 
allocation; clinical end-points were objective (percentage of ulcer healing, amputation and 
death) and all DFU measurements were performed using a digital laser measuring device. 
Due to the defined criteria, our diabetic foot clinic team referred for HBOT mainly DFUs that 
reached the bone, were infected, ischemic (grade III and stage D in the UTC) and after minor LEA 
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has occurred. This fact may limit the results’ generalizability and it may diminish the measure 
magnitude of effect. So, if such clinical results were observed under HBOT, it is expected even 
better outcome in a less severely affected population. 
In sum, our data reinforces the potential molecular and clinical efficacy and benefit of HBOT 
when added to current standard treatment of DFU. But further studies are required, particularly, 
evaluation of the HBOT modulator effect on DFU bed tissue using an animal model; increase the 
total number of patients in whom angiogenic, vasculogenic and inflammatory markers are 
studied not only in serum but also in the DFU bed. It is also crucial to define the optimal HBOT 
timing after revascularization for DFU treatment, since revascularization improves 
macrovascular disease and HBOT seems to ameliorate microvasculature, and referral. 
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VI. Improving hyperbaric oxygen 
therapy referral for diabetic foot 
ulcer treatment: a nationwide 
models’ validation and refinement 
study 
A. Material and methods 
1. Participants selection 
A multicentre retrospective cohort study was conducted in all Portuguese hyperbaric medicine 
centres treating diabetic foot patients (n=2) including all subjects that underwent HBOT for DFU 
treatment from January 1, 2008 to June 30, 2013. 
Participants with only one appointment, associated auto-immune diseases, pressure and 
malleoli ulcers, under treatment at the time of data collection and/or missing data concerning 
outcome (healing, non-healing, LEA) were excluded. 
The study was approved by the Ethics Committee of both institutions. 
2. Data collection 
Clinical records were reviewed and data collected from July 1 to the August 31, 2013. 
Demographic characteristics (age at the time of inclusion, gender), DM type (classified according 
to the World Health Organization definition [WHO, 2006]), duration (in years) and treatment (oral 
medication or insulin), metabolic control (through HbA1C), smoking habits (in packs-year) and 
the character and severity of any DM complications (retinopathy, laser photocoagulation; 
nephropathy, dialysis; neuropathy; cerebrovascular and/or cardiovascular disease) were 
recorded.  
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Factors of interest specific to the DFU were: the presence of PAD; TcPO2; ABI; DPN and previous 
DFU or LEA. We also collected the ulcer area (in cm2), reported duration (in months), location, 
Wagner grade [Wagner F, 1981], number of DFUs and the presence or absence of infection. In the 
case of multiple DFUs, only the largest was considered. 
PAD was considered as present when the foot with DFU presented one or fewer pedal pulses 
[Monteiro-Soares M et al, 2010]. TcPO2 was determined by measuring once at 2 points peri-DFU and 
reporting the highest value. 
DFU area was calculated multiplying the 2 larger axes. Time zero for DFU duration estimation 
was considered the last major surgical debridement or LEA. In the absence of either, we 
calculated the actual duration of DFU.  
Considering HBOT, we recorded the total number of sessions, whether or not the planned 
number of sessions was completed and outcome (complete healing vs not healed or LEA). 
Complete healing was considered as DFUs full epithelialization without the need of further 
treatment [Younes N & Albsoul A, 2004]. Minor LEA was defined as the surgical removal of toe(s), ray(s) 
or forefoot. Major LEA was considered amputation of any part at or above the entire foot. 
3. Existing models of healing prediction 
We conducted a systematic review (Section IV, C) in order to retrieve all studies proposing 
predictive models for DFU healing with HBOT. We identified only two: Fife 2007 [Fife C et al, 2007] 
and Hawkins 2006 [Hawkins G et al, 2006]. 
Using the Fife model we can calculate the odds of healing with HBOT compared to the odds of 
healing without HBOT by using the following formula: Log (OR) = 0.99 + 0.21 x [Ln (HBOT number 
of sessions + 1)] + 0.004 x (TcPO2 in mmHg) – 0.04 x (RAMP) – 0.15 x (modified Wagner) – 0.04 
x (age in years x diabetes duration in years) – 0.19 x (1 if interrupted treatment or 0 if no 
interruption occurred) where RAMP is a function for pack-years of smoking (those with ≤10 
pack-years = 0; those with >10 pack years = number of pack years – 10) [9]. In Fife’s article [Fife C 
et al, 2007], the authors made use of the Wagner grading scale modified by Kominsky, which varies 
from II (superficial) to VI (gangrene of the entire foot). 
Hawkins’ model for the odds of healing with HBOT is: Log (OR) =2.30 – 0.09 x (DFU area in cm2) 
– 0.11 x (DFU duration in months) + 0.06 (TcPO2 in mmHg). 
Both models were applied to all subjects. 
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4. Statistical analysis 
For continuous variables, we used Student’s t-test to compare groups when the data appeared 
acceptably normally distributed (using both histogram and Kolmogorov-Smirnov testing) and 
the Mann-Whitney U-test when the assumption of normality was not appropriate.  Categorical 
variables were compared using the Χ2 test or Fisher’s exact test, when applicable. 
Multivariate analysis, and consequent variables’ adjustment and predictive models’ proposal, 
was performed using logistic regression. 
All statistical analyses were conducted using the program IBM SPSS, version 20.0 (Chicago, IL, 
USA). All tests were two sided, p values less than 0.05 were considered statistically significant 
and less than 0.1 as pertinent for inclusion in the predictive models.  
As Fife’s model uses post-treatment variables (such as HBOT number of sessions and treatment 
interruption) and our goal was to create a model using only pre-treatment variables), we 
decided just to validate this and refine the one proposed by Hawkins, if pertinent.  
Therefore, we started by using all the variables included in the Hawkins model and those 
considered pertinent for inclusion in our univariate analysis. Missing and indeterminate results 
were excluded from analysis. 
For the resultant optimized predictive model, a prognostic accuracy assessment was made 
including sensitivity, specificity, predictive values, likelihood ratios (LR), AUC and respective 95% 
CI calculation, comparing the CI and evaluating if there was an overlap to identify statistically 
significant differences. 
B. Results 
1. Hyperbaric Oxygen therapy facilities and program characterization 
The center of the FNH (Centro de Medicina Subaquática e Hiperbárica) has been treating DFU 
patients since January 1990, it has two connected multiplace chambers with capacity to treat 24 
individuals simultaneously. The treatment program performed for DFU is 75 minutes at 2.5 ATA, 
once a day, five days a week. 
The center in the north of Portugal (Unidade de Medicina Hiperbárica of PHH) is equipped with 
a 16 place chamber, and started treating subjects with DFU in January 2008. The therapy 
protocol used is 80 minutes at 2.4 ATA, once a day, five days a week. 
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2. Participants characteristics 
This study included 128 patients (85 from the FNH). The majority were males (73.4%), with a 
mean age of 62.9 (SD 11.8) years and 62.7% were active or past smokers. Most had type DM, 
with a mean duration of 18.2 (SD 9.9) years, and more than half were on insulin, with a mean 
HbA1c of 8.6% (SD 1.8). The most frequent DM complications were retinopathy [44.7%, of whom 
more than half (27.7% of the total) had received laser photocoagulation] and nephropathy 
(34.6%; 12.2% on dialysis). 
Most of the subjects had PAD (84.8%) and DPN (89.5%). We observed that in PHH, DPN was 
diagnosed using the SWM, while in the FNH the procedure was never described.  
The mean TcPO2 was 33.5 (range 1-76) and ABI 0.78 (SD 0.28) (data only available from PHH). 
The median baseline DFU area was 8.2 (range 0.3-60.0) cm2 with a median duration of 2.5 (0-
36) months. The majority were post-LEA (54.7%) and were infected (89.8%). DFUs were 
classified as Wagner grade III-V in 71.7% of cases. Multiple DFUs were present in 22.1% of 
patients.  
After a mean of 55 HBOT sessions (SD 34.1), 16 (12.5%) subjects required LEA and in 44 (34.4%) 
the DFU remained unhealed. The majority of patients (66.4%) completed the prescribed 
treatment. The most common reasons for failure to complete were the withdrawal of health 
administration approval and worsening of the clinical condition. 
Subjects from PHH presented more often with retinopathy (p < 0.001), previous DFU (p = 0.02) 
and longer DFU duration (p < 0.001) than those from FNH. However, PAD was more frequent in 
those from FNH (p < 0.001). No differences were observed between facilities in the remaining 
variables (Table 18).  
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Table 18: Patient characteristics according to Hyperbaric Oxygen therapy unit 
Variables 
Total 
(n=128) 
Former Navy’s 
Hospital 
(n= 85) 
Matosinhos Hospital 
(n= 43) p value 
DEMOGRAPHIC AND DIABETES CHARACTERISTICS 
Male [n (%)] 94 (73.4) 65 (76.5) 29 (67.4) 0.30 * 
Age (in years) [mean (SD)] 62.9 (11.8) 64.1 (12.1) 60.7 (11.1) 0.13 
Diabetes duration (in years) [mean (SD)] 18.2 (9.9) ª 17.7 (10.9) ª 18.7 (8.8) 0.64 
Age+ Diabetes duration [mean (SD)] 1123.3 (655.7) ª 1109.5 (721.3) ª 1139.2 (578.3) 0.83 
HbA1C (in %) [mean (SD)] 8.6 (1.8) b 8.9 (2.1)c 8.6 (1.7)d 0.64 
Type 2 diabetes [n (%)] 113 (89.0)e 74 (88.1) e 39 (90.7) 0.77 * 
Insulin use [n (%)] 75 (65.8)f 45 (63.4) f 30 (69.8) 0.55 * 
Smoking habits (in pack-year)[median (range)] 30.0 (0.0-100.0) g 38.0 (0.0-100.0)g 20.0 (0.0-96.0) 0.12 
MACRO AND MICROVASCULAR COMPLICATIONS 
Retinopathy [n (%)]  42 (44.7)h 10 (19.6) h 32 (74.5) 
<0.001 # 
Laser photocoagulation [n (%)] 26 (27.7) 4 (7.8) 22 (51.2) 
Nephropathy [n (%)] 34 (34.6)i 15 (27.3) i 19 (44.2) 
0.19 # 
Dialysis [n (%)] 12 (12.2) 6 (10.9) 6 (14.0) 
Previous stroke history [n (%)] 14 (14.6)j 5 (9.4) j 9 (20.9) 0.15 * 
Previous myocardial infarction history [n (%)] 28 (28.9)k 19 (35.2) k 9 (20.9) 0.18 * 
FOOT CHARACTERISTICS 
0 or 1 foot pulses 106 (84.8)l 74 (89.1) m 32 (76.2) e <0.001 # 
TcPO2 [median (range)] 33.5 (1.0-76.0)n NP 33.5 (1.0-76.0)o NP 
ABI [mean (SD)] 0.78 (0.28)p NP 0.78 (0.28)d NP 
DPN [n (%)] 17 (89.5)q 8 (80.0) r 9 (100.0) s 0.47 * 
Previous DFU [n (%)] 42 (38.9)t 19 (29.2) t 23 (53.5) 0.02 * 
Previous LEA [n (%)] 27 (25.0)t 14 (21.5) t 13 (30.2) 0.37 * 
DFU CHARACTERISTICS 
Area (in cm2) [median (range)] 8.2  (0.3-60.0)u 9.8 (0.4-60.0)e 6.4 (0.3-54.0)v 0.35§ 
Duration (in months) [median (range)] 2.5 (0-36)w 1.8 (0.0-24.0)w 4.0 (1.0-36.0) <0.001§ 
Multiple DFU [n (%)] 29 (22.7) 20 (23.5) 9 (20.9) 0.83 * 
Located at toes [n (%)] 19 (14.8) 14 (16.5) 5 (11.6) 0.60* 
Post-LEA [n (%)] 70 (54.7) 51 (60.0) 19 (44.2) 0.09* 
Wagner grade III-V [n (%)] 91 (71.7)e 62 (73.8) e 29 (67.4) 0.54 * 
Infection [n (%)] 115 (89.8) 75 (88.2) 43 (93.0) 0.54* 
HBOT CHARACTERISTICS AND OUTCOME     
Complete healing [n (%)] 68 (53.1) 45 (52.9) 23 (53.5) 1.00 * 
Number of sessions [mean (SD)] 54.9 (34.1) 52.1 (32.0) 60.4 (37.6) 0.19  
Completed treatment [n (%)] 85 (66.4) 56 (65.9) 32 (74.4) 0.42 * 
 
*: Fisher’s exact test; : t-test for independent samples; # Χ2 test for association and trend; § Mann-Whitney test; ª: 35 missing 
values; b:83 missing values; c: 77 missing values; d: 6 missing values;e: 1 missing value; f: 14 missing values; g: 51 missing values; h: 34 
missing values; i: 30 missing values; j: 32 missing values; k: 31 missing values; l:3 missing values; m: 2 missing values; n:104 missing 
values; o: 19 missing values; p:91 missing values; q:109 missing values; r: 75 missing values; s: through Semmes-Weinstein 
monofilament and with 34 missing values; t: 20 missing values; u: 6 missing values; v: 5 missing values; w: 27 missing values; HbA1C: 
Glycated Hemoglobin; ABI: Ankle-Brachial Index; DFU: Diabetic Foot Ulcer; DPN: Diabetic Peripheral Neuropathy; LEA: Lower 
Extremity Amputation; NP: Not Possible; SD: Standard Deviation; TcPO2: Transcutaneous Oxygen Tension 
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3. Predictive variables for diabetic foot ulcer healing 
Univariate analysis (Table 19) 
Univariate analysis suggested that the patient characteristics associated with healing were 
female gender (p = 0.03), lower median duration of smoking (pack years, p = 0.01), no PAD (p = 
0.002), no previous DFU (p = 0.01) and no LEA (p = 0.04).  
No macro or microvascular complication had an impact on healing (p > 0.05).  
Smaller (p = 0.002) and more superficial DFU (p = 0.03) healed more frequently. 
Ulcers that healed received more HBOT sessions on average (p = 0.07), while those that 
completed their planned treatment were more likely to heal (p < 0.001). 
 
Table 19: Patient characteristics by outcome  
Variables 
Complete healing 
(n=68) 
Non-healing / LEA 
(n=60) 
p value 
DEMOGRAPHICS  
Male [n (%)] 44 (64.7) 50 (83.3) 0.03 * 
Age (in years) [mean (SD)] 61.4 (12.1) 64.7 (11.4) 0.12  
Diabetes duration (in years) [mean (SD)] 19.5 (10.5) a 16.5 (8.9) b 0.15  
Age * Diabetes duration [mean (SD)] 1178.3 (697.6) a 1050.3 (596.6) b 0.35  
HbA1c (in %) [mean (SD)] 8.8 (1.7) c 8.5 (1.8) d 0.62  
Type 2 diabetes [n (%)] 57 (85.1) e 56 (93.3) 0.17 * 
Insulin use [n (%)] 42 (67.7) f 33 (63.5) g 0.69 * 
Smoking habits (in pack-year) [median (range)] 0.0 (0.0-90.0) h 40.0 (0.0-100.0) b <0.001 § 
MACRO AND MICROVASCULAR COMPLICATIONS 
Retinopathy [n (%)] 19 (35.9) a 23 (56.1) i 
0.13 # 
Laser photocoagulation [n (%)] 11 (20.8) 14 (36.6) 
Nephropathy [n (%)] 16 (28.5) j 18 (42.9) k 
0.30 # 
Dialysis [n (%)] 5 (8.9) 7 (16.7) 
Previous stroke history [n (%)] 9 (16.7) l 5 (11.9) k 0.57 * 
Previous myocardial infarction history [n (%)] 14 (25.5) m 14 (33.3) k 0.50 * 
FOOT CHARACTERISTICS 
0 or 1 foot pulses [n (%)] 49 (74.2) n 57 (96.8) e 0.002 # 
TcPO2 [median (range)] 21.0 (1.0-76.0) o 37.0 (3.0-67.0) p 0.52 § 
ABI [mean (SD)] 0.9 (0.3) q 0.7 (0.3) d 0.15  
DPN [n (%)] 8 (80.0) r 9 (100.0) q 0.47 * 
Previous DFU [n (%)] 16 (27.1) s 26 (53.1) t 0.01 * 
Previous LEA [n (%)] 10 (16.9) s 17 (34.7) t 0.04 * 
DFU CHARACTERISTICS 
Area (in cm2) [median (range)] 6.1 (0.3-41.0) n 12.0 (0.8-60.0) u 0.002 § 
Duration (in months) [median (range)] 2.0 (0.0-30.0) v 3.0 (0.0-36.0) w 0.14 § 
Multiple DFU [n (%)] 15 (22.1) 14 (23.3) 1.00 * 
Located at toes [n (%)] 13 (19.1) 6 (10.0) 0.21* 
After LEA [n (%)] 33 (48.5) 37 (61.7) 0.16* 
Wagner grade III-V [n (%)] 43 (63.2) 48 (81.4) e 0.03 * 
Infection [n (%)] 58 (85.3) 57 (95.0) 0.08 * 
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HBOT CHARACTERISTICS 
Matosinhos’ Hospital [n (%)] 23 (33.8) 20 (33.3) 1.00 * 
Number of sessions [mean (SD)] 60.1 (32.8) 40.0 (3.0-120.0) 0.07  
Completed treatment [n (%)] 65 (95.6) 23 (38.3) <0.001 * 
 
*: Fisher’s exact test; : t-test for independent samples; # Χ2 test for association and trend; § Mann-Whitney test; a: 15 missing 
values; b: 20 missing values; c: 43 missing values; d: 40 missing values; e: 1 missing values; f: 6 missing values; g: 8 missing values; h: 31 
missing values; i: 19 missing values; j: 12 missing values; k: 18 missing values; l: 14 missing values; m: 13 missing values; n: 2 missing 
values; o: 59 missing values; p: 45 missing values; q: 51 missing values; r: 58 missing values; s: 9 missing values; t: 11 missing values; u: 
4 missing values; v: 17 missing values; w: 10 missing values; HbA1C: Glycated Hemoglobin; ABI: Ankle-Brachial Index; CI: Confidence 
Interval; DFU: Diabetic Foot Ulcer; DPN: Diabetic Peripheral Neuropathy; LEA: Lower Extremity Amputation; SD: Standard Deviation; 
TcPO2: Transcutaneous Oxygen Tension 
 
Multivariate analysis 
Following univariate analysis, we performed a multivariate analysis including all factors 
identified as potentially predictive of healing (p-value on univariate analysis < 0.1) plus the 
elements in the Hawkins model. We substituted the TcPO2 value in the Hawkins model with PAD 
(defined as ≤1 pedal pulse in the affected foot) because of the high number of missing values 
for TcPO2 in our data. Using a backward stepwise elimination approach, we have derived the 
best model. Twenty-eight subjects were excluded from analysis due to missing data. 
Using this methodology, we propose an optimized model, derived from the one proposed by 
Hawkins in 2006 (3), with a score calculation based on the following equation: Score = 2.96– 
1.34 x (≤ 1 pedal pulse) – 0.04 x (DFU area in cm2) – 0.84 x (DFU graded as Wagner III-V) – 1.15 
x (previous DFU – yes= 1, no = 0).  
Through receiver operating characteristic (ROC) curves analysis, we have also proposed the 
creation of three diagnostic categories for DFU healing and determined cut-off values to 
maximize predictive ability: healing not probable for values < -0.91, probable for values from -
0.91 to 0.36 and highly probable to heal with HBOT for values > 0.36. 
 
4. Predictive model accuracy 
 
 
Figure 13 shows the ROC curves for the existing models (Fife 2007 and Hawkins 2006) 
compared with our optimized models.  
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Figure 13: Predictive models receiver operating characteristic curve 
  
 
 
The left image represents the Fife 2007 (in black) and Hawkins 2006 (in grey) score area under the receiver operating characteristic 
curve. The right image represents the optimized model scores (in blue) and categories (in green) area under the receiver operating 
characteristic curve.  
 
The AUC values are higher for the latter [0.51% (95% CI 0.24-0.78) in Fife 2007, 0.63% (95% CI 
0.37-0.90) in Hawkins 2007 vs 0.78% (95% CI 0.69-0.87)] in optimized model). However, these 
differences are not statistically significant (Table 20). 
 
Table 20: Predictive models area under the receiver operating characteristic curve 
Model AUC 95% CI 
Fife C et al, 2007 ª 0.51 0.24-0.78 
Hawkins G et al, 2006 0.63 0.37-0.90 
Optimized model c   
Score 0.78 0.69-0.87 
Categories 0.75 0.65-0.85 
 
ª: 104 missing values; b: 107 missing values; c: 28 missing values; AUC: Area Under the Receiver Operating Characteristic Curve; CI: 
Confidence Interval 
 
Our model had good accuracy values, with LR values having a potential small to moderate effect 
on clinical decision, with negative LR smaller than 0.5 and positive LR superior to 1.3 [Fritz J & 
Wainner R, 2001]. Predictive values (negative and positive) were superior to 60% (Table 21). 
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Table 21: Optimized models prognostic accuracy measures 
 
Subjects 
n (%) 
Healed 
n (%) 
Accuracy measures 
Sens 
% (CI 95%) 
Spec 
% (CI 95%) 
LR+ 
% (CI 95%) 
LR- 
% (CI 95%) 
PPV 
% (CI 95%) 
NPV 
% (CI 95%) 
OPTIMIZED MODEL ª 
Highly 
probable 
48  
(48.0) 
38  
(79.2) 
67.9 
(55.6-80.1) 
77.3 
(64.9-90.0) 
3.0 
(1.7-5.3) 
0.4 
(0.3-0.6) 
79.2 
(67.7-90.7) 
65.4 
(52.5-78.3) 
Highly 
probable+  
Probable 
87  
(87.0) 
54  
(62.1) 
96.4 
(91.6-100.0) 
25.0 
(12.2-37.8) 
1.3 
(1.1-1.5) 
0.1 
(0.03-0.6) 
62.1 
(51.9-72.3) 
81.6 
(65.0-100.0) 
 
ª: 28 missing values; CI: Confidence Interval; Spec: Specificity; Sens: Sensitiviy; LR-: Negative Likelihood Ratio; LR+: Positive 
Likelihood Ratio; NPV: Negative Predictive Value; PPV: Positive Predictive Value 
 
C. Discussion 
Standardized referral systems are essential for optimal resource allocation and prognostic 
estimation, especially concerning expensive adjunctive therapeutics (such as HBOT in chronic 
DFU). 
This is the first study evaluating all subjects treated over a period of five years with HBOT for 
DFUs in continental Portugal. 
The sample size is limited (n= 128), and this reduces the power of our analysis to draw definitive 
conclusions. There are potentially two main reasons for this small sample size. First, HBOT is a 
poorly understood and promoted treatment modality, and second, even when considered, it is 
a treatment of last resort given the financial constraints within the healthcare system in 
Portugal.  
Furthermore, we have excluded subjects with associated auto-immune diseases, pressure and 
malleoli wounds as these ulcers have different clinical and pathophysiological characteristics 
than the “standard” DFU, with potential impact on healing rates. 
The review period corresponds with the start of DFU treatment at PHH HBOT unit, while the 
FNH unit has been operating since 1989. This may in part explain the fact that 2/3 of the included 
subjects were treated at the FNH. 
Our population is similar to those reported in the available literature [Abidia A et al, 2003; Albuquerque-
Sousa J, 2005;  Baroni G et al, 1987; Chen CE et al, 2010; Doctor N et al, 1992; Duzgun A et al, 2008; Faglia E et al, 1996; Faglia E et 
al, 1998; Kalani M et al, 2002; Kessler L et al, 2003; Löndahl et al, 2010; Löndahl et al, 2011; Oriani G et al, 1990; Wang CJ et al, 2009; 
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Wang CJ et al, 2011; Zamboni W et al, 1997]; i e, mainly men, above 60 years, with type 2 DM, for around 
15 years and an HbA1c greater than 8%. 
In our population almost 30% presented with a Wagner wound grade of I or II, which suggests 
our population had less severe DFU than the majority of previously reported studies [Albuquerque-
Sousa J, 2005; Duzgun A et al, 2008; Faglia E et al, 1996; Faglia E et L, 1998; Oriani G et al, 1990] but comparable to the 
largest randomized controlled trial published in this field [Löndahl M et al, 2010]. 
The majority of our subjects presented diminished palpable pulses (84.8%) and infected DFU 
(89.8%) with a median duration of 2.5 months. 
We observed a higher percentage of PAD in the FNH participants. This might be due to the fact 
that in the North (referral area of PHH), there is a lower PAD prevalence [Menezes JD et al, 2009], but 
it is also possible that vascular surgeons take a more active approach to chronic DFU patients, 
including a higher use of angioplasty techniques and revascularization surgery (personal 
communication). 
Conversely, DFU duration was longer at the PHH (median difference of 2.2 months). This is a 
more recent unit and so HBOT is less widespread among referral healthcare institutions, thus 
professionals tend to send only patients with persisting DFU despite all other treatments. 
Additionally, we considered the last major surgical intervention as time 0 for duration 
estimation, and in the FNH there was a higher rate of post-LEA wounds with immediate referral 
for HBOT. 
We observed that subjects from PHH tended to present higher rates of DM-related 
complications (retinopathy, nephropathy and stroke). It is not clear if subjects from the North 
of the country tend to present more complications (although DM duration and HbA1c values 
were similar) or if the detection rate is superior [OND 2013]. 
However, despite these differences between centres, the healing rates, number of HBOT 
sessions and proportion who completed the planned treatment are similar. 
Eleven studies [Chen CE et al, 2010; Fife C et al, 1997; Fife C et al, 2007; Hawkins G et al, 2006; Löndahl M et al, 2010; Löndahl 
M et al, 2011; Mathieu D et al 1997; Ong M, 2008; Otto G et al, 2000; Wattel F et al, 1991; Zgonis T et al, 2005] have reported 
patient factors that may be predictive of healing in DFU treated with HBOT. In our population, 
clinical factors associated with DFU healing were female gender, lower smoking pack-years, 
smaller and more superficial DFU as well as absence of PAD, previous DFU and/or LEA. Some of 
the previous studies have similarly reported both smoking habit and Wagner grade as predictive 
[Fife C et al, 1997; Fife C et al, 2007; Otto G et al, 2000]. 
In contrast to Fife 2003, we could not demonstrate an impact of (age + diabetes duration) [Fife C 
et al, 1997; Fife C et al, 2007; Otto G et al, 2000], renal failure [Fife C et al, 2007] or previous LEA on outcome. 
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Similarly, in contrast to Hawkins, we observed a statistically significant predictive ability for 
gender, DFU area and duration. 
During the follow-up period, 12.5% of our subjects required an LEA and in 34.4% DFU persisted 
unhealed immediately after the last HBOT session. These data are in accordance with several 
studies, including the two largest randomized controlled trials [Çerkes N et al, 1994; Cianci P & Hunt T, 1997; 
Duzgun A et al, 2008; Kaya A et al, 2009; Löndahl M et al, 2010; Löndahl M et al, 2011]. 
Because the practice in Portugal is to continue wound care in the referring facility, we believe 
our results confirm a true benefit from HBOT, rather than reflecting any change in wound care 
management in a specialized unit.  Our data also suggest this benefit is greater if the prescribed 
course of HBOT is completed. While this seems likely, based on common sense, it may also be 
biased through the tendency for those doing well to keep attending, while those seeing little or 
no progress may be less inclined to do so.  It is worth noting that the mean number of sessions 
was 55, which is slightly higher than most studies have reported [Abidia A et al, 2003; Baroni G et al, 1987; 
Faglia E et al, 1996; Faglia E et al, 1998; Kessler L et al, 2003; Wang CJ et al, 2009; Wang CJ et al, 2011; Zamboni W et al, 1997].  
Of the two previously reported predictive models, we observed that both had low accuracy (with 
the AUC value inferior to 0.63), and we considered that optimization of one or both these models 
was appropriate. Ultimately, we have excluded Fife’s model because it also used post-treatment 
variables (number of sessions and episodes of treatment interruption), making it unsuitable for 
pre-HBOT decision making – including when it is appropriate to refer for HBOT.  
We have therefore optimized the Hawkins model using logistic regression, by including two 
additional variables (Wagner grade and previous DFU) and removing DFU duration variable. Due 
to the number of missing values and in order to increase the optimized models’ application in 
daily clinical care, we decided to replace the variable TcPO2 by the number of palpable pedal 
pulses. 
In this way, we proposed a model easy to apply and tending to produce higher accuracy 
measures in comparison to the Hawkins’ baseline model. 
Due to the low sample size and high number of missing values in the models’ included variables, 
CI were wide and no statistical differences were detected between the original and the 
optimized models’ AUC values. For this reason, we were also unable to compare other accuracy 
measures. 
Evaluating the retrospective performance of our optimized model, we observe that it is 
characterised by low specificity and LR but also by potentially useful sensitivity and predictive 
values. We therefore consider that a larger prospective study for model validation and 
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refinement is appropriate, and that such a study should be conducted prospectively to avoid the 
pitfalls of retrospective data collection. 
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VII. Conclusion 
A. Main Conclusions  
 
The independent contribution of DFU on LEA and mortality risk 
1. Cumulative incidence at 3 years was  
a. DFU 26.6% (95% CI 23.2-30.0),  
b. recurrent DFU 34.5% (95% CI 27.4-48.4),  
c. minor LEA 2.7% (95% CI 1.4-4.0),  
d. major LEA 3.1% (95% CI 1.8-4.4),  
e. total LEA 5.8% (95% CI 3.9-7.5) and  
f. death 14.0% (95% CI 11.3-16.7). 
2. Therefore, we have a  
a. high rate of DFU development, 
b. mortality rate in accordance with the Eurodiale study [Schaper N, 2012] and a 
c. LEA rate inferior to Eurodiale results [Schaper N, 2012], as they included only patients 
with active DFU. 
3. In multivariate analysis 
a. physical impairment, PAD complication history, complication count and 
previous DFU were associated with DFU, 
b. complication count, foot pulses and previous DFU with LEA and age, and 
c. complication count and previous DFU with death. 
4. These predictive models’ AUC ranged from 0.80 to 0.83 and may be applicable in 
different healthcare settings to identify patients at higher risk of DFU, LEA and death. 
5. Previous DFU was associated with all outcomes, even when adjusted for complication 
count, in addition to more complex models (including age, gender, visual and physical 
impairment, diabetes type and duration, PAD complications history, complication count 
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and previous LEA. So, DFU seems more than a marker of complication status, having 
independent impact on LEA and mortality risk. 
6. The most frequent causes of death were infections and oncologic disease. 
 
Effect of HBOT in DFU healing: a systematic review and meta-analysis 
1. Forty studies were included 
a. 11 RCT,  
b. 8 NRT,  
c. 22 observational studies.  
2. Mean proportion of items satisfied, using CONSORT and STROBE methodological quality 
reporting checklists, was low.  
a. Thus, important information was absent in most studies.  
b. Even RCTs were inadequately reported and conducted (specially, regarding 
sample size). 
3. The majority of the included studies were retrieved outside the MEDLINE Indexed 
search, which points out that the many works were either never published in full, or only 
in the “Grey” literature.  
4. Participant characteristics were poorly described in general and total sample size, in 
more than half of the studies, was less than 50 subjects.  
5. There was considerable variation in HBOT protocols across these studies, namely in 
sessions number, duration, frequency and pressure.  
6. Substantial DFU area reduction was reported in the HBOT group at 6 months, but MA 
was not possible.  
7. Time to healing was lower in HBOT group although not reaching statistical significance.  
8. DFU healed more often with HBOT.  
9. Major amputations were significantly less frequent in those undergoing HBOT.  
10. A small amount of studies assessed independent variables’ impact on healing with only 
age and TcPO2 being evaluated in 2 or more studies.  
11. We retrieved only two models to identify subjects that would benefit most of HBOT. 
a. Hawkins et al [Hawkins G et al, 2006] included variables that were not associated with 
healing in univariate analysis;  
b. Fife et al [Fife C et al, 2007] used post-HBOT variables; 
c. neither has been externally validated.  
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12. Using the SIGN system for grading recommendations [Harbour R & Miller J, 2001], for 
major LEA prevention HBOT presents A grade.  However, for the remaining DFU related 
outcomes the grade lowers to B.  
 
Molecular environment characterization, HBOT modulator effect and clinical impact on DFU 
healing 
1. Almost all DFUs proposed for HBOT by our diabetic foot clinic team reached the bone, 
were infected, ischemic and post-minor LEA. 
2. After 3 months of therapy, HBOT DFU individuals presented: 
a.  significantly lower leukocyte and CRP level,  
b. tended to have lower VEGF levels and  
c. remaining laboratory markers, did not reveal statistically significant differences.  
3. At every time points, the HBOT group achieved better outcomes  
a. less amputation and death, 
b. higher DFU reduction,  
c. increasing epithelialization percentage. 
d. Comparison was not possible with the non-HBOT group. 
4. The median number of vessels in the HBOT group tended to increase after 1 month, 
while the opposite occurred in the NHBOT DFU patients (without statistical significance). 
5. Our data reinforced the potential molecular and clinical efficacy and benefit of HBOT 
when added to current standard treatment of DFU.  
 
Improving HBOT referral for DFU treatment: a nationwide models’ validation and refinement 
study 
1. Lisbon’s FNH was responsible for the treatment of 66.4% of the population and patients 
from this hospital presented less frequently retinopathy or previous DFU and had ulcers 
of shorter duration.  
2. The majority of all subjects presented chronic, infected and ischemic DFUs.  
3. During the study period, LEA was necessary in 12.5% of cases, DFU persisted unhealed 
immediately after the last HBOT session in 34.4% and 53.1% healed. 
a. Complete healing was more likely in non-smoking females without arterial 
disease, previous DFU or history of LEA.  
b. Completion of the planned treatment and higher number of sessions had a 
positive impact on outcome.  
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c. Healing rates, number of HBOT sessions and proportion of who completed the 
planned treatment are similar between institutions.  
4. Available models, by Fife et al and Hawkins et al, demonstrated low predictive accuracy 
(with the AUC < 0.63).  
5. We proposed an optimized version of the Hawkins’ et al model with higher accuracy by 
including two additional variables (Wagner grade and previous DFU) and removing DFU 
duration variable.  
 
B. Main Strengths and Limitations 
 
The independent contribution of DFU on LEA and mortality risk 
Strengths 
1. We have conducted a study  
a. assessing DFU impact on LEA and death risk,  
b. in a large cohort of consecutively enrolled subjects, 
c. using the STROBE [Vandenbroucke J et al, 2007] and STARD [Bossuyt PM et al, 2003] checklists 
as the basis for its development and reporting,  
d. conducting adequate statistical adjustment.  
2. Due to the cohort design,  
a. observers were blind to outcome occurrence when collecting baseline data and 
b. all the assessed patient-related events occurred prior to the research being 
undertaken. 
3. For the variables included in the models we had no missing data.  
4. We have confidence in having identified the great majority of outcome occurrence by 
applying a comprehensive use of the available data platforms.  
Limitations  
1. Retrospective nature.  
2. Exclusion of patients outside our direct referral area. 
3. Presence and exclusion from analysis of missing data regarding VST and HbA1c values. 
4. Limited generalizability of the results since it was a high risk referral practice, with great 
prevalence of type 2 DM, and low education level.  
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5. Variables collected by clinical interview may present information bias, namely non 
differential misclassification bias. 
 
Effect of HBOT in DFU healing: a systematic review and meta-analysis 
Strengths 
1. First study simultaneously meta-analyzing all the available studies for HBOT efficacy on 
DFU healing and evaluating the methodological quality of those studies. 
2. A systematic review of factors or models to identify patients that would most benefit 
from HBOT had never been done.  
3. MOOSE [Stroup D et al, 2000] and PRISMA [Liberati A et al, 2009] checklists were used for study 
planning and reporting. 
4. As our conclusions were based on all the available clinical evidence, currently, represent 
the best possible estimate of the true clinical impact of HBOT in DFU treatment. This 
approach potentially improved the validity of our results, diminished the chance of 
selection bias.  
Limitations 
1. The inclusion of non-randomized studies, may lead to participant selection bias, with 
consequent confounded result.  
2. Studies frequently presented small sample sizes, including RCTs (under powering their 
results) and were conducted in single institutions, representing low evidence levels and 
diminished generalizability.  
3. As there was a great variation in the HBOT protocols, high heterogeneity was observed 
in several MA measures. 
4. Methodological quality assessment was made by only one of the researchers. 
 
Molecular environment characterization, HBOT modulator effect and clinical impact on DFU 
healing 
Strengths 
1. First study concurrently evaluating and comparing biochemical markers and clinical 
outcome in DFU patients undergoing or not HBOT, 
2. with prospective design and 
3. including baseline molecular and clinical characterization and comparison with non-DFU 
subjects.  
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4. All laboratory/molecular and microvessel density evaluation analysis were performed 
by investigators blinded to the group allocation.  
5. Selection of DFU individuals for HBOT was performed by a team, independent of the 
study, including only patients with optimized standard care and still no DFU 
improvement. 
6. Clinical end-points were objective: percentage of ulcer healing, amputation, death. 
7. All DFU measurements were performed using a digital laser measuring device. 
Limitations 
1. Allocation was not randomized. 
2. Allocation occultation limitations, since the principal investigator and patients were not 
blinded. 
3. Small sample size. 
4. DFU bed tissue was not representative in several collected samples. 
 
Improving HBOT referral for DFU treatment: a nationwide models’ validation and refinement 
study:  
Strengths 
1. First study 
a. evaluating all subjects treated over a period of five years with HBOT for DFUs in 
continental Portugal and  
b. validating and optimizing predictive model for HBOT referral. 
2. Proposed a model including easily collectable and available variables. 
3. Our optimized model, presented potentially useful sensitivity and predictive values.  
Limitations 
1. Retrospective nature. 
2. The sample size was limited and the missing values in the models’ included variables, 
resulted in wide CI and no statistical differences between the original and the optimized 
models’ AUC values. 
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C. Future research 
 
The independent contribution of DFU on LEA and mortality risk 
1. Derived models should be tested in primary care to assess if they are clinically relevant 
and valid enough per se, or if they should be added to pre-existing 
models/classifications.  
2. The link between DFU history and poorer outcomes in patients with diabetes needs 
further studies to better understand it. 
  
Effect of HBOT in DFU healing: a systematic review and meta-analysis 
1. To optimize available evidence in the future there should be: 
a. therapy protocol definition improvement,  
b. RCTs with larger sample sizes and improved methodological reporting, 
c. cost-effectiveness assessment and 
d. creation of a specific checklist to enhance quality reporting and stimulate 
multicentre studies by consensus of scientific and medical societies of the area.  
 
Molecular environment characterization, HBOT modulator effect and clinical impact on DFU 
healing 
1. Study, in an animal model, more precisely and adequately, the HBOT modulator effect 
on DFU bed tissue. 
2. Increase the total number of patients in whom angiogenic, vasculogenic and 
inflammatory markers are studied. 
3. Develop a study to define optimal HBOT timing after revascularization for DFU 
treatment, since revascularization improves macrovascular disease and HBOT seems to 
ameliorate microvasculature. 
4. Conduct an RCT with the same outcomes in a larger multicentre sample. 
 
Improving HBOT referral for DFU treatment: a nationwide models’ validation and refinement 
study 
1. To conduct a study to assess HBOT knowledge and attitudes of Primary and Hospital 
Care Physicians in Portugal. 
2. Analyze the impact of educational interventions about HBOT, in the same settings, in 
referral improvement. 
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3. Perform a larger multicenter prospective study for predictive model’s validation and 
refinement. 
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ABSTRACT 
This study characterizes the population with diabetic foot ulcer (DFU) undergoing 
hyperbaric oxygen therapy (HBOT) in Portugal over the last 5 years and validates and 
optimizes the existing models for the prediction of healing of HBOT treated DFU; 
through a multicentre retrospective cohort study of all patients treated with HBOT from 
2008 to mid-2013 in Portuguese continental hyperbaric medicine centres (n=2). We 
included 128 individuals. 66.4% underwent HBOT in Lisbon’s former Navy’s Hospital 
(FNH). Subjects from this hospital presented less frequently retinopathy (19.6% versus 
74.5%, p<0.001) or previous DFU (29.2% versus 53.5%, p=0.02), and had ulcers of shorter 
duration (median 1.8 months versus 4.0 months, p<0.001) than Pedro Hispano’s 
Hospital. Overall, 53.1% healed, which was more likely in non-smoking females without 
arterial disease, previous DFU or history of lower extremity amputation (LEA). Both 
completion of the planned series of treatments and increasing number of treatments 
had a positive impact on outcome. Available models had low predictive accuracy. We 
propose an optimized version of the Hawkins’ model that has higher accuracy. There 
were some differences in the patients referred to each of these facilities, but healing 
rates were similar. Further studies are still needed to improve referral criteria for HBOT. 
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INTRODUCTION 
With an estimated 371 million people with Diabetes mellitus (DM) around the world, this 
pathology is considered one of the most frequent metabolic disorders [1].  
Hyperbaric oxygen therapy (HBOT) is indicated in chronic diabetic foot ulcers (DFU) with 
evidence revealing it can decrease the risk of consequent major lower extremity amputation 
(LEA) [2]. Nevertheless, it is an expensive treatment with limited availability, so identification of 
patients with best possible response is fundamental for proper allocation of limited healthcare 
resources. 
In Continental Portugal there are only two Hyperbaric Medicine Centres treating patients with 
active DFU, one in Oporto, located in Pedro Hispano’s Hospital (PHH) in Matosinhos (a public 
civil hospital, referral area from the north to the centre of the country) and one in Lisbon, in the 
former Navy’s Hospital (FNH) (military hospital, referral area from the centre to the south). 
In our experience we have noted large variations in the clinical criteria in referring patients for 
HBOT. To the best of our knowledge, there is no established and validated model specifically 
created for identifying those patients with DFU who are appropriate for referral to HBOT. 
Two models have been reported with the aim of predicting DFU healing for patients undergoing 
HBOT (Hawkins 2006 [3] and Fife 2007 [4]). However, neither have been externally validated, 
nor accuracy measures reported. Furthermore, Fife’s model includes post-therapeutic variables 
(namely HBOT session number and treatment interruption) that make it unsuitable for the 
purpose of clinical decision-making. 
Given this uncertainty, we decided to 1) characterize the Portuguese population undergoing 
HBOT; 2) compare the characteristics of patients and outcomes between the two facilities; 3) 
identify the subjects with better healing and 4) validate and optimize the existing models. The 
main goal is to understand Portugal’s pattern of DFU referral and subsequent outcome, and to 
propose an optimal simple referral model. 
  
- 136 - 
 
METHODS 
Participants’ selection 
A multicentre retrospective cohort study was conducted in all Portuguese hyperbaric 
medicine centres treating diabetic foot patients (n=2) including all subjects that 
underwent HBOT for DFU treatment from January 1, 2008 to June 30, 2013. 
Participants with only one appointment, associated auto-immune diseases, pressure 
and malleoli ulcers, under treatment at the time of data collection and/or missing data 
concerning outcome (healing, non-healing, LEA) were excluded. 
The study was approved by the Ethics Committee of both institutions. 
 
Data collection  
Clinical records were reviewed and data collected from July 1 to the August 31, 2013. 
Demographic characteristics (age at the time of inclusion, gender), DM type (classified 
according to the World Health Organization definition [5]), duration (in years) and 
treatment (oral medication or insulin), metabolic control [through glycated 
haemoglobin (HbA1C)], smoking habits (in packs-year) and the character and severity of 
any DM complications (retinopathy, laser photocoagulation; nephropathy, dialysis; 
neuropathy; cerebrovascular and/or cardiovascular disease) were recorded.  
Factors of interest specific to the DFU were: the presence of peripheral vascular disease 
(PAD); transcutaneous partial pressure of oxygen (TcPO2); ankle-brachial index (ABI); 
diabetic peripheral neuropathy (DPN) and previous DFU or LEA. We also collected the 
ulcer area (in cm2), reported duration (in months), location, Wagner grade [7], number 
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of DFUs and the presence or absence of infection. In the case of multiple DFUs, only the 
largest was considered. 
PAD was considered as present when the foot with DFU presented one or fewer pedal 
pulses [6]. TcPO2 was determined by measuring once at 2 points peri-DFU and reporting 
the highest value. 
DFU area was calculated multiplying the 2 larger axes. Time zero for DFU duration 
estimation was considered the last major surgical debridement or LEA. In the absence 
of either, we calculated the actual duration of DFU.  
Considering HBOT, we recorded the total number of sessions, whether or not the 
planned number of sessions was completed and outcome (complete healing vs. not 
healed or LEA). 
Complete healing was considered as DFUs full epithelisation without the need of further 
treatment [8]. Minor LEA was defined as the surgical removal of toe(s), ray(s) or 
forefoot. Major LEA was considered amputation of any part at or above the entire foot. 
  
Existing models of healing prediction 
We conducted a systematic review in order to retrieve all studies proposing predictive 
models for DFU healing with HBOT. We identified only two: Fife 2007 [4] and Hawkins 
2006 [3]. 
Using the Fife model we can calculate the odds of healing with HBOT compared to the odds 
of healing without HBOT by using the following formula: Log (OR) = 0.99 + 0.21 x [Ln (HBOT 
number of sessions + 1)] + 0.004 x (TcPO2 in mmHg) – 0.04 x (RAMP) – 0.15 x (modified 
Wagner) – 0.04 x (age in years x diabetes duration in years) – 0.19 x (1 if interrupted 
treatment or 0 if no interruption occurred) where RAMP is a function for pack-years of 
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smoking (those with ≤10 pack-years = 0; those with >10 pack years = number of pack 
years – 10) [9]. In Fife’s article [4], the authors made use of the Wagner grading scale 
modified by Kominsky, which varies from II (superficial) to VI (gangrene of the entire 
foot). 
Hawkins’ model for the odds of healing with HBOT is: Log (OR) =2.30 – 0.09 x (DFU area 
in cm2) – 0.11 x (DFU duration in months) + 0.06 (TcPO2 in mmHg). 
Both models were applied to all subjects. 
 
Statistical analysis  
For continuous variables, we used Student’s t-test to compare groups when the data 
appeared acceptably normally distributed (using both histogram and Kolmogorov-
Smirnov testing) and the Mann-Whitney U-test when the assumption of normality was 
not appropriate.  Categorical variables were compared using the Χ2 test or Fisher’s exact 
test, when applicable. 
Multivariate analysis, and consequent variables’ adjustment and predictive models’ 
proposal, was performed using logistic regression. 
All statistical analyses were conducted using the programme IBM SPSS, version 20.0 
(Chicago, IL, USA). All tests were two sided, p values less than 0.05 were considered 
statistically significant and less than 0.1 as pertinent for inclusion in the predictive 
models.  
As Fife’s model uses post-treatment variables (such as HBOT number of sessions and 
treatment interruption) and our goal is to create including model using only pre-
treatment variables) we decided to validate and refine the one proposed by Hawkins if 
pertinent.  
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Therefore, we started by using all the variables included in the Hawkins model and those 
considered pertinent for inclusion in our univariate analysis. Missing and indeterminate 
results were excluded from analysis. 
For the resultant optimized predictive model, a prognostic accuracy assessment was 
made including sensitivity, specificity, predictive values, likelihood ratios (LR), AUC and 
respective 95% confidence intervals (CI) calculation, comparing the CI and evaluating if 
there was overlap to see if there were statistically significant differences. 
RESULTS 
HBOT facilities and program characterization 
The center of the FNH (Centro de Medicina Subaquática e Hiperbárica) has been treating 
DFU patients since January 1990, it has two connected multiplace chambers with 
capacity to treat 24 individuals simultaneously. The treatment program performed for 
DFU is 75 minutes at 2.5 ATA, once a day, five days a week. 
The centre in the north of Portugal (Unidade de Medicina Hiperbárica of PHH) is 
equipped with a 16 place chamber, and started treating subjects with DFU in January 
2008. The therapy protocol used is 80 minutes at 2.4 ATA, once a day, five days a week. 
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Patient characteristics (See table 1) 
This study included 128 patients (85 from the FNH). The majority were males (73.4%), 
with a mean age of 62.9 (SD11.8) years and 62.7% were active or past smokers. Most 
had type DM, with a mean duration of 18.2 (SD 9.9) years, and more than half were on 
insulin, with a mean HbA1c of 8.6% (SD 1.8). The most frequent DM complications were 
retinopathy [44.7%, of whom more than half (27.7% of the total) had received laser 
photocoagulation] and nephropathy (34.6%; 12.2% on dialysis). 
Most of the subjects had PAD (84.8%) and DPN (89.5%). We observed that in PHH, DPN 
was diagnosed using the Semmes-Weinstein monofilament, while in the FNH the 
procedure was never described.  
The mean TcPO2 was 33.5 (range 1-76) and ABI 0.78 (SD 0.28) (data only available from 
PHH). 
The median baseline DFU area was 8.2 (range 0.3-60.0) cm2 with a median duration of 
2.5 (0-36) months. The majority were post-LEA (54.7%) and were infected (89.8%). DFUs 
were classified as Wagner grade III-V in 71.7% of cases. Multiple DFUs were present in 
22.1% of patients.  
After a mean of 55 HBOT sessions (SD 34.1), 16 (12.5%) subjects required LEA and in 
44(34.4%) the DFU remained unhealed. The majority of patients (66.4%) completed the 
prescribed treatment. The most common reasons for failure to complete were the 
withdrawal of health administration approval and worsening of the clinical condition. 
Subjects from PHH presented more often with retinopathy (p < 0.001), previous DFU (p 
= 0.02) and longer DFU duration (p < 0.001) than those from FNH. However, PAD was 
more frequent in those from FNH (p < 0.001). No differences were observed between 
facilities in the remaining variables (See table 1). 
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Predictive variables for DFU healing (See table 2) 
Univariate analysis 
Univariate analysis suggested that the patient characteristics associated with healing 
were female gender (p = 0.03), lower median duration of smoking (pack years, p = 0.01), 
no PAD (p = 0.002), no previous DFU (p = 0.01) and no LEA (p = 0.04).  
No macro or microvascular complication had an impact on healing (p > 0.05).  
Smaller (p = 0.002) and more superficial DFU (p = 0.03) healed more frequently. 
Ulcers that healed received more HBOT sessions on average (p = 0.07), while those that 
completed their planned treatment were more likely to heal (p < 0.001). 
 
 
Multivariate analysis 
Following univariate analysis, we performed a multivariate analysis including all factors 
identified as potentially predictive of healing (p-value on univariate analysis < 0.1) plus 
the elements in the Hawkins model. We substituted the TcPO2 value in the Hawkins 
model with PAD (defined as ≤1 pedal pulse in the affected foot) because of the high 
number of missing values for PtcO2 in our data. Using a backward stepwise elimination 
approach, we have derived the best model. Twenty-eight subjects were excluded from 
analysis due to missing data. 
Using this methodology, we propose an optimized model, derived from the one 
proposed by Hawkins in 2006 (3), with a score calculation based on the following 
equation: Score = 2.96– 1.34 x (≤ 1 pedal pulse) – 0.04 x (DFU area in cm2) – 0.84 x (DFU 
graded as Wagner III-V) – 1.15 x (previous DFU – yes= 1, no = 0).  
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Through ROC curves analysis, we have also proposed the creation of three diagnostic 
categories for DFU healing and determined cut-off values to maximize predictive ability: 
healing not probable for values < -0.91, probable for values from -0.91 to 0.36 and highly 
probable to heal with HBOT for values > 0.36.  
 
Predictive model accuracy  
Figure 1 shows the receiver operating characteristic (ROC) curves for the existing models 
(Fife 2007 and Hawkins 2006) compared with our optimized model. The AUC values are 
higher for the latter [0.51% (95% CI 0.24-0.78) in Fife 2007, 0.63% (95% CI 0.37-0.90) in 
Hawkins 2007 vs. 0.78% (95% CI 0.69-0.87)] in optimized model). However, these 
differences are not statistically significant (See tables 3). 
 Our model had good accuracy values, with LR values having a potential small to 
moderate effect on clinical decision, with negative LR smaller than 0.5 and positive LR 
superior to 1.3 [10]. Predictive values (negative and positive) were superior to 60% (See 
table 4). 
DISCUSSION 
Standardized referral systems are essential for optimal resource allocation and 
prognostic estimation, especially concerning expensive adjunctive therapeutics (such as 
HBOT in chronic DFU). 
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This is the first study evaluating all subjects treated over a period of five years with HBOT 
for DFUs in continental Portugal. 
The sample size is limited (n= 128), and this reduces the power of our analysis to draw 
definitive conclusions. There are potentially two main reasons for this small sample size. 
First, HBOT is a poorly understood and promoted treatment modality, and second, even 
when considered, it is a treatment of last resort given the financial constraints within 
the healthcare system in Portugal.  
Furthermore, we have excluded subjects with associated auto-immune diseases, 
pressure and malleoli wounds as these ulcers have different clinical and 
pathophysiological characteristics than the ‘standard’ DFU, with potential impact on 
healing rates. 
The review period corresponds with the start of DFU treatment at PHH HBOT unit, while 
the FNH unit has been operating since 1989. This may in part explain the fact that 2/3 
of the included subjects were treated at the FNH. 
Our population is similar to those reported in the available literature [11-26]; i e, mainly 
men, above 60 years, with Type-II diabetes for around 15 years and an HbA1c greater 
than 8%. 
In our population almost 30% presented with a Wagner wound grade of I or II, which 
suggests our population had less severe DFU than the majority of previously reported 
studies [13,17,22,25,26] but comparable to the largest randomized controlled trial 
published in this field [11]. 
The majority of our subjects presented diminished palpable pulses (84.8%) and infected 
DFU (89.8%) with a median duration of 2.5 months. 
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We observed a higher percentage of PAD in the FNH participants. This might be due to 
the fact that in the North (referral area of PHH), there is a lower PAD prevalence [27], 
but it is also possible that vascular surgeons take a more active approach to chronic DFU 
patients, including a higher use of angioplasty techniques and revascularization surgery 
(personal communication). 
Conversely, DFU duration was longer at the PHH (median difference of 2.2 months). This 
is a more recent unit and so HBOT is less widespread among referral healthcare 
institutions, thus professionals tend to send only patients with DFU persisting despite all 
other treatment. Additionally, we considered the last major surgical intervention as time 
0 for duration estimation, and in the FNH there was a higher rate of post-LEA wounds 
with immediate referral for HBOT. 
We observed that subjects from PHH tended to present higher rates of DM-related 
complications (retinopathy, nephropathy and stroke). It is not clear if subjects from the 
North of the country tend to present more complications (although DM duration and 
HbA1c values were similar) or if the detection rate is superior [28]. 
However, despite these differences between centres, the healing rates, number of HBOT 
sessions and proportion who completed the planned treatment are similar. 
Eleven studies [3,4,9,11,12,23,29-33] have reported patient factors that may be predictive 
of healing in DFU treated with HBOT. In our population, clinical factors associated with DFU 
healing were female gender, lower smoking pack-years, smaller and more superficial 
DFU as well as absence of PAD, previous DFU and/or LEA. Some of the previous studies 
have similarly reported both smoking habit and Wagner grade as predictive [4,9,29]. 
In contrast to Fife 2003, we could not demonstrate an impact of (age + diabetes 
duration) [4,9,29] , renal failure [4] or previous LEA on outcome. Similarly, in contrast to 
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Hawkins, we observed a statistically significant predictive ability for gender, DFU area 
and duration. 
During the follow-up period, 12.5% of our subjects required an LEA and in 34.4% DFU 
persisted unhealed immediately after the last HBOT session. These data are in 
accordance with several studies, including the two largest randomized controlled trials 
[11-13, 34-36]. 
Because the practice in Portugal is to continue wound care in the referring facility, we 
believe our results confirm a true benefit from HBOT, rather than reflecting any change 
in wound care management in a specialized unit.  Our data also suggest this benefit is 
greater if the prescribed course of HBOT is completed. While this seems likely, based on 
common sense, it may also be biased through the tendency for those doing well to keep 
attending, while those seeing little or no progress may be less inclined to do so.  It is 
worth noting that the mean number of sessions was 55, which is slightly higher than 
most studies have reported [14-18,21,22,24].  
Of the two previously reported predictive models, we observed that both had low 
accuracy (with the AUC < 0.63), and we considered that optimization of one or both 
these models was appropriate. Ultimately, we have excluded Fife’s model because it 
also used post-treatment variables (number of sessions and episodes of treatment 
interruption), making it unsuitable for pre-HBOT decision making – including when it is 
appropriate to refer for HBOT.  
We have therefore optimized the Hawkins model using logistic regression, by including 
two additional variables (Wagner grade and previous DFU) and removing DFU duration 
variable. Due to the number of missing values and in order to increase the optimized 
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models’ application in daily clinical care, we decided to replace the variable TcPO2 by 
the number of palpable pedal pulses. 
In this way, we proposed a model easy to apply and tending to produce higher accuracy 
measures in comparison to the Hawkins’ baseline model. 
Due to the low sample size and high number of missing values in the models’ included 
variables, confidence intervals were wide and no statistical differences were detected 
between the original and the optimized models’ AUC values. For this reason, we were 
also unable to compare other accuracy measures. 
Evaluating the retrospective performance of our optimized model, we observe that it is 
characterised by low specificity and LR but also by potentially useful sensitivity and 
predictive values. We therefore consider that a larger prospective study for model 
validation and refinement is appropriate, and that such a study should be conducted 
prospectively to avoid the pitfalls of retrospective data collection. 
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ABI  Ankle–brachial Index 
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LR  Likelihood Ratio 
  
- 147 - 
 
OR  Odds Ratio 
PHH  Pedro Hispano’s Hospital 
PAD  Peripheral Arterial Disease   
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TcPO2  Transcutaneous Partial Pressure of Oxygen 
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Table 1. Patient characteristics according to Hyperbaric Oxygen Therapy Unit 
Variables 
Total 
(n=128) 
Former Navy’s 
Hospital 
(n= 85) 
Matosinhos Hospital 
(n= 43) p value 
DEMOGRAPHIC AND DIABETES CHARACTERISTICS 
Male [n (%)] 94 (73.4) 65 (76.5) 29 (67.4) 0.30 * 
Age (in years) [mean (SD)] 62.9 (11.8) 64.1 (12.1) 60.7 (11.1) 0.13 
Diabetes duration (in years) [mean (SD)] 18.2 (9.9) ª 17.7 (10.9) ª 18.7 (8.8) 0.64 
Age+ Diabetes duration [mean (SD)] 1123.3 (655.7) ª 1109.5 (721.3) ª 1139.2 (578.3) 0.83 
HbA1C (in %) [mean (SD)] 8.6 (1.8) b 8.9 (2.1)c 8.6 (1.7)d 0.64 
Type 2 diabetes [n (%)] 113 (89.0)e 74 (88.1) e 39 (90.7) 0.77 * 
Insulin use [n (%)] 75 (65.8)f 45 (63.4) f 30 (69.8) 0.55 * 
Smoking habits (in pack-year)[median (range)] 30.0 (0.0-100.0) g 38.0 (0.0-100.0)g 20.0 (0.0-96.0) 0.12 
MACRO AND MICROVASCULAR COMPLICATIONS 
Retinopathy [n (%)]  42 (44.7)h 10 (19.6) h 32 (74.5) 
<0.001 # 
Laser photocoagulation [n (%)] 26 (27.7) 4 (7.8) 22 (51.2) 
Nephropathy [n (%)] 34 (34.6)i 15 (27.3) i 19 (44.2) 
0.19 # 
Dialysis [n (%)] 12 (12.2) 6 (10.9) 6 (14.0) 
Previous stroke history [n (%)] 14 (14.6)j 5 (9.4) j 9 (20.9) 0.15 * 
Previous myocardial infarction history [n (%)] 28 (28.9)k 19 (35.2) k 9 (20.9) 0.18 * 
FOOT CHARACTERISTICS 
0 or 1 foot pulses 106 (84.8)l 74 (89.1) m 32 (76.2) e <0.001 # 
TcPO2 [median (range)] 33.5 (1.0-76.0)n NP 33.5 (1.0-76.0)o NP 
ABI [mean (SD)] 0.78 (0.28)p NP 0.78 (0.28)d NP 
DPN [n (%)] 17 (89.5)q 8 (80.0) r 9 (100.0) s 0.47 * 
Previous DFU [n (%)] 42 (38.9)t 19 (29.2) t 23 (53.5) 0.02 * 
Previous LEA [n (%)] 27 (25.0)t 14 (21.5) t 13 (30.2) 0.37 * 
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DFU CHARACTERISTICS 
Area (in cm2) [median (range)] 8.2  (0.3-60.0)u 9.8 (0.4-60.0)e 6.4 (0.3-54.0)v 0.35§ 
Duration (in months) [median (range)] 2.5 (0-36)w 1.8 (0.0-24.0)w 4.0 (1.0-36.0) <0.001§ 
Multiple DFU [n (%)] 29 (22.7) 20 (23.5) 9 (20.9) 0.83 * 
Located at toes [n (%)] 19 (14.8) 14 (16.5) 5 (11.6) 0.60* 
Post-LEA [n (%)] 70 (54.7) 51 (60.0) 19 (44.2) 0.09* 
Wagner grade III-V [n (%)] 91 (71.7)e 62 (73.8) e 29 (67.4) 0.54 * 
Infection [n (%)] 115 (89.8) 75 (88.2) 43 (93.0) 0.54* 
HBOT CHARACTERISTICS AND OUTCOME     
Complete healing [n (%)] 68 (53.1) 45 (52.9) 23 (53.5) 1.00 * 
Number of sessions [mean (SD)] 54.9 (34.1) 52.1 (32.0) 60.4 (37.6) 0.19  
Completed treatment [n (%)] 85 (66.4) 56 (65.9) 32 (74.4) 0.42 * 
 
*: Fisher’s exact test; : t-test for independent samples; # Χ2 test for association and trend; § Mann-Whitney 
test; ª: 35 missing values; b:83 missing values; c: 77 missing values; d: 6 missing values;e: 1 missing value; f: 14 missing 
values; g: 51 missing values; h: 34 missing values; i: 30 missing values; j: 32 missing values; k: 31 missing values; l:3 
missing values; m: 2 missing values; n:104 missing values; o: 19 missing values; p:91 missing values; q:109 missing values; 
r: 75 missing values; s: through Semmes-Weinstein monofilament and with 34 missing values; t: 20 missing values; u: 
6 missing values; v: 5 missing values; w: 27 missing values; HbA1C: Glycated Hemoglobin; ABI: Ankle-Brachial Index; 
DFU: Diabetic Foot Ulcer; DPN: Diabetic Peripheral Neuropathy; LEA: Lower Extremity Amputation; NP: Not Possible; 
TcPO2: Transcutaneous Oxygen Tension; SD: Standard Deviation 
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Table 2. Patient characteristics by outcome  
Variables 
Complete healing 
(n=68) 
Non-healing / LEA 
(n=60) 
p value 
DEMOGRAPHICS  
Male [n (%)] 44 (64.7) 50 (83.3) 0.03 * 
Age (in years) [mean (SD)] 61.4 (12.1) 64.7 (11.4) 0.12  
Diabetes duration (in years) [mean (SD)] 19.5 (10.5) a 16.5 (8.9) b 0.15  
Age * Diabetes duration [mean (SD)] 1178.3 (697.6) a 1050.3 (596.6) b 0.35  
HbA1c (in %) [mean (SD)] 8.8 (1.7) c 8.5 (1.8) d 0.62  
Type 2 diabetes [n (%)] 57 (85.1) e 56 (93.3) 0.17 * 
Insulin use [n (%)] 42 (67.7) f 33 (63.5) g 0.69 * 
Smoking habits (in pack-year) [median (range)] 0.0 (0.0-90.0) h 40.0 (0.0-100.0) b <0.001 § 
MACRO AND MICROVASCULAR COMPLICATIONS 
Retinopathy [n (%)] 19 (35.9) a 23 (56.1) i 
0.13 # 
Laser photocoagulation [n (%)] 11 (20.8) 14 (36.6) 
Nephropathy [n (%)] 16 (28.5) j 18 (42.9) k 
0.30 # 
Dialysis [n (%)] 5 (8.9) 7 (16.7) 
Previous stroke history [n (%)] 9 (16.7) l 5 (11.9) k 0.57 * 
Previous myocardial infarction history [n (%)] 14 (25.5) m 14 (33.3) k 0.50 * 
FOOT CHARACTERISTICS 
0 or 1 foot pulses [n (%)] 49 (74.2) n 57 (96.8) e 0.002 # 
TcPO2 [median (range)] 21.0 (1.0-76.0) o 37.0 (3.0-67.0) p 0.52 § 
ABI [mean (SD)] 0.9 (0.3) q 0.7 (0.3) d 0.15  
DPN [n (%)] 8 (80.0) r 9 (100.0) q 0.47 * 
Previous DFU [n (%)] 16 (27.1) s 26 (53.1) t 0.01 * 
Previous LEA [n (%)] 10 (16.9) s 17 (34.7) t 0.04 * 
DFU CHARACTERISTICS 
Area (in cm2) [median (range)] 6.1 (0.3-41.0) n 12.0 (0.8-60.0) u 0.002 § 
Duration (in months) [median (range)] 2.0 (0.0-30.0) v 3.0 (0.0-36.0) w 0.14 § 
Multiple DFU [n (%)] 15 (22.1) 14 (23.3) 1.00 * 
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Located at toes [n (%)] 13 (19.1) 6 (10.0) 0.21* 
After LEA [n (%)] 33 (48.5) 37 (61.7) 0.16* 
Wagner grade III-V [n (%)] 43 (63.2) 48 (81.4) e 0.03 * 
Infection [n (%)] 58 (85.3) 57 (95.0) 0.08 * 
HBOT CHARACTERISTICS 
Matosinhos’ Hospital [n (%)] 23 (33.8) 20 (33.3) 1.00 * 
Number of sessions [mean (SD)] 60.1 (32.8) 40.0 (3.0-120.0) 0.07  
Completed treatment [n (%)] 65 (95.6) 23 (38.3) <0.001 * 
 
*: Fisher’s exact test; : t-test for independent samples; # Χ2 test for association and trend; § Mann-Whitney 
test; a: 15 missing values; b: 20 missing values; c: 43 missing values; d: 40 missing values; e: 1 missing values; f: 6 missing 
values; g: 8 missing values; h: 31 missing values; i: 19 missing values; j: 12 missing values; k: 18 missing values; l: 14 
missing values; m: 13 missing values; n: 2 missing values; o: 59 missing values; p: 45 missing values; q: 51 missing values; 
r: 58 missing values; s: 9 missing values; t: 11 missing values; u: 4 missing values; v: 17 missing values; w: 10 missing 
values; HbA1C: Glycated Hemoglobin; ABI: Ankle-Brachial Index; CI: Confidence Interval; DFU: Diabetic Foot Ulcer; 
DPN: Diabetic Peripheral Neuropathy; LEA: Lower Extremity Amputation; TcPO2: Transcutaneous Oxygen Tension; SD: 
Standard Deviation;  
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Figure 1. Predictive models’ receiver operating characteristic curve 
  
 
 
The left image represents the Fife 2007 (in black) and Hawkins 2006 (in grey) score area under the receiver 
operating characteristic curve. The right image represents the optimized model scores (in blue) and 
categories (in green) area under the receiver operating characteristic curve.  
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Table 3. Predictive models’ area under the receiver operating characteristic curve 
 
Model AUC 95% CI 
Fife C et al, 2007 ª 0.51 0.24-0.78 
Hawkins G et al, 2006 0.63 0.37-0.90 
Optimized model 1c   
Score 0.78 0.69-0.87 
Categories 0.75 0.65-0.85 
 
ª: 104 missing values; b: 107 missing values; c: 28 missing values; AUC: Area Under the Receiver Operating 
Characteristic Curve; CI: Confidence Interval 
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Table 4. Optimized models’ prognostic accuracy measures 
 
Subjects 
n (%) 
Healed 
n (%) 
Accuracy measures 
Sens 
% (CI 95%) 
Spec 
% (CI 95%) 
LR+ 
% (CI 95%) 
LR- 
% (CI 95%) 
PPV 
% (CI 95%) 
NPV 
% (CI 95%) 
OPTIMIZED MODEL 1 ª 
Highly probable 48 (48.0) 38 (79.2) 
67.9 
(55.6-80.1) 
77.3 
(64.9-90.0) 
3.0 
(1.7-5.3) 
0.4 
(0.3-0.6) 
79.2 
(67.7-90.7) 
65.4 
(52.5-78.3) 
Highly probable+ 
Probable 
87 (87.0) 54 (62.1) 
96.4 
(91.6-100.0) 
25.0 
(12.2-37.8) 
1.3 
(1.1-1.5) 
0.1 
(0.03-0.6) 
62.1 
(51.9-72.3) 
81.6 
(65.0-100.0) 
 
ª: 28 missing values; CI: Confidence Interval; Spec: Specificity; Sens: Sensitiviy; LR-: Negative Likelihood Ratio; LR+: Positive Likelihood Ratio; NPV: Negative Predictive Value; 
PPV: Positive Predictive Value 
 
 
 
 
 
 
 
 
 
  
- 159 - 
 
ORIGINAL ARTICLE SUMBMITTED FOR PUBLICATION 
Title 
Hyperbaric oxygen therapy in clinical outcome of patients with diabetic foot ulcers: local and 
systemic improvement 
1Daniela Martins-Mendes, MD; 2Raquel Costa, MSc; 3João Moura, PhD; 2Ilda Rodrigues, MSc; 
2Alice Cortez, BSc; 1Manuela Ribeiro, MD; 4Jorge Lima, PhD; 2Raquel Soares, PhD 
  
1Diabetic Foot Clinic; Endocrinology, Diabetes and Metabolism Department/ Internal Medicine 
Department - Centro Hospitalar de Vila Nova de Gaia/Espinho EPE; Vila Nova de Gaia, Portugal  
2Biochemistry Department (U38-FCT) - Faculty of Medicine of the University of Porto; Oporto, 
Portugal 
3Escola Superior de Saúde - Polytechnic Institute of Viana do Castelo 
4Cancer Biology Group - Institute of Molecular Pathology and Immunology of the University of 
Porto; Oporto; Portugal 
 
Corresponding author and requests for reprints:  
Raquel Soares, PhD 
Department of Biochemistry; Faculty of Medicine, University of Porto 
Al. Prof. Hernâni Monteiro, s/n; 4200-319 Porto; Portugal 
Tel/Fax: +351-225513624; Email: raqsoa@med.up.pt 
 
Short title: HBOT in recalcitrant diabetic foot 
Keywords: Diabetes ∙ Diabetic Foot ∙ Foot ulcer ∙ Hyperbaric Oxygen Therapy ∙ Angiogenesis ∙ 
Microvessel density 
  
- 160 - 
 
ABSTRACT  
Oxygenation of diabetic foot ulcer (DFU) by hyperbaric oxygen therapy (HBOT) promotes wound 
healing. However, human studies regarding HBOT local and systemic efficacy are scarce. Herein, 
we aim to 1) compare serum biochemical and angiogenic biomarkers in patients with and 
without active DFU; 2) assess HBOT efficacy in DFU reduction and closure, in serum markers 
modulation and in local microvasculature. We conducted a non-randomized trial enrolling a 
group of patients without active DFU (n=5) and one with active DFU (n=20). We compared those 
treated with HBOT (n=14) with untreated ones (n=6). Endpoints (at 3, 6 and 12 months) included 
lab markers, clinical outcome, DFU size. The groups were identical with a sample mean age of 
62 yrs. and 18-year DM duration, mostly men, with type 2 DM, insulin-treated, with several 
complications and acceptable glycaemic and lipid control. Patients had significant serum 
leukocyte, C-reactive protein levels, and all DFU measurements reduction 3 months after HBOT. 
At every time-points, HBOT group achieved less amputation and death rates and DFU reduction 
with increasing epithelialization percentage. Microvessels in the DFU were increased upon 1 
month HBOT. Our data reinforces the potential molecular and clinical efficacy of HBOT when 
added to current standard DFU treatment. 
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INTRODUCTION 
Worldwide, diabetes mellitus (DM) is one of the most frequent metabolic disorders (1,2) and its 
global burden is attributed to its several complications, namely diabetic foot ulcers (DFU) with 
impaired healing that frequently require lower extremity amputation (3,4). DM leads to 
defective wound repair due to alterations in the micro- and macro-vasculature, cellular and 
molecular environment, where neuropathy and frequent infection also play a role (4-6). 
Wound healing is divided in four different phases: haemostasis, inflammation, proliferation and 
tissue remodelling (7), which mostly depend on oxygen content (7-10). Therefore, tissue 
vascularization to support oxygen availability is of paramount importance for the whole wound 
healing process. 
In adults, neovascularisation can occur through angiogenesis, by migration and in situ 
differentiation of mature resident endothelial cells, and/or from bone marrow-derived 
undifferentiated angioblasts or endothelial progenitor cells (EPC) (11,12). 
Interestingly enough, in diabetic organs like retina, angiogenesis is exacerbated, while in others, 
for instance distal microvasculature of the inferior limbs, it is decreased (6,13). 
DFUs frequently evolve to chronic wounds, which are lesions that do not heal in the usual time 
(4-6 weeks) with conventional therapy. Local hypoxia is common in this situation with tissue 
oxygen pressure (pO2) scarcely reaching 10 to 30 mmHg, while optimum values range from 50 
to 100 mmHg (8,13). These features led to the use of hyperbaric oxygen therapy (HBOT), which 
consists in the administration of oxygen in an hyperbaric chamber, at pressures usually between 
1,5 and 3 ATA (atmospheres absolute) (152,0 – 304,0 kilopascal (kPa)). In agreement, a recent 
systematic review demonstrated that HBOT was associated with a significant reduction in the 
risk of major LEA in subjects with chronic DFU (14).  These findings are also corroborated by 
animal studies that point out that HBOT stimulates healing namely by improving 
neovascularisation through several mechanisms, including growth factors synthesis in the 
wound bed and recruitment of EPC (4,6,15,16). However, studies in human subjects with 
diabetes and active DFU are still lacking. 
Given the current state of knowledge, the aim of the current study are: 1) to quantify systemic 
angiogenic, vasculogenic and biochemical markers in subjects with diabetes with and without 
active DFU; 2) to examine the efficacy of HBOT through analysis of its impact in a) ulcer reduction 
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and closure, b) serum markers modulation and c) the microvasculature improvement of the 
ulcer bed. 
 
Material and Methods 
Study design and participants selection 
A non-randomized clinical trial was conducted at Centro Hospitalar de Vila Nova de 
Gaia/Espinho, EPE (Entidade Pública Empresarial) Diabetic Foot Outpatient Clinic, which is a 
tertiary care unit with a multidisciplinary team. The clinical trial was registered in the Brazilian 
Clinical Trial Registry (Registro Brasileiro de Ensaios Clínicos) number UTN U1111-1146-8232 and 
approved by the Ethics Committee of our institution.  
Subjects with active DFU, a full-thickness skin defect distal to the malleoli requiring more than 
15 days to heal (17), that, after 8 weeks of standard treatment (including angioplasty and/or 
revascularization surgery if needed), had no significant wound improvement (no healing or ulcer 
area reduction < 30%) were consecutively proposed to HBOT. 
Participants were included from the October 1st, 2010 until the December 31st, 2012.  
HBOT proposal was performed in accordance to the multidisciplinary team and financial 
department approval. Team decision relied on selecting patients that would most benefit of 
healing, excluding namely patients bedridden and dependent on third person for daily life 
activities. Therefore, HBOT was used, depending on hospital economic resources and availability 
of the HBOT facility, as last resource in people that despite maximized macrovascular blood flow 
had no healing. These participants were divided in two groups: HBOT – treated with HBOT and 
non-HBOT – patients that refused the treatment or had a contra-indication.  
Both groups with DFU were compared with a group of non-DFU diabetic subjects that were 
participating in an educative program on diabetes in our department.  
HBOT was performed in the referral area HBOT center (Unidade de Medicina Hiperbárica of 
PHH) according to the used treatment protocol - 80 minutes at 2.4 ATA (243.2 kPa), once a day, 
five days a week, up to a maximum of 100 sessions. 
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Standard care was conveyed in the DFU groups by a team independent of the investigators. In 
case of multiple ulcers, evolution of the larger DFU was evaluated through the decrease in the 
wound measures.  
All subjects were followed for twelve months to evaluate healing in the DFU groups and the 
potential occurrence of lesions in the non-DFU subjects. 
 
Participants and diabetic foot ulcer characteristics  
At enrollment, the following demographic characteristics were collected: age at the time of 
inclusion; gender; DM type (classified according to the World Health Organization definition 
(18)), duration (in years) and treatment (oral anti-diabetic agents or insulin); metabolic control 
(through glycated haemoglobin (HbA1c)); smoking habits; presence of any DM related 
complications (namely, retinopathy, nephropathy, neuropathy, cerebrovascular, cardiovascular 
and/or PAD and metabolic),  were registered in accordance to the definition used in the Diabetes 
Complications Severity Index created by Young et al (19).  
For the foot characterization we used the presence of PAD, when only one or fewer pedal pulses 
were palpable on the DFU foot (20) and/or the ankle-brachial index (ABI) was inferior to 0.8  
(21); TcPO2, determined by measuring once at 2 points peri-DFU and reporting the highest 
value; DPN, defined as inability to feel the SWM at one or more of 4 specific sites on the foot 
(22); and previous DFU or LEA. We also recorded the ulcer area (in cm2), reported duration (in 
months), location, Texas University classification (TUC) (21), number of DFUs and the presence 
or absence of infection.  
DFU photographic and dimensional records (area, maximum and mean depths and volume) 
were performed using a digital wound measurement device (Aranz Medical Silhouette Mobile 
TM), at baseline, and if still with active DFU, at months 3, 6 and at the end of follow-up (12 
months). Based on the area measurements, percentage of epithelialization was calculated at the 
same endpoints. 
Considering the HBOT description, the total number of sessions, whether or not the planned 
number of sessions was completed and side-effects were registered. Complete healing was 
considered whenever the DFU presented full epithelialization without the need of further 
dressing (23). Minor LEA was defined as amputation distal to or including the forefoot and major 
LEA was considered amputation above or by the ankle (24).  
Clinical outcome occurrence was also assessed at 3, 6 and 12 months. 
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Laboratory analysis of serum parameters 
In all three groups (non-DFU, HBOT, non-HBOT) blood samples were collected at baseline and 3 
months after, in the HBOT group a sample was drawn also at 6 months. Additionally, in the DFU 
groups ulcer debridement material was collected at 0 and 1 months. Blood samples were 
collected to EDTA (ethylenediamine tetraacetic acid) and gel and clot activator tubes.  
Full blood count was performed using an automated hematology analyzer XE 2100 or 5000 
(Sysmex Corporation, Norderstedt, Germany). 
Serum was analysed for glucose, urea, creatinine, total proteins, albumin, lipid profile, uric acid 
and C-reactive protein (CRP) with the Cobas 8000c701 (Roche Diagnostics; Hitachi High-
Technologies Corporation, Tokyo, Japan). 
HbA1c was determined through high pressure chromatography in the Horiba Medical G7 device 
(Horiba Medical; Horiba ABX SAS, Kyoto, Japan). 
Microalbuminuria level was evaluated by immunoturbidimetry with Cobas 6000 c501 analyzer 
(Roche Diagnostics; Hitachi High-Technologies Corporation, Tokyo, Japan). 
Angiogenic (VEGF, PlGF) and vasculogenic (SDF1-α) markers were determined by enzyme-linked 
immunoabsorbent assay (ELISA) multiplex using Quantikine ELISA Immunoassay kits (R&D 
Systems, Abingdon, United Kingdom (UK)), according to manufacturer instructions. 
 
Immunohistochemistry assays 
Ulcer bed tissue was collected, when DFU debridement was performed, for histological and 
immunohistochemistry studies. The tissue specimens were fixed in 10% neutral-buffered 
formalin solution and paraffin-embedded. Three-micrometer sections were stained with 
hematoxylin and eosin (H&E) or used for capillary endothelial cells immunostaining. Endogenous 
peroxidase activity was blocked with 4% hydrogen peroxide in phosphate buffered saline (PBS) 
for 30 minutes at room temperature. To retrieve antigen, sections were placed in 10 mM citrate 
buffer (pH = 6) and heated at 98°C. After blocking with 10% bovine serum albumin (BSA) in PBS 
for 1 hour, sections were incubated with primary antibody against Cluster of differentiation 31 
(CD31) (1:100) (Abcam, Cambridge, UK) overnight at 4°C. Then, anti-rabbit secondary antibody 
(1:200) (Santa Cruz Biotechnology, USA) was applied for 30 minutes. Avidin Biotin Complex (ABC) 
complex method (Vectastain ABC kit, Vector, Burlingame, CA, USA) was used according to the 
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manufacturer’s instructions. The antigen-antibody reaction was developed using 
diaminobenzidine (DAB) (DAB substract kit, Abcam, Cambridge, UK) as peroxidase substrate, 
rendering CD31 positive cells with a brown staining. Sections were counterstained with 
hematoxylin (Sigma-Aldrich, Portugal), dehydrated and coverslipped. CD31-expressing 
microvessels were counted in the three most vascularized areas with magnification of 200 x, and 
the data were averaged and normalized to the total area of the tissue section. Any positive-
staining endothelial cell or endothelial cell cluster that was separated from adjacent 
microvessels was considered an individual vessel (25). 
Every laboratory and molecular studies were performed by investigators blinded to the subjects’ 
group allocation. 
 
Statistical analysis 
Continuous variables will be described by mean and standard deviation (SD), in the case of 
having normal distribution, or median and range otherwise. Normality of the distribution will be 
assessed through the histogram analysis.  
Comparison between 2 groups will be conducted with t-test for independent samples or Mann-
Whitney U test, according to the variable distribution. For the comparison between 2 time-
points in the same group we used the t-test for paired samples or Wilcoxon signed rank test, 
when pertinent. For the comparison between 3 time-points, the Wilcoxon signed rank or the 
Friedman test were used, according to the variable distribution. 
For differences’ evaluation between variables in the 3 groups, the One-Way ANOVA test (using 
the Bonferroni correction) or the Kruskall-Wallis test were applied. 
For categorical variables description, frequency and percentage were used and, for association 
analysis, the Χ2 or Fisher’s exact test (when applicable). 
All tests were two sided, p values less than 0.05 were considered as statistically significant. 
Statistical analysis was performed using the IBM SPSS version 22.0 (Chicago, IL, USA). 
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Results 
Participants characteristics 
A total of 25 patients were included in the study: 5 in the non-DFU, 6 in the non-HBOT DFU and 
14 in the HBOT DFU groups described in Table 1. The DFU participants were allocated not to 
undergo HBOT due to refusal of treatment in 5 patients and 1 for presenting a contra-indication. 
There was no significant difference between groups regarding mean age and disease duration. 
Taken the whole group of patients into account, the mean age in our sample was 62 years and 
DM duration 18 years, and the majority were male, with type 2 DM treated with insulin, with 
visual and physical impairment. Concerning DM complications, most had retinopathy, PAD 
complications and neuropathy. The mean complications count was 4 and the non-DFU group 
had significantly less PAD complications and tended to present less frequently the remaining 
complications. 
The non-DFU group was composed mainly by female subjects by way of chance, such difference 
presented statistical significance. 
Concerning the total foot pulses number, non-DFU persons had a significantly higher number 
comparing to both DFU groups. Intermittent claudication was significantly more common in the 
non-HBOT DFU participants, as they tended to present more PAD complications, ischemia 
diagnosed by pulses palpation and statistically significant less frequently DPN diagnosed by 
SWM. 
Almost all DFUs reached the bone and were infected and ischemic. Several were post-minor LEA 
and 25% were located in the toes. 
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Laboratory markers  
At the beginning the study, patients presented a mean HbA1c of 7.9-8.5%, total cholesterol 
around 170 mg/dl and triglycerides ranging from 112 to 146 mg/dl (Table 2). These findings 
indicated that glycaemic control and lipid profile were acceptably controlled in the three groups 
of patients.  
Non DFU patients did not exhibit microalbuninuria. Interestingly, the HBOT DFU group had 
significantly less microalbuminuria at baseline comparing to non-HBOT DFU subjects. 
DFU subjects presented normal total proteins, albumin and uric acid serum levels (data not 
shown). 
After 3 months of therapy, HBOT DFU individuals presented significantly lower leukocyte and 
CRP level, and tended to have lower VEGF levels, when compared to NHBOT DFU subjects.  
No statistically significant differences were found for the remaining laboratory markers (values 
are described in Table 2).  
 
Clinical outcome 
Three months after HBOT, there were significant differences in the clinical outcome between 
DFU subjects who underwent HBOT as compared to non-treated patients. There were four LEA 
(three major and one midfoot) in the non-HBOT DFU group. One patient died in the early post-
operative period and another from lung cancer. In addition, one subject died after refusing 
major LEA (Table 3). In contrast, all HBOT DFU participants improved or presented complete 
healing upon 3 and 6 months treatment, and none required LEA. However, three patients died 
12 months later due to DFU non-related causes. Altogether these findings reveal that statistically 
significant differences between groups at every endpoint were observed.  
 
Diabetic foot ulcer characterization 
We next examined DFU features in NHBOT and HBOT patientsAt baseline, DFUs had equivalent 
dimensions in the two groups of patients (Table 4). As only one subject remained alive and 
without major LEA at the 3rd month in the non-HBOT DFU, no comparison was possible between 
baseline at this time-point. Nevertheless, this patient exhibited a larger and deeper ulcer when 
comparing to the median values in the HBOT DFU group. 
All measurements (mean depth, maximum depth and volume of DFUs), presented or tended to 
present significantly lower values at the 3rd month of HBOT when comparing to baseline. 
Considering long-term follow-up, the remaining non-HBOT DFU subject healed 6 months after 
the beginning of the study, again, impeding the comparison between groups (Table 5).  
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In the HBOT DFU group, all measurements improved at months 6 and 12 (p=0.006 for maximum 
depth; p=0.001 for mean depth and DFU volume). 
 
Percentage of epithelialization 
To determine whether complete healing was achieved, epithelialization was then addressed in 
the two DFU groups. The only subject remaining with active DFU at month 3 presented a median 
percentage of epithelialization of 79.4%. The DFU was completely healed at 6 months and 
remained 100% epithelialized at 12 months. 
Conversely, in the HBOT DFU group, significant and gradual improvement was observed in all 
three time points (median percentage of epithelialization of 64.4%, 85.7% and 100.0% at months 
3, 6 and 12 respectively, p=0.001) for all subjects. 
 
Vessel density evaluation  
To examine whether HBOT improved microvasculature within the DFU, microvessel density was 
assessed. As DFU bed tissue was gathered only when debridement was performed, not all 
collected samples presented viable tissue. Therefore, immunohistochemistry for CD31-
expressing microvessels samples paired by subject, were only possible in 3 and 6 patients in the 
non-HBOT DFU and HBOT DFU groups, respectively. 
In the HBOT group the mean number of vessels tended to increase after 1 month (617 vs 
709/three 200x magnification fields). In contrast, a slight reduction was observed in the number 
of microvessels for the non-HBOT DFU patients (746 vs 680/three 200x magnification fields), not 
achieving, however, statistical significance (Figure 1). Figure 2A-2D illustrate the 
immunohistochemistry results. 
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Discussion 
 
Several studies have addressed HBOT impact on DFU healing (14). However, this is the first study 
to simultaneously evaluate and compare biochemical markers and clinical outcome in subjects 
with no DFU and with DFU undergoing or not HBOT. 
Our sample presented a mean age, gender, DM duration and HbA1c, similar to the populations 
reported in randomized controlled trial (RCT) (26-33) and non-randomized trial (NRT) (34-37). 
Median TcPO2 was lower than in most studies (31,34,38,39). Regarding depth, we included 
deeper DFUs than RCT (21,28,31) but similar to NRT (34,36,37,40). Therefore, our subjects 
present comparable or worse baseline prognosis to the ones in previous studies from the 
literature.  
Interestingly, at every time-point, the HBOT group achieved better outcomes when compared 
to those with DFU without undergoing such adjunctive therapy. Less major LEA rates, less death 
rates and longer survival rates were observed. 
Assessing all DFU measures, a high DFU reduction and an increasing epithelialization percentage 
were observed along the whole study period in the HBOT group. Analysing the RCT and NRT in 
the literature, we noticed that our clinical outcome rates were equivalent (within the 95% CI) to 
those reported by the long term, at least 12 months, to RCT and NRT for both groups (26-
28,32,35,38-40). 
During a mean number of 86 HBOT sessions, a gradual DFU improvement, continuing after the 
prescribed therapy program completion, was observed. Comparing to the available literature 
(26,28,35,37-40), we realized that our patients were exposed to a higher number of sessions, 
which may have positively affected the results. 
Our findings showed that in patients submitted to merely 3 months of HBOT exhibited a 
significantly lower leukocyte and CRP level. These findings support the evidence that HBOT 
results in a reduction in infection and inflammatory response (41,42).  
Another effect widely suggested in the literature is the improvement of the reduced 
vascularization within DFU tissues. Consequently, we examined whether HBOT influenced 
systemic VEGF levels. Our results indicated that DFU patients have higher levels of VEGF when 
compared to non-DFU. Serum VEGF diminished to values similar to those in the non-DFU group 
in the HBOT group, although not reaching statistical significance. Interestingly, these VEGF levels 
decreased upon HBOT. Since VEGF is up-regulated by hypoxia and by inflammatory 
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environment, VEGF reduction may be explained by a decrease in hypoxia as well as in 
inflammatory factors, which altogether led to “normalized” VEGF levels.  
SDF1-α is involved in the recruitment of circulating bone marrow-derived EPCs, which are known 
to be decreased in diabetes. We further investigated this growth factor in sera of non-DFU and 
DFU individuals submitted or not to HBOT. In the HBOT group, SDF1-α increased at month 3, 
returning to baseline levels at month 6. Since at 3 months all subjects received HBOT, and at 6 
months, all had finished the treatment, we hypothesize that HBOT augments SDF1-α values, 
with a possible rise in the number of circulating EPCs, but this effect halts with treatment 
suspension (43). 
DFU healing is accompanied by tissue vascularization. To further investigate the effect of HBOT 
in the tissue, we evaluated the number of vessels within the DFU throughout the study. Despite 
a reduction in systemic VEGF levels was observed after 3 months treatment, DFUs exhibited a 
tendency towards increased median number of vessels in the HBOT group one month upon 
treatment initiation, while the opposite tendency occurred in the non-HBOT DFUs. These 
findings imply that locally, at the DFU tissue, HBOT improves vascularization. These conflicting 
results (reduced VEGF serum levels and increased microvessel density in DFU of HBOT subjects), 
can be explained by the fact that local environment plays a crucial role in the angiogenic process 
in diabetic patients. This assumption comes in line with the well-established angiogenic paradox 
hupothesis, which highlights that the same patient may present exacerbated angiogenesis in 
organs like retina and kidney, and simultaneously angiogenesis impairment in others (e.g. limbs 
and myocardial ischemia) (44) 
Infection and PAD are considered by several classifications as the most important factors along 
with wound depth, for DFU prognostic assessment (45). HBOT improves circulation by 
stimulating micro-vascularization and optimizes oxygen delivery ameliorating leucocytes 
function and anti-bacterial effect. We believe that such mechanisms are responsible for such 
good clinical outcomes and are evident in our results.  
Remarkably, only one subject suffered a minor side effect due to HBOT (ear barotrauma), that 
responded to treatment. Thus, these findings reinforce the role of this treatment in diabetic 
patients exhibiting aggressive DFU. 
According to our non-randomized trial study, HBOT represents a more feasible methodology in 
clinical practice for DFU patients. However, it presents several limitations. DFU control group 
(non-HBOT subjects), was selected by refusal or contra-indication, instead of using 
randomization techniques. This may lead to a selection bias. Comparing baseline characteristics, 
we observed that the main difference lies in the fact that there was significantly more history of 
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previous DFU in the non-HBOT DFU individuals than in the HBOT DFU. This might be one of the 
possible reasons for them to refuse HBOT as they might be depressed (46) and tired of long-
term unsuccessful therapies. Moreover, a small sample size was achieved, due to limited 
selection of adequate patients and financial constraints. Nevertheless, significant results were 
obtained for several measures.  
Due to ethical reasons, we were unable to perform DFU biopsy. Small fragments were collected 
from wound debridement. Therefore, not all collected samples were representative of DFU bed 
tissue, limiting the evaluation of microvessel density. Despite this, it appears that HBOT DFU 
subjects tend to have an increase in vessel number after 1 month of therapy, with the opposite 
occurring in the non-HBOT group. 
In order to overcome the described weaknesses of the study, the selection of DFU individuals 
for HBOT was performed by an independent team, including only patients with optimized 
standard care and still no DFU improvement; further, laboratory/molecular and microvessel 
density evaluation analysis were performed by blinded researchers; clinical end-points were 
objective (percentage of ulcer healing, amputation and death) and all DFU measurements were 
performed using a digital laser measuring device. 
Due to defined criteria, our diabetic foot clinic team referred for HBOT mainly DFUs that reached 
the bone, were infected, ischemic (grade III and stage D in the UTC) and after minor LEA has 
occurred. This fact may limit the results’ generalizability and it may diminish the magnitude of 
effect. Accordingly, if such clinical results were observed, an even better outcome in a less 
severely affected population is expected. 
In conclusion, our data reinforces the potential molecular and clinical efficacy and benefit of 
HBOT when added to current standard treatment of DFU. But further studies are required, 
particularly, increase the total number of patients in whom angiogenic, vasculogenic and 
inflammatory markers are studied not only in serum but also in the DFU bed; and evaluation of 
the HBOT modulator effect on DFU bed tissue using an animal model. These would highlight the 
molecular mechanisms involved. 
It is also crucial to define the optimal HBOT timing after revascularization for DFU treatment, 
since revascularization improves macrovascular disease and HBOT seems to ameliorate 
microvasculature.  
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LIST OF ABBREVIATIONS 
ABI  Ankle–brachial Index 
ATA  Atmospheres Absolute 
CRP  C-reactive Protein 
DFU   Diabetic Foot Ulcer 
DM  Diabetes mellitus 
DPN  Diabetic Peripheral Neuropathy 
EPC  Endothelial Progenitor Cells 
ESR  Erythrocyte Sedimentation Rate 
HBOT  Hyperbaric Oxygen Therapy 
H&E  Haematoxilin-eosin 
HIF-1  Hypoxia Inducible Factor 1 
kPa  Kilopascal 
LEA  Lower Extremity Amputation 
non-HBOT Non-Hyperbaric Oxygen Therapy  
PlGF   Placental Growth Factor 
PAD  Peripheral Arterial Disease 
pO2  Tissue Oxygen Pressure  
SDF1-α  Stromal Derived Factor-alfa 
TcPO2  Transcutaneous Partial Pressure of Oxygen 
VEGF  Vascular Endothelial Growth Factor 
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Table 1. Participants baseline characteristics 
Variables 
Global 
(n=25) 
Non-DFU  
(n=5) 
 
NHBOT DFU 
(n=6) 
HBOT DFU 
(n=14) p value 
SUBJECT CHARACTERIZATION 
Age (mean (SD)) 62 (12) 68 (10) 63 (11) 61 (13) 0.6*,a 
Male gender (n (%)) 18 (72) 1 (20) 6 (100) 11 (79) 0.009/0.006¥ 
Visual impairment (n (%)) 19 (76) 3 (60) 5 (83) 11 (79) 0.6/0.5¥ 
Physical impairment (n (%)) 16 (64) 3 (60) 4 (67) 9 (64) 0.7/0.9¥ 
Past or present smoker (n (%)) 13 (52) 1 (20) 4 (67) 8 (57) 0.3/0.3¥ 
DM AND ITS COMPLICATIONS 
Type 2 (n (%)) 23 (92) 4 (80) 6 (100) 13 (93) 0.5/0.5¥ 
Duration (in years) (mean (SD)) 18 (9) 26 (19) 15 (7) 20 (10) 0.3*, a 
Insulin use (n (%)) 17 (68) 3 (60) 5 (83) 9 (64) 0.6/0.9¥ 
Cardiovascular complications history (n (%)) 7 (28) 1 (20) 1 (17) 5 (36) 0.6/0.4¥ 
Retinopathy complications history (n (%)) 21 (84) 3 (60) 6 (100) 12 (86) 0.2/0.3¥ 
Nephropathy complications history (n (%)) 12 (48) 1 (20) 5 (83) 6 (43) 0.1/0.7¥ 
Cerebrovascular complications history (n (%)) 3 (12) 0 (0) 0 (0) 3 (21) 0.3/0.1¥ 
PAD complications history (n (%)) 18 (72) 1 (20) 6 (100) 13 (93) 0.001/0.003¥ 
Neuropathy complications history (n (%)) 22 (88) 5 (100) 4 (67) 13 (93) 0.2/1.0¥ 
Metabolic complications history (n (%)) 11 (44) 2 (40) 2 (33) 7 (50) 0.8//0.6¥ 
Complications count (mean (SD)) 4 (1) 3 (1) 4 (2) 4 (2) 0.1*, a 
DFU FOOT CHARACTERIZATION 
Foot deformity (n (%)) b 14 (61) 3 (60) 2 (14) 9 (64) 0.7/0.8¥ 
Total foot pulses ≤ 1 (n (%)) 20 (80) 1 (20) 6 (100) 13 (93) 0.001/0.003¥ 
ABI < 0.8 (n (%)) 5 (75) NA 2 (33) 3 (21) 0.6γ 
TcPO2 (median (range)) 18 (67) NA 24 (34) 16 (67) 0.6 α 
Intermittent claudication (n (%)) 12 (48) 0 (0) 5 (83) 7 (50) 0.02/0.2¥ 
DPN symptoms (n (%)) 23 (92) 5 (100) 5 (83) 13 (93) 0.6/0.8¥ 
Altered SWM sensation (n (%)) c 17 (81) 3 (60) 3 (60) 11 (100) 0.07/0.04¥ 
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Previous DFU (n (%)) 15 (60) 1 (20) 6 (100) 8 (57) 0.03/0.4¥ 
Previous LEA (n (%)) 7 (28) 0 (0) 3 (50) 4 (29) 0.2/0.4¥ 
DFU CHARACTERIZATION      
Texas grade       
III (Bone or joint) (n (%)) 25 (100) NA 6 (100) 14 (100) 1.0γ 
Texas stage      
B (Infection) (n (%)) 1 (5) NA 0 (0) 1 (7) 
1.0γ 
D (Infection plus ischemia) (n (%)) 19 (95) NA 6 (100) 13 (93) 
Located at toes (n (%)) 5 (25) NA 3 (50) 2 (14) 0.1γ 
 
*: One-Way ANOVA test with Bonferroni correction, : Chi-square test for association, ¥: Chi-square test for tendency, α : Mann-
Whitney U test, γ: Fisher’s exact test, a: No statistical difference between groups, b: in 2 subjects it was not applicable, c: in 4 subjects 
it was not possible to conduct, ABI: Ankle-brachial index, DFU: Diabetic foot ulcer, DPN: Diabetic peripheral neuropathy, HbA1c: 
Glycated haemoglobin, HBOT: Hyperbaric oxygen therapy, LEA: Lower extremity amputation, NA: Not applicable, NHOTB: No 
hyperbaric oxygen therapy,  PAD: Peripheral arterial disease, SD: Standard deviation, SWM: Semmes-Weistein monofilament, TcPO2: 
Transcutaneous Partial Pressure of Oxygen 
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Table 2. Laboratory markers 
Variables Global 
Non 
DFU 
(n=5) 
NHBOT DFU 
patients 
(n=6) 
Paired 
samples 
tests 
p value 
HBOT DFU patients 
(n=14) 
Paired 
samples 
tests 
p value 
Independent 
samples tests 
p value 
 
M0 
(n=25) 
M3 
(n=20) 
M6 
(n=14) 
M0 M0 M3 M0 M3 M6 M0 M3 
Glucose (mg/dl) 
(mean (SD)) 
172 
(75) 
213 
(82)a 
211 
(75) 
165 
(60) 
194 
(110) 
236a 
(109) 
0.3ε 
165 
(64) 
200 
(68) 
211 
(75) 
0.2*,b 0.5ж 0.4ж 
HbA1C (in %) 
(mean (SD)) 
8.1 
(1.7) 
8.3 
(1.8)a 
8.2 
(1.6) 
8.5 
(1.5) 
8.3 
(2.1) 
9.5 
(2.9)a 
0.2ε 
7.9 
(1.7) 
7.8 
(1.1) 
8.2 
(1.6) 
0.8*,b 0.6ж 0.3ж 
Haemoglobin 
(g/dl) (mean (SD)) 
12 (1) 12 (2)a 12 (2) 
13 
(2) 
12 (1) 11 (2)a 0.3ε 12 (1) 12 (2) 12 (2) 0.8*,b 0.8ж 0.6ж 
Leukocytes 
(x103/dl) (mean 
(SD)) 
9.5 
(3.4) 
10.0  
(3.7)a 
7.9 
(1.8) 
6.6 
(0.9) 
11.5 
(4.1) 
12.5 
(4.4) 
0.4ε 
9.4 
(3.0) 
8.7 
(2.7) 
7.9 
(1.8) 
0.3*,b 0.2ж 0.03ж 
Platelets (x103/dl) 
(mean (SD)) 
267 
(71) 
265 
(79)a 
229 
(76) 
236 
(34) 
256 
(57) 
305 
(90)a 
0.2ε 
277 
(81) 
244 
(67) 
229 
(76) 
0.2*,b 0.6ж 0.1ж 
C-reactive 
protein (mg/dl) 
(median (range)) 
0.8 
(15.7) 
0.3 
(22.5)a 
0.3 
(11.2) 
0.7 
(0.6) 
2.1 
(11) 
11.8 
(22.4)a 
0.1* 
0.7 
(15.7) 
0.3 
(5.4) 
0.3 
(11.2) 
0.3 Ϫ 0.2 α 0.03α 
Total cholesterol 
(mg/dl) (mean 
(SD)) 
170 
(54) 
153 
(37)a 
151 
(24) 
180 
(68) 
163 
(68) 
168 
(57)a 
0.5ε 
170 
(46) 
147 
(26) 
151 
(24) 
0.2*,b 0.8ж 0.3ж 
LDL cholesterol 
(mg/dl) (mean 
(SD)) 
101 
(47) 
84 
(32)a 
83 
(24) 
98 
(56) 
97 
(57) 
97 
(53)a 
0.5ε 
104 
(43) 
79 
(20) 
83 
(24) 
0.1*,b 0.8ж 0.3ж 
HDL cholesterol 
(mg/dl) (mean 
(SD)) 
44 
(10) 
41 
(12)a 
42 
(17) 
55 
(10) 
43 
(10) 
36 
(13)a 
0.1ε 41 (9) 
43 
(11) 
42 
(17) 
0.9*,b 0.7ж 0.3ж 
Triglycerides 
(mg/dl) (mean 
(SD)) 
130 
(70) 
143 
(85)a 
131 
(70) 
146 
(119) 
112 
(44) 
177 
(82)a 
0.1ε 
133 
(60) 
130 
(86) 
131 
(70) 
0.8*,b 0.5ж 0.3ж 
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Creatinine 
(mg/dl) (median 
(range)) 
0.8 
(7.3) 
0.9 
(8.2)a 
0.9 
(2.2) 
0.6 
(0.8) 
1.3 
(7.3) 
1.6 
(8.2)a 
0.2* 
1.0 
(1.8) 
0.9 
(2.9) 
0.9 
(2.3) 
0.8 Ϫ 0.7α 1.0α 
Urea (mg/dl) 
(mean (SD)) 
55 
(23) 
69 
(47)a 
63 
(34) 
42 
(7) 
66 
(33) 
92 
(65)a 
0.1ε 
54 
(21) 
57 
(32) 
63 
(34) 
 0.5ж 0.3ж 
Microalbuminuria 
(mg/dl) (n (%)) 
12 
(48) 
12 
(63)a 
7 (64) 0 (0) 5 (83) 4 (80)a NA 7 (50) 8 (57) 7 (64) NA 0.02/0.2¥ 0.6 γ 
VEGF  (pg/ml) 
(median (range)) 
70 
(268) 
66 
(355)a 
40 
(131) 
37 
(101) 
189 
(236) 
99 
(344)a 
0.9* 
72 
(268) 
56 
(129) 
40 
(131) 
0.6 Ϫ 0.6α 0.07α 
PlGF (pg/ml) 
(median (range)) 
12.6 
(66.5) 
8.5 
(65.8)a 
10.5 
(51.2) 
6.8 
(8.3) 
3.1 
(14.7)) 
7.4 
(12.1)a 
0.7* 
14.8 
(65.7) 
9.6 
(64.0)) 
10.5 
(51.2) 
0.4 Ϫ 0.2α 0.4α 
SDF1- α (pg/ml) 
(mean (SD)) 
1911 
(642) 
2030 
(713)a 
1739 
(2136) 
1992 
(470) 
2297 
(514) 
2062 
(1054)a 
0.5ε 
1716 
(691) 
2017 
(562) 
1739 
(2136) 
0.8*,b 0.08ж 0.9ж 
 
ε: Student’s t test for paired samples, ж: Student’s t test for independent samples, α: Mann-Whitney U test, *: Wilkoxon signed ranks 
test, *: One-Way ANOVA test with Bonferroni correction, Ϫ: Friedman test, : Chi-square test for association, ¥: Chi-square test for 
tendency, γ: Fisher’s exact test, a: 1 missing value, b: No statistical difference between groups, %: Percentage, DFU: Diabetic Foot 
Ulcer, dl: Deciliter, g: Gram, HbA1c: Glycated Hemoglobin, HBOT: Hyperbaric Oxygen Therapy, HDL: High Density Lipoprotein, LDL: 
Low Density Lipoprotein, M0: Month 0, M3: Month 3, M6: Month 6, mg: Milligram, ml: Millilitre, NA: Not Applicable, NHOTB: No 
Hyperbaric Oxygen Therapy, pg: Pico gram; PlGF: Placental Growth Factor, SD: Standard Deviation, SDF1- α: Stromal Cell-derived 
Factor 1 Alpha, VEGF: Vascular Endothelial Growth Factor 
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Table 3. Clinical outcome 
Variables 
Global 
(n=20) 
NHBOT DFU 
patients 
(n=6) 
HBOT DFU patients 
(n=14) 
Comparison between 
groups 
Fisher’s exact test  
p value 
M3 M6 M12 M3 M6 M12 M3 M6 M12 M3 M6 M12 
Complete healing / 
improvement (n 
(%))  
15 
(75) 
15 
(75) 
12 
(60) 
1 
(17) 
1 
(17) 
1 
(17) 
14 
(100) 
14 
(100) 
11 
(79) 
<0.001 <0.001 0.02 
LEA or death (n 
(%)) 
5 
(25) 
5 
(25) 
8 
(40) 
5 
(83) 
5 
(83) 
5 
(83) 
0  
(0) 
0  
(0) 
3 
(21) 
 
HBOT: Hyperbaric oxygen therapy, LEA: Lower extremity amputation, M0: Month 0, M6: Month 6, M12: Month 12, NHBOT: No 
hyperbaric oxygen therapy 
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Table 4. Diabetic foot ulcer characteristics at baseline and third month of follow-up 
Variables 
Global 
(n=20) 
NHBOT DFU 
patients 
(n=6) 
Paired 
samples tests 
p value  
HBOT DFU patients 
(n=14) 
Paired 
samples 
tests 
p value 
Independent 
samples tests 
p value 
M0 M3 M0 M3 M0 M3 M0 M3 
Baseline ulcer area (in cm2) (median (range)) 
11.0 
(31.1)a 
2.7 
(24.8)b 
12.1 
(16.1) 
13.1 
(23.5)b 
NP 
7.3 
(31.1)a 
2.7 
(16.3) 
0.001* 0.4 α NP 
Mean depth (in mm) (median (range)) 
2.3 
(11.6)c 
1.7 
(6.5)d 
1.8 
(4.7) 
3.5 (3.6)b NP 
2.3 
(11.6)c 
1.4 
(6.5)a 
0.1* 0.6 α NP 
Maximum depth (in mm) (median (range)) 
4.6 
(18.3)c 
3.3 
(10.7)d 
3.6 
(8.2) 
7.9 (5.2)b NP 
4.6 
(18.1)c 
3.2 
(10.7)a 
0.03* 0.3 α  NP 
Volume (in cm3) (median (range)) 
1.2 
(24.8)c 
0.4 
(13.8)d 
1.5 
(10.4) 
7.0 
(13.6)b 
NP 
1.2 
(24.5)c 
0.4 
(10.7)a 
0.006* 0.8 α NP 
*: Wilkoxon signed ranks test, α: Mann-Whitney U test, a: 1 missing values, b: 4 missing values, c: 2 missing values, d: 5 missing values, cm2: Squared Centimetre, cm3: Cubic Centimetre, DFU: Diabetic Foot Ulcer, DFU: 
Diabetic Foot Ulcer, HBOT: Hyperbaric Oxygen Therapy, M0: Month 0, M3: Month 3, mm: Millimetre, NHBOT: No Hyperbaric Oxygen Therapy, NP: Not Possible 
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Table 5. Diabetic foot ulcer characteristics at baseline, 6th and 12th month of follow-up 
 
Ϫ: Friedman test, α: Mann-Whitney U test, a: 1 missing values, b: 5 missing values, c: 8 missing values, d: 3 missing values, e: 2 missing values, f: 4 missing values, g: 7 missing values, h: 9 missing values, cm2: Squared 
Centimetre, cm3: Cubic Centimetre, DFU: Diabetic Foot ulcer, HBOT: Hyperbaric Oxygen Therapy, M0: Month 0, M3: Month 3, mm: Millimetre, NP: Not Possible, NHOTB: No Hyperbaric Oxygen Therapy 
 
 
  
Variables 
Global 
(n=20) 
NHBOT DFU patients 
(n=6) 
Paired samples 
tests 
p value 
HBOT DFU patients 
(n=14) 
Paired samples 
tests 
p value M0 M6 M12 M0 M6 M12 M0 M6 M12 
Baseline ulcer area (in cm2) (median 
(range)) 
11.0 (31.1)a 
0.4 
(6.3)b 
0.0 (1.9)c 12.1 (16.1) 
0.0 
(0.0)b 
0.0 
(0.0) b 
NP 7.3 (31.1)a 0.4 (6.3) 0.0 (1.9)d <0.001 Ϫ 
Mean depth (in mm) (median (range)) 2.3 (11.6)e 0.7 (2.2)f 
0.0 
(2.7)g 
1.8 (4.7) 
0.0 
(0.0)b 
0.0 
(0.0) b 
NP 2.3 (11.6)e 0.9 (2.2)e 0.4 (2.7)f 0.001 Ϫ 
Maximum depth (in mm) (median 
(range)) 
4.6 (18.3)c 1.3 (4.3)g 0.0 (4.7)h 3.6 (8.2) 
0.0 
(0.0)b 
0.0 
(0.0) b 
NP 4.6 (18.1)e 1.7 (4.3)e 1.3 (4.7)f 0.006 Ϫ 
Volume (in cm3) (median (range)) 1.2 (24.8)e 0.0 (6.2)g 0.0 (0.3)h 1.5 (10.4) 
0.0 
(0.0)b 
0.0 
(0.0) b 
NP 1.2 (24.5)e 0.0 (6.2)e 0.0 (0.3)f 0.001 Ϫ 
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FIGURE LEGEND 
 
Figure 1. Boxplot of number of vessels at baseline and 1 month in patients undergoing or not 
Hyperbaric Oxygen therapy.  
Figure 2. Microvessel density as evaluated by CD31 immunostaining at baseline and one month 
after HBOT in patients with active DFU. (A) Patient treated with HBOT, at baseline; (B) Non-HBOT 
patient at baseline; (C) Patient treated with HBOT at one month after treatment initiation; (D) 
Non-HBOT patient one month after treatment initiation. Magnification 200x. 
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Figure 1. 
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Figure 2. 
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